Official Title of Study:  
A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG -221 (CC -
[ZIP_CODE]) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia 
Harboring an Isocitrate Dehydrogenase 2 Mutation  
 
  
PROTOCOL(S) AG-221-AML -004 
 
Study ID: [REMOVED] 
  
Document Date (Date in which document w as last revised): November  30, 2017  
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
1 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017 
A PHASE 3, MULTICENTER, OPEN-LABEL , 
RANDOMIZED STUDY COMPARING THE EFFICA CY 
AND SAFETY OF AG-221 (CC-[ZIP_CODE]) VERSUS 
CONVENTIONAL CARE RE GIMENS IN OLDER 
SUBJECT S WITH LATE STAGE ACUTE MYELOID 
LE[LOCATION_006]EMIA HARBORING A N ISOCITRATE 
DEHYDROGENASE 2 MUTATION
The “IDHENTIFY” Trial
PROTOCOL NUMBER: AG-221- AML - 004
DATE FINAL: 13Aug 2015
AMENDMENT 1.0 : 11Oct2016
AMENDMENT 2.0: 30Nov [ADDRESS_539400] NUMBER: 2015 -000344-42 
IND NUMBER: 117631 (Enasidenib [AG -221, 
CC
-[ZIP_CODE]]) 
064251 (Azacitidine)
SPONSOR NAME/ ADDRESS: Celgene Corporati on
[ADDRESS_539401]
Summit, NJ [ZIP_CODE]
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
2 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017MEDICAL MONITOR / EMERGENCY CONTACT [CONTACT_27615]:
Name:     
[CONTACT_1641]:        
Address: 
                
Phone:     
E-mail:    
Note: The back -up [ADDRESS_539402] call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back -up [ADDRESS_539403] Call Center: 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
3 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017CELGENE THERAPEUTIC AREA HEAD SIGNATURE [CONTACT_1783]
{See appended electronic signature [CONTACT_3264]}
Signature [CONTACT_72655] [CONTACT_27616], I i ndicate I have reviewed this protocol and find its content to be 
acceptable.  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
4 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_27503]:_______________________________________
By [CONTACT_27616], I agree to personally  supervise the conduct of this study  at my  study  
site and to ensure i ts conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from
Celgene representati ves, the Declarat ion of Helsinki, International Council on 
Harm onisat ion (ICH) Good Clinical Practices Guidelines, and local regulat ions 
governing the conduct of clinical studies.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
5 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017COORDINATING PRINCIPAL INVESTIGATOR [INVESTIGATOR_27504]:_______________________________________
By [CONTACT_27616], I agree the protocol has been written to comply  with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study  as 
needed.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
6 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017PROTOCOL SUMMARY
Study Title
A Phase 3, Mult icenter, Open -label, Randomized Study  Com paring the E fficacy and Safety of
AG-221 (CC- [ZIP_CODE]) Versus Convent ional Car e Regimens in Older Subjects with Late Stage
Acute Myelo id Leukemia Harboring an Isoci trate Dehydrogenase 2 Mutation .
Indication
Treatment of subjects 60 yearsor older with acute myelo id leukemia (AML) refractory  to or 
relapsed after second -or thi rd-line AML therapy and positive for an isocitrate d ehydrogenase 2
(IDH2) m utation
 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
7 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Objectives
Primary
To deter mine the primary efficacy, measured as o verall survival (OS), of AG-221 
compared wi th convent ional care regimens (CCRs) in subje cts [ADDRESS_539404]-line AML therapy and positive 
for an IDH2 mutation
Secondary
To determine the supporting efficacy of AG -221 com pared wi th CCRs
To determine the safet y and tol erabili ty of AG-221 com pared wi th CCRs
To determine the effect o f AG-221 com pared wi th CCRs on H ealth-related Quali ty-
of-Life (HRQoL )
Study Design
This is an international, mult icenter, open -label, rando mized, Phase [ADDRESS_539405]-line AML therapy and positive for an IDH2 mutation .
Screening procedures are to occur within 28 days pri or to the start of study  treatm entand after 
the informed consent form (ICF ) is signed.   Diagnosis of AML di sease and AML disease status 
at screening will be based on local review of pathology  and cytogeneti cs.  Positivity of IDH2 
gene mutation in bone m arrow aspi [INVESTIGATOR_6706]/or peripheral blood will be confirmed centrally at 
screening .(Note: in the event that the central laboratory  resul t isdelayed and preclude sacute 
clinical management of a subject who has confirmed IDH2 gene mutationby [CONTACT_426830], 
the subject m ay be eligible for randomizat ion withapproval  by[CONTACT_1689] .)
Following review of eligibilit y, subjects will be assigned by [CONTACT_426831]’s assessment of subjects’ eligibilit y.  The CCR 
treatm ent opti ons include best supportive care (BSC) only, azacit idine subcutaneously  (SC) plus 
BSC , low-dose cy tarabine (LDAC) SC plus BSC, or intermediate -dose cy tarabine (IDAC)
intravenously ( IV) plus BSC .  The CCR treatment option chosen and the reason(s) for select ing 
the CCR treatment option will be recorded for all subjects prior to randomizat ion.
Following the sel ection of  aCCR treatm ent option, subjects will be rando mized centrally  in a 1:1 
ratiotoreceive either the AG-221 treatm entor the CCR treatm entoption pre -selected by [CONTACT_1275].  Randomizat ion will be stratified by [CONTACT_426832] (yes versus 
no), primary refractory (ie, morphologic co mplete remission [CR], CR with incomplete 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
8 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017neutrophil recovery  [CRi ] or CR wi th incomplete pl atelet recovery  [CRp] has never been 
attain ed)(yesversus no ), and prior allogeneic hema topoi etic stem  cell transplantati on(HSCT)
for AML (yesversus no).
Study  treatm ent starts within 3 daysafter randomization.  No crossover between any of the 
treatm ent options, incl uding the CCR treatm ent opti ons, will be permitted during the course of 
study  treatm ent.
Assessments during study  treatm ent include efficacy , safet y, HRQoL ,  
  
A retrospective central  review of all bone marrow aspir ates and/or biopsies, peripheral blood 
smears and cy togeneti cs collected during the study will be conducted by [CONTACT_426833] .  The central assessments will be used in the statist ical analyses .  Disagreement 
between central  and l ocal assessments will be adjudi cated by a third party  reviewer andthe
adjudicated assessment will be used in the statist ical analyses .
Response to treatment and hematologic improvement (HI) will be assessed by [CONTACT_426834] a blinded Independent Response Assessment Committee (IRAC) 
according t o modified Internati onal Working Group (IWG) AML Response Criteria
(Append ixF)and IWG myelodysplas tic syndro mes HI criteria ( Appendix H ), respectively .
Dosing interruptions, dosing delays or dose modification smay occur for managing toxicit ies 
and/or augment ing treatm ent response during study treatm ent (refer to Secti on 7.2).
Subjects can continue to receive study treatment pro vided that they benefit fro m study treatm ent 
and all protocol -specified criteria for continuing study treatm entare m et.  Study treatment will
be discont inued ifthe invest igator has alternat ive therapi[INVESTIGATOR_014] ( eg, HSCT ) and/or considers study  
treatm ent to be no l onger beneficial to the subject, or the rapi[INVESTIGATOR_193107] y of change o f disease state 
renders it unacceptable for further study  treatm ent in the judgment of the investigator .  Refer to 
Secti on11.[ADDRESS_539406] one do se of study treatment shoul d undergo endof
treatment (EOT) evaluation s
(Secti on6.2.3 ) when study  treatm ent is discont inued.  The reason 
for discontinuation will be recorded in the electronic case report form (eCRF) pages and in the 
source document.
All subjects di scont inued fro m study  treatm ent for any reason other than withdrawal of consent 
for follow-up will continue to be assess ed for adverse events ( AEs), concomitant medicat ions, 
concomitant procedures , transfusio ns,  response, hematologic 
improvement, subseque nt AML therapi[INVESTIGATOR_426785].  Refer to Section 6.3for details regarding 
the assessment sscheduled after the EOT visit .
The study  will be conducted in com pliance wi th Internati onal Council on Harm onisat ion (ICH) 
Good Clinical Pract ices (GCPs) .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
9 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539407]-line AML therapy and positive for an IDH2 mutation.
Length of Study
The expected duration of this study  is approximately  78months, including an enro llment period 
of approximately  42months, fo llowed by [CONTACT_3450] 7 months of treatment and/or 
posttreatment fo llow-up to reach the total number of events (see below Statist ical Methods 
Secti on and Secti on 9) requi red for a f ully-powered analysis o f OS.
The End of Trial is defined as either the date of [ADDRESS_539408] is available for 
survival fo llow
-up,  whichever is the later date. 
Study Treatments
The opti ons in the CCR treatm ent arm include :
BSC only: continuous [ADDRESS_539409] supportive care includes, but is 
not limited to, hydroxyurea for leukocy tosis and/ or differentiation s yndro me 
associ ated wi th therapy  of mutant IDH i nhibit ion (ie, IDH differentiation s yndro me),
anti-infectives, analgesics, antiemeti cs, ant ipyretics, transfusio ns and nut ritional 
support (refer to Section 7.1.5 and Secti on8for details);
Azacitidine SC pl us BSC: continuous 28 -day cycles of azacit idine 75 m g/m2/day SC
for 7 days , plus BSC ;
LDAC SC pl us BSC : continuous 28- day cycles of cytarabine 20 m g SC twice a day
(BID) for 10 days , plus BSC ;
IDAC IV pl us BSC : 28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for [ADDRESS_539410] institutional practice , plus BSC ;only BSC given after IDAC 
therapy concludes per standard inst itutional pract ice. (N ote: any local standard 
regimen different from the above specificati on will need review and approval by  [CONTACT_5134] .)
Subjects rando mized to the AG -221 treatment arm will receive continuous 28 -day cycles of 
AG-221 100 m g orally  (PO) once a day (QD) for 28 day s, plus BSC .  Dose escalat ion to 200 mg
may occur for augm enting treatment response (detailed in Section7.2.1.2 ).
Study  treatm entsas described above can continue until the End of Trial , unless discont inued for 
any of the reasons detailed in Section11.1.
Overview of Key Efficacy Assessments
Theprimary  efficacy  endpoint is OS .  
The key  secondary  efficacy  endpoint s include overall response rate and event -free survival .  
Response will be asses sedretrospectively bya blinded IRAC through collect ion of central
hematol ogy parameters , central assessments of bone marrow aspir ates and/o r biopsies, peripheral
blood sm ears and cy togeneti cs, and results o f other pertinent tests .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
10 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Overview of Key Safety Assessments
Safety assessments include physical  examinat ion, vital signs, electrocardi ogram , hematol ogy, 
serum  chemistry , cardi ac markers, fasting(preferred) lipid panel, pregnancy test ing (for females 
of childbearing potential only), AEs, con comitant medicat ions, concomitant procedures and 
transfusio ns.  After screening, e chocardiogram, urinalysis and coagulat ion will  be repeated as 
clinica lly indicated.
Statistical Methods
The primary  efficacy  endpoint of OS is defined as time fro m rando mizat ion to death due to any 
cause.   The equalit y of overall survival cures will be compared b etween the AG-[ADDRESS_539411].  Assuming a median OS of 5 .6months in the CCR 
treatm ent arm(Roboz, 2014 ),a median OS of 8 months in the AG-221 treatm ent arm ( 42.9% 
improvement), and a drop-out rate of approxim ately  
9%, thi s design requires 250deaths and 316
subjects ( 158per treatment arm) to be randomized in order to achieve 80% power to detect a 
constant hazard ratio of 0. 7
and demonstrate a statistically significant difference in OS at a Type 
I error rate of 0.05 (two- sided).   An interim an alysis for superiorit y will be cond ucted at 65% 
inform ation (ie,163deaths) based on Lan-DeMets versio n of the O’Brien -Fleming alpha 
spending funct ion
.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
11 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017TABLE OF CONTENTS
TITLE PAGE .............................................................................................................................. 1
PROTOCOL SUMMARY .......................................................................................................... 6
2. STUDY OBJECTIVES AND ENDPOINTS ........................................................... 26
3. OVERALL STUDY DESIGN ................................................................................ 29
3.1. Study  Design .......................................................................................................... 29
3.1.1. Screening Phase ...................................................................................................... 29
3.1.2. Treatment Phase ..................................................................................................... 30
3.1.3. Follow-up Phase ..................................................................................................... 31
3.1.4. Interim Analysis ..................................................................................................... 31
3.1.5. Data Monitoring Committee ................................................................................... 32
3.2. Study  Durati on for Subj ects.................................................................................... 32
3.3. End of Trial ............................................................................................................ 32
4. STUDY POPULATION ......................................................................................... 34
4.1. Numbe r of Subjects ................................................................................................ 34
4.2. Inclusio n Cri teria.................................................................................................... 34
4.3. Exclusio n Cri teria................................................................................................... 36
5. TABLE OF EVENTS ............................................................................................. 39
6. PROCEDURES ...................................................................................................... 45
6.1. Screening Phase ...................................................................................................... 45
6.2. Treatment Phase ..................................................................................................... 48
6.2.1. Baseline .................................................................................................................. 51
6.2.2. Unsched uled Visi ts.................................................................................................51
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
12 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539412] ing (Preferred) Lipid Panel ......................................................................... [ADDRESS_539413](s) ................................................................ [ADDRESS_539414] Supportive Care Only ..................................................................................... 59
7.2. Treatment Administration and Schedule .................................................................59
7.2.1. AG-221 Treatm ent.................................................................................................. 60
[IP_ADDRESS]. Dispensat ion and Administration of AG -221 .......................................................... 60
[IP_ADDRESS]. Dose Modificat ions for AG -221.............................................................................. 60
[IP_ADDRESS]. Reference Toxicit ies During AG
-221 Treatm ent..................................................... 61
[IP_ADDRESS]. Initiation of  Each AG -221 Treatm ent Cy cle............................................................ 63
7.2.2. Azacit idine Treatment ............................................................................................. 64
[IP_ADDRESS]. Dose Modificat ions for Azacit idine........................................................................ [ADDRESS_539415] Supportive Care Only Treatment ..................................................................... 67
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
13 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539416] Disposit ion................................................................................................
.74
9.6. Efficacy Analysis .................................................................................................... 74
9.6.1. Primary Efficacy  Analysis ...................................................................................... 75
9.6.2. Secondary  Efficacy  Analyses .................................................................................. 75
[IP_ADDRESS]. Key Secondary  Efficacy  Analyses .......................................................................... 75
[IP_ADDRESS]. Addit ional Secondary  Efficacy Analyses ................................................................ 76
9.7. Safety Analysis ....................................................................................................... 77
9.8. Interim Analysis ..................................................................................................... 77
9.9. Other Topi [INVESTIGATOR_1102]........................................................................................................... 78
9.9.1. Data Monitoring Committee ................................................................................... 78
9.9.2. Steering Committee ................................................................................................ 78
9.9.3. Health-Related Qualit y-of-Life............................................................................... 78
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
14 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201710. ADVERSE EVENTS .............................................................................................. 80
10.1. Moni toring, Recording and Reporting of Adverse Events ....................................... 80
10.2. Evaluat ion of Adverse Events ................................................................................. 80
10.2.1. Seriousness ............................................................................................................. 80
10.2.2. Severity/Intensi ty.................................................................................................... [ADDRESS_539417] Informat ion and Informed Consent ............................................................. 91
13.4. Confident iality........................................................................................................ 91
13.5. Protocol  Amendments ............................................................................................. 91
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
15 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539418]/Independent Ethics Committee Review and 
Approval ................................................................................................................ [ADDRESS_539419]/ Ethics Co mmit tee................ 92
13.8. Terminat ion of the Study ........................................................................................ 92
14. DAT A HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] ..................................................... 94
14.1. Data/Documents ..................................................................................................... [ADDRESS_539420] ions............................................................................................ 96
16. PUBLICATIONS ................................................................................................... 97
17. REFERENCES ....................................................................................................... 98
18. APPENDICES ...................................................................................................... 103
Appendix A:  T able o f Abbreviat ions...................................................................................... 103
Appendix B:  World Health Organizat ion Classification of Acute My eloid Leukemia ............. 109
Appendix C:  Acute My eloid Leukemia Risk Status ................................................................ 110
Appendix D:  Eastern Cooperative Onco logy Group (ECOG) Performance Status .................. 111
Appendix E:  [LOCATION_001] Heart Asso ciation Classificat ion for Congestive Heart Failure .......... 112
Appendix F:  Internat ional Working Group Acute Myelo id Leukemia Response Criteria........ 113
Appendix G:  Definit ions of Pri or Line of AML Therapy ........................................................ 114
Appendix H:  Hematologic Improvement According to the International Working Group 
for My elodysplasti c Syndrom es............................................................................ 115
Appendix I:  European Organizat ion for Research and Treatment of Cancer Qualit y-of-
Life quest ionnaire (Versio n 3.0) ........................................................................... 116
Appendix J:  EQ -5D- 5L Health Questionnaire (English Versio n for the [LOCATION_006]) .......................... 118
Appendix K:  Subcutaneous Preparation and Administration of Azacit idine ............................ 120
Appendix L:  Azacit idine Dose Modificat ions due to Hem atologic Toxi city –Subjects 
without Reduced Baseline Blood Counts .............................................................. 124
Appendix M:  Azacit idine Dose Modificat ions due to Hematologic Toxicit y –Subjects 
with Reduced Baseline Blood Counts ................................................................... 125
Appendix N:  Cy tochrom e Sensi tive Substrates ....................................................................... 126
Appendix O:  Transporter Sensit ive Substrates ........................................................................ 127
Appendix P:  Monitoring of Liver Funct ion............................................................................. 128
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
16 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539421] OF TABLES
Table 1: Study  Objectives ..................................................................................................... 26
Table 2: Study  Endpo ints..................................................................................................... 26
Table 3: Table of Events ....................................................................................................... 39
Table 4: Abbreviat ions and Specialist Terms ...................................................................... 103
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
17 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539422] OF FIGURES
Figure 1: Overall Study  Design .............................................................................................. 33
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
18 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
19 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
20 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
21 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
22 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
23 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
24 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
25 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
26 AG-221-AML -004 Amendment 2.0 Final :30 Nov [ZIP_CODE]. STUDY OBJECTIVES AND ENDPOINTS
Table 1: Study Objectives
Primary Objective
The pr imary objective of the study is
To deter mine the primary efficacy, measured as overall survival (OS), of AG -221 compared 
with conventional care regimens (CCRs) in subjects [ADDRESS_539423] -line AML therapy and positive for an IDH2 mutation
Secondary Objective (s)
The secondary objectives are
To determine the supporting efficacy of AG-221 compared with CCRs
To deter mine the safety and tolerability of AG -221 compared with CCRs
To determine the effect o f AG -221 compared with CCRs on Health -related Quality-of- Life
Table 2: Study Endpoints
Endpoint Name [CONTACT_426891] ~ 49months
Secondary Overall response rate Rate of MLFS + CR + CRi + CRp + PR 
according to modified IWG AML 
response criteria ( Appendix F)Up to ~ 49months
Rate of CR/CRh ( assessed by [CONTACT_426835];Appendix F).Up to ~ 49months
Event -free survival Time from randomization to 
documented morphologic relapse , PD 
according to modified IWG AML 
response criteria ( Appendix F)or death 
from any cause, whichever occurs firstUp to ~ 49months
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
27 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 2: Study Endpoints ( Continued)
Endpoint Name [CONTACT_426892]
(continued)Duration of response Time fr om the first documented 
MLFS/CR/CRi/CRp/PR to documented 
morphologic relapse, PD  according to 
modified IWG AML response criteria 
(Appendix F) or death due to any cause, 
whichever occurs fir stUp to ~ 49months
Time from the first documented 
CR/CRh to documented morphologic 
relapse, PD according to modified IWG 
AML response criteria ( Appendix F) or 
death from any cause, whichever occurs 
firstUp to ~ 49months
Time to response Time from randomization to first 
documented MLFS/ CR/CRi/CRp/PR 
according to modified IWG AML 
response criteria ( Appendix F)Up to ~ 49months
Time from randomization to first 
documented CR/CRh (Appendix F)Up to ~ 49months
Treatment mortality at 30 
and 60 daysRate of death from any cause within 
30 and 60 days of initiation of study 
treatmentAt 30 and 60 days
after treatment 
start
One-year survival The probability of survival at 1year 
from randomization Up to ~ 49months
Overall remission rate Rate of CR + CRi + CRp according to 
modified IWG AML response criteria 
(Appendix F)Up to ~ 49months
Complete remission rate Rate of CR according to modified IWG 
AML response criteria ( Appendix F)Up to ~ 49months
Hematologic improvement 
rateRate of HI -N + HI -P + HI -E according 
to IWG MDS HIcriteria ( Appendix H )Up to ~ 49months
Rate of HSCT Rate of bridge -to-HSCT through study 
treatmentUp to ~ 49months
Time to treatment failure Time from randomization to 
discontinuation of study treatment due 
to any causeUp to ~ 49months
Safety and tolerability Type, frequency, severity, seriousness 
and relationship of adverse events to 
study treatments; vital signs; ECG; 
clinical laboratory evaluationsUp to ~ 78months
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
28 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 2: Study Endpoints ( Continued)
Endpoint Name [CONTACT_426892]
(continued)HRQoL European Organization for Research 
and Treatment of Cancer Quality -of-
Life  questionnaire (EORTC QLQ -C30) 
(Appendix I ) and EuroQoL Group 
EQ-5D-5L instrument ( Appendix J )Up to ~ 49months
Abbreviations: AML = acute myeloid leukemia; CR = morphologic complete remission; CRh = morphologic 
complete remission with partial hematologic recover y; CRi=morphologic complete remission with incomplete 
neutrophil recovery ; CRp = morphologic complete remission with i ncomplete platelet recover y;ECG = 
electrocardiogram; EORTC= European Organization for Research and Treatment of Cancer; 
HI = hematologic improvement ; HI-E = hematologic improvement erythroid response; 
HI-N
=hematologic improvem entneutrophil response ; HI-P = hematologic improvement platelet response ; 
HRQoL = Health -related Quality of Life; HSCT =hematopoietic stem cell t ransplantatio n; IWG =International 
Working Group; MDS = myelodysplastic syndromes ;MLFS = morphologic leukem ia-free state; 
 PR = partial remission ; PD =progr essive disease.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
29 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539424]-line AML therapy and positive for an IDH2 mutation .
The study  will be conducted in com pliance wi th the International Council on Harmo nisat ion 
(ICH) of Technical Require ments for Registration of Pharmaceut icals for Hum an Use/Good 
Clinical Practice (GCP) and applicable regulatory  requi rements .
The study  consists of a Screening Phase, a Treatment Phase and a Follow-up Phase.
Figure 1 provides a schemat ic of the overall study design.
3.1.1. Screening Phase
Screening procedures are to occur during the Screening Phase within 28 days pri or to thestart of 
study  treatm entand after th e informed consent form (ICF ) is signed .  
Diagnosis of AML disease according to World Heal th Organizati on (WHO) classificat ion 
(Appendix B )and AML disease status at screening according to modified Internat ional Working 
Group (IWG) AML Response Criteria ( Append ixF)will be based on local review o f pathol ogy 
and cy togeneti cs.  
A retrospective central  review of screening bone marrow a spi[INVESTIGATOR_26631]/or bi opsies, peripheral
blood sm ears and cy togeneti cs will be conducted by  [CONTACT_426836]. The 
central  cytogeneti c review will provide standardized analysis and reporting for all subjects, 
regardl ess of the l aboratory  performing th e initial analysis (local or central ; Section 6.1).  The 
central assessments will be used to confirm AML disease status at screening . If the central  and 
local review sdisagree on AML disease status of a subject at screening , a thi rd party reviewer 
will adjudicate and make the final assessment.   If the subject was centrally  confirmed to be 
ineligible for the study , the subject will be allowed to remain in the study , but will  be excluded 
from the modified intent -to-treat ( mITT)populat ion(Secti on9.2.2 ).  Instructions for submissio n 
slides of bone m arrow aspi[INVESTIGATOR_337](and/or biopsy) and peripheral blood smear, and pertinent reports 
to central review are provided in the Study  Reference Manual and Study  Central  Laboratory  
Manual .
Positivity of IDH2 gene m utation in bone marrow aspi[INVESTIGATOR_6706]/or peripheral blood will be 
confirmed centrally  at screening .(Note: in the event that the central laboratory result is delayed 
and precludes acute clinical management of a subject who has confirmed IDH2 gene mutation by 
[CONTACT_426837], the subject may  be eligible for randomizat ion with approval  by [CONTACT_53977].)
Following review ofeligibilit y, subjects will be assign ed by [CONTACT_426838]’s assessment of subjects’ eligibilit y.  The CCR 
treatm ent opti ons include best supportive care (BSC) only, azacit idine SCplus BSC, LDAC SC 
plus BSC, or IDAC IVplus BSC :
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
30 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017BSC only: continuous [ADDRESS_539425] supportive care includes, but is 
not limited to, hydroxyurea for leukocyto sis and/or differentiation s yndro me 
associ ated wi th therapy  of mutant IDH i nhibition (ie, IDH Different iation Syndrom e), 
anti-infectives, analgesics, antiemeti cs, ant ipyretics, transfusio ns and nutritional 
support ( refer to Section 7.1.5 and Secti on8for details );
Azacit idine SC plus BSC: continuous 28- day cycles of azacitidine 75 m g/m2/day SC
for 7 days, plus BSC;
LDAC SC plus BSC: continuous 28- day cycles of cy tarabine 20 m g SC BID for
10days, plus BSC;
IDAC IV plus BSC: 28- day cycles of cytarabine 0.5 to 1.5 g/m2/day IV f or [ADDRESS_539426] institutional practice, plus BSC; only BSC given after IDAC
therapy  concludes per standard inst itutional pract ice.(Note: any local standard 
regimen different from the above specification will need review and approval by [CONTACT_5134] .)
The CCR treat ment option chosen and the reason(s) for select ing the CCR treatment option will 
be recorded for all subjects prior to randomizat ion.
Following the sel ection of  a CCR treatm ent opti on, subjects will be rando mized centrally  in a 1:1 
ratiotoreceive either the AG-221 treatm ent or the CCR treatment option pre -selected by [CONTACT_1275].  Randomizat ion will be stratified by [CONTACT_426839] (y es versus 
no), primary refractory (ie, CR, CRi or CRp has never been attained) (yes versus no), and prior 
allogeneic HSCT for AML (y es versus no )
.
Approximately  316 eligible subjects wi ll be enrolled with 158 subjects per treatment arm.
3.1.2. Treatment Phase
Study  treatm ent starts within 3 days after randomization .  No crossover between any of the 
treatm ent options, incl uding the CCR treatm ent opti ons, will be permitted during the course of 
study  treatm ent.
Assessments during study  treatm ent include efficacy , safet y, Health-related Quali ty-of-Life 
(HRQoL ) questionnaires,  
.
A retrospective central  review of all bone marrow aspir ates and/or bi opsies, peripheral blood 
smears and cy togeneti cs collected after the start of study  treatm entwill be conducted by  
[CONTACT_426840].  The central cytogenet ic review will provide standardized 
analysis and reporting for all subjects, regardless of the laboratory performing th e initial analysis 
(local or central ).  The central assessments will be used in the statist ical analyse s.  Disagreement 
between central and local assessments will be adjudi cated by a third party  reviewer and t he
adjudicated assessment will be used in the statist ical analyses .  Instructions for submissio n slides
of bone marrow aspi[INVESTIGATOR_337] ( and/or biopsy )and peripheral  blood sm ear, and pertinent reports to 
central  review are provided in the Study  Reference Manual and Study  Central  Laboratory  
Manual .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
31 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Response to treatment and hematological improvement (HI) will be assessed by  [CONTACT_426841]  a blinded Independent Response Assessment Committee (IRAC) according to modified 
IWG AML Response Criteria ( Appendix F)and IWG myelodysplastic syndrom es (MDS) HI
criteria ( Appendix H ), respect ively.
Dosing interruptions, dosing delays or dose m odificati onsmay occur for managing toxicit ies 
and/or augment ing treatm ent response during study  treatm ent (refer to Secti on7.2fordetails) .
Subjects can cont inue to receive study treatment pro vided that they benefit fro m study treatm ent 
and all protocol -specified criteria for continuing study treatm entare m et.  Study treatment will
be discont inued ifthe invest igator has alternat ive therapi[INVESTIGATOR_014] ( eg, HSCT )and/or considers the 
study  treatm ent to be no l onger beneficial to the subject, or the rapi[INVESTIGATOR_426786] .  Study 
treatm ent will be discont inued iffemales of childbearing potential (FCBP s)beco me pregnant 
during the study .Refer to Section 11for events that are considered sufficient reasons for 
discontinuing a subject from study  treatm ent.
The decisio n to di scont inue a subject, which will not be delayed or refused by [CONTACT_1034], 
remains the responsibilit y of the treati ng physician. However, prior to discont inuing a subject, 
the invest igator may contact [CONTACT_22951] M onitor and forward appropri ate supporti ng docum ents 
for review and discussio n.
All subjects who have received at least one dose of study treatment shoul d undergo end of
treatm ent (EOT) evaluations (Secti on6.2.3 ) when study  treatm ent is discont inued.  The reason 
for discont inuat ion will be recorded in the electronic case report form (eCRF) pages and in the 
source document.
3.1.3. Follow -up Phase
All subjects di scont inued fro m study  treatm ent for any reason other than withdrawal of consent 
for follow-up will continue to be assessed for AEs, concomitant medicat ions, concomitant 
procedures, transfusions,  response, hematologic improvement, 
subseque nt AML therapi[INVESTIGATOR_426787].  Refer to Secti on6.3fordetails regarding the 
assessments scheduled after the EOT visit.  Females of childbearing potential shoul d avoi d 
beco ming pregnant for [ADDRESS_539427] study treatment ([ADDRESS_539428] dose of 
cytarabine) , and male subjects and th eir partners shoul d avoi d concept ionfor [ADDRESS_539429] study treatment ([ADDRESS_539430] dose of cytarabine ; [ADDRESS_539431] dose of 
azacit idinein Canada ).
3.1.4. Interim Analysis
The study  will have one interim analysis for superiori ty(Section9.8).  The interim efficacy 
analysis will be perform ed by [CONTACT_426842] .  The interim result s will be 
provi ded to an independent Data Monitoring Committee (DMC) who will review and give 
advice to the Spons or regarding the study  conduct. The analysis results will not be disseminated 
among invest igators and those direct ly involved with the study  conduct.    
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
32 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539432] is approximately  up to 78months, an enrollment period of 
approximately  42 m onths including a screening period for up to 28 days, followed by 
[CONTACT_3450]  7 months of treatment and/or posttreatment fo llow-up to reach the total number of 
events (see Section Sect ion9) requi red for a f ully-powered analysis o f OS.
3.3. End of Trial
The End of Trial is defined as either the date of [ADDRESS_539433] been analyzed, and the availabilit y of a roll-over or extensio nprotocol  exists into 
which any  subjects who remain on study treatm entmay be consented and continue to receive 
access to study treatment .  Such a protocol would be written for a compound that woul d not y et 
be co mmercially available .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
33 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Figure 1: Overall Study Design
                                                         
                               
Key: AML =acute myeloid leukemia; BSC = best supportive care; CCR = conventional care regimen ; CR = morphologic 
complete remission ; CRi =morphologic complete remission with incomplete neutrophil recovery; CRp = morphologic 
complete remission with incomplete platelet recovery; EOT = end of treatment ; HSCT =hematopoietic stem cell 
transplantation ; IDAC= intermediate -dose cytarabine ; IDH2 = isocitrate dehydrogenase isoform 2 ; IV = intravenously; LDAC 
= low-dose cytarabine ; PD= progressive disease ; PO = orally; SC = subcutaneously .
*Stratification factors: prior intensive therapy for AML (yes versu s no), primary refractory (yes versus no) , and prior allogeneic 
HSCT for AML (yes versus no) .Randomization* 1:1
N = [ADDRESS_539434] or 
withdrawal from study treatment .
Follow -up
Follow -up for adverse events , concomitant medications, concomitant 
procedures, transfusions, response, 
hematologic improvement, subsequen t AML therapi[INVESTIGATOR_014] , response / disease 
status to subsequent AML therapi[INVESTIGATOR_426787].  Refer to Section 6.3for 
details regarding the asse ssments scheduled after the EOT visit .CCR Arm
BSC only ; or
Azacitidine SC plus BSC ;or 
LDAC SC plus BSC ;or
IDAC IV plus BSC
N = 158AG-221 Arm
AG-221 PO plus BSC
N = 158Screening (Day -28 to Day -1)
Eligibility Check
 ≥ 60 years old
 AML refractory to or relapsed after second -/third -line AML therapy
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
34 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539435] satisfy the fo llowing cri teria to be enro lled in the study:
1.Subject i s ≥ [ADDRESS_539436] has primary  (ie, de novo ) or secondary  (progression of MDS or 
myeloproliferat ive neopl asms ([MPN], or therapy -related)AML according to WHO
classificat ion (Appendix B )
3. Subject has received second -or thi rd-line o f AML therapy (seeAppendix G for the 
definit ion of prior AML line; note that, for subjects having AML se condary  to pri or 
higher ri sk [Interm ediate -2 or High risk according to the International Prognostic Scoring 
System ] MDS treated wi th a hypo methylat ing agent [eg, azacit idine or decitabine], the 
hypo methylat ing therapy c an be counted as a line if there is disease progression to AML 
during or shortly [eg, wit hin 60 days] after the hypom ethylat ing therapy .)
4.Subject has the following disease status :
a.Refractory  to or relapsed after second -or thi rd-line of intensive therapy for AML 
(eg, the “7 + 3” regimen ):
at least5% leukemic blasts in bone marrow (the minimum number of treatment 
cycles of the intensive therap yis per the invest igator’s discretion );or
b.Refractory  to or relapsed after second -or thi rd-line low -intensity AML therapy
(eg,LDAC , azaci tidine or deci tabine) :
at least 5% leukemic blasts in bone marrow after at least [ADDRESS_539437] igator's assessment (Note: S ubjects with degenerat ive and toxic 
encephalopathies, especially after the use of methotrexate or treatment with ionizing 
radiation, should not receive cytarabine .)
6.Subject has Eastern Cooperative Onco logy Grou p (ECOG) performance status of 0, 1 or 
2 (Appendix D )
7.Subject has IDH2 gene mutations tested centrally (using the “invest igational use only” 
PCR assay, Abbott RealTime IDH2 ) insamples of bone marrow aspi[INVESTIGATOR_426788] , and confirmed posit ive in bone marrow aspi[INVESTIGATOR_6706]/or peripheral blood. (Note: in 
the event that the central laboratory  resul t is delayed and precl udes acute clinical 
management of a subject who has confirmed IDH2 gene mutationby [CONTACT_426837], the 
subject may be eligible for randomization wit h approval by [CONTACT_1689].)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
35 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539438] ion defined as:
Aspartate aminotransferase (AST)/ serum glutamic oxaloacetic transaminase (SGOT) 
and alanine aminotransferase (ALT)/serum glutamic py ruvic transaminase (SGPT)
≤ 3 x upper limit of normal (ULN), unless considered due to leukemic organ 
involvement , following review by [CONTACT_1689] ; and
Serum  total  bilirubin ≤ 1.[ADDRESS_539439], unless considered due to Gilbert’s syn drom e(eg, a 
gene mutati on in UGT1A1 )or leukemic organ involvement , following review by [CONTACT_426843]; and
Creatinine clearance 30 mL/min based on the Modificat ion of Diet in Renal Disease 
(MDRD ) glomerular fil tration rate (GFR):
GFR (mL/min/1.73 m2) = 175× (serum creat inine )-1.154× (Age)-0.203× (0.742 if 
female) × (1.212 if African American)
9.Females of childbearing potential (FCBP)*may participate, providing they  meet the 
following condit ions:
Agree to practice true abstinencefrom sexual int ercourse or to use highly effective 
contraceptive methods ( eg, combined [containing estrogen and progestogen] or 
progestogen -only associated wi th inhibit ion of ovulat ion, oral, injectable, 
intravaginal, patch, or implantable hormonal contraceptive; bilateral  tubal  occlusion; 
intra-uterine device; intrauterine horm one-releasing sy stem ; ormale partner 
sterilizat ion[note that v asectomiz ed partner i s a highly  effect ive birth control method 
provi ded that partner is the sole sexual partner of the F CBP tri al participant and that 
the vasectomiz ed partner has received med ical assessment of the surgical success ]) at 
screening and throughout the study , and for [ADDRESS_539440] study  
treatm ent([ADDRESS_539441] dose of cy tarabine); and
Have a negat ive serum β-subunit of human chorionic gonadotropin (β-hCG ) 
pregnancy test (sensit ivity of at least 25 mIU/mL) at screening; and
Have a negat ive serum or urine (investigator’s discretion under local regulat ions)
β-hCG pregnancy test (sensit ivity of at least 25 m IU/m L) within 72 hours prior to the 
start of study treatment inthe Treatment Phase (note that the screening serum  
pregnancy test can be used as the test prior to the start of study  treatment inthe 
Treatment Phase if it is performed wit hin the 72 -hour timeframe) .
10.Male subjects must agree to practice true abst inence **from sexual  intercourse or to the 
use of highly effect ive contraceptive method s (as described above )with non-pregnant 
                                                            
*A female of childbearing potential is a sexually mature woman who 1) has not undergone a hysterectomy (the 
surgical removal of the uterus) or bilate ral oophorectomy (the surgical removal of both ovaries) or 2) has not been 
naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at 
least 24 consecutive months (ie, has had menses at any time during the preceding 24 consecutive months).  
True abstinence is only accepted as a method of contraception when it is the preferred and usual lifestyle of the 
subject.  Periodic abstinence (calendar, symptothermal, post -ovulatio n methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method are not considered to be acceptable methods of 
contraception.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
36 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539442] study  treatm ent ([ADDRESS_539443] dose of 
cytarabine; [ADDRESS_539444] dose of azaci tidine in Canada)
11.Subject must understand and vo luntarily sign an ICF prior to any  study -related 
assessme nts/procedures being conducted
12.Subject is willing and able to adhere to the study  visit schedule and other protocol  
requi rements
4.3. Exclusion Criteria
The presence of any o f the following will exclude a subject from enrollment:
1.Subject is s uspected or proven to have acute promyelocyt ic leukemia based on 
morphol ogy, immunophenoty pe, m olecular assay , or kary otype (Appendix B )
2.Subject has AML secondary to chronic myelogenous leukemia (CM L; Appendix C )
3.Subject has received a targeted agent against an IDH2 mutation
4.Subject has received systemic ant icancer therapy  or radi otherapy  <14 day s prior to the 
start of study  treatm ent.  Note that hy droxyurea i s allowed prior to the start of study  
treatm ent for the control of leukocy tosis (however, hy droxyurea shoul d not be given 
within 72 hours pri or to and after administration of azacit idine).
5.Subject has received non-cytotoxi c or invest igational agents < [ADDRESS_539445] di sease (GVHD).  The use of a s table dose of oral  steroi d 
post-HSCT and/or topi[INVESTIGATOR_426789] .
7. Subject has persistent, clinically significant non- hematol ogic toxi cities from prior 
therapi [INVESTIGATOR_014]
8. Subject has or is suspected of having centra l nervous system (CNS) leukemia .  
Evaluat ion of cerebrospi[INVESTIGATOR_426790] .
9.Subject has a ctive uncontrolled systemic fungal, bacterial, or viral infect ion (defin ed as 
ongoing signs/symptoms related to the infect ion without improvement despi[INVESTIGATOR_426791], antiviral therapy, and/or other treatment )
10.Subject has immediately life -threatening, severe complicat ions of leukemia such as 
uncontrolled bleeding, pneumo nia wit h hypoxia or shock, and/or dissemi nated 
intravascular coagulat ion
11.Subject has significant active cardiac disease within 6 months prior to the start of study 
treatm ent, including [LOCATION_001] Heart Associat ion(NYHA) class III or IV congestive 
heart failure ( Appendix E ); acute coronary syndrome (ACS); and/or stroke ; orleft 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
37 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017ventri cular ej ection fraction (LVEF ) < 40% by [CONTACT_6751] (ECHO) or multi-gated 
acquisit ion (MUGA) scan obtained within [ADDRESS_539446] has been free of the disease for ≥ 1 y ear prior to the start of study  treatment.  
However, subjects with the fo llowing history /concurrent condi tions are allowed:
Basal or squamous cell carcino ma of the skin
Carcino ma in situ of  the cervix
Carcino ma in situ of  the breast
Incidental histologic finding o f prostate cancer ( T1a or T1b using the tumor, node, 
metastasis clinical staging system)
13.Subject is k nown seroposi tive or active infect ion wit h human immunodeficiency v irus 
(HIV), or acti ve infect ionwith hepatitis B v irus (HBV) o r hepatit is C v irus (HCV)
14.Subject is k nown to have dysphagia, short -gut syndrome, gastroparesis, or other 
condi tions that limit the ingest ion or gastrointestinal absorption of drugs administered 
orally
15.Subjects has uncontrolled hypertension (systolic blood pressure [BP] > 180 mmHg or 
diastolic BP > 100 mmHg)
16. Subject is a p regnant or l actating female
17. Subject hasknown or suspected to have hypersensitivit y to any  ofthe com ponents of 
study  treatm ent
18.Subject is taking thosemedications (listed i n Sect ion8.2) that are known to pr olong QT 
interval unless the subject can be transferred to other medications at least [ADDRESS_539447] hasQTc interval (ie, Fridericia’s correctio n [QTcF ]) ≥ 450 m sor other factors 
that increase the risk of QT prolongat ion or arrhy thmic events (eg, heart failure, 
hypokal emia, family  history  of long QT inter val syndro me)at screening
20.
Subject is taking the fo llowing sensit ive CYP substrate medications that have a narrow 
therapeuti c range are exc luded fro m the study  unless the subject can be transferred to 
other m edicati ons at least 5 half -lives prior to the start of study  treatm ent: paclitaxel and 
docetaxel (CYP2C8), phenyto in (CY P2C9), S -mephenyto in (CYP2C19), thioridazine 
(CYP2D6), theophylline ,and ti zanidine (CYP1A2)   
21. Subject is taking the breast cancer resistance protein (BCRP) transporter -sensit ive 
substrate rosuvastatin should be exc luded fro m the study  unless the subject can be 
transferred to other medicat ions at least [ADDRESS_539448] at unacceptable risk if he/she w ere to parti cipate in the study
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
38 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539449] has any  condi tion that confounds the abilit y to interpret data from  the study
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
39 AG-221-AML -004 Amendment 2.0 Final :30 Nov [ZIP_CODE]. TABLE OF EVENTS
Table 3: Table of Events
EventsScreening Phase Treatment Phase aFollow -up Phasea
Screening28-day cycles
EOTbFollow -upCycles 1 to 2 Cycles 3 to 4 Cycle 5 and 
beyond
Days -28 to -1 Day 1 Day 8 Day 15 Day 22 Day 1 Day 15 Day 1
Informed Consent c
IVRS Registration and Calls  d  
Inclusion & Exclusion Criteria  e, f
Demographics 
Initial AML Diagnosis 
Prior AML Therapi[INVESTIGATOR_014] 
AML Disease Status g
Central Testing of IDH2 Gene 
Mutation son BMA and PBg
Medical History 
Prior Medications and 
Proceduresh
Eligibility of CCR Options i
EORTC QLQ -C30 and 
EQ-ED-5L   
ECOG Performance Status     
Physical Exam j    
Vital Signs         
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
40 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 3: Table of Events (Continued)
EventsScreening Phase Treatment Phase aFollow -up Phasea
Screening28-day cycles
EOTbFollow -upCycles 1 to 2 Cycles 3 to 4 Cycle 5 and 
beyond
Day -28 to -1 Day 1 Day 8 Day 15 Day 22 Day 1 Day 15 Day 1
Height 
Body Weight     
BSA Calculationk   
ECHO lm As clinically indicated
12-Lead ECGl     
Pregnancy Test (FCBP only)nol, plll
Urinalysiso
As clinically indicated
Coagulation Laboratory o
Hematology Laboratory o         q
Chemistry Laboratoryo     
UGT1A1 Gene Mutation Test o
(for Diagnosis of Gilbert’s 
syndrome; refer to Section 4.2)
Cardiac Markers ofr
Fasting (preferred) Lipid Panelo s
Adverse Event Continuous starting after signing ICF until [ADDRESS_539450] study treatment or until the EOT visit, whichever is longer
Transfusions u
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
41 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 3: Table of Events (Continued )
EventsScreening Phase Treatment Phase aFollow -up Phasea
Screening28-day cycles
EOTbFollow -upCycles 1 to 2 Cycles 3 to 4 Cycle 5 and 
beyond
Day -28 to -1 Day 1 Day 8 Day 15 Day 22 Day 1 Day 15 Day 1
BMA for Assessing Disease 
Status /Response to Treatmentvgwxyzq
BMB ddgwxyzq
PB Smear gwxyzq
Cytogenetics Testing gw, eex, eey, eez, eeq, ee
Response and HI wxyzq
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
42 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 3: Table of Events (Continued)
EventsScreening Phase Treatment Phase aFollow -upPhasea
Screening28-day cycles
EOTbFollow -upCycles 1 to 2 Cycles 3 to 4 Cycle 5 and 
beyond
Day -28 to -1 Day 1 Day 8 Day 15 Day 22 Day 1 Day 15 Day 1
Treatment Accountabilityjjkk  
IP Dispensation   
Treatment Administration See Section 7.2for details
Survival Follow -up ll
Subsequent AML Therapi[INVESTIGATOR_014] / 
Response / Disease Status to 
Subsequent AML Therapi[INVESTIGATOR_426792] ll
Abbreviations: AML = acute myeloid l eukemia ; β-hCG = β -subunit of human chorionic gonadotropin; BMA = bone marrow aspi[INVESTIGATOR_337]; BMB = bone marrow 
biopsy; BSA = body surface area; CCR = conventional care regimen; CR = morphologic complete remission; CRi= mo rphologic complete remission with 
incomplete neutrophil recover y; CRp= morphologic complete remission with incomplete platelet recover y; ECHO = echo cardiogram; eCRF = electronic case 
report form; ECG = electrocardiogram ; ECOG = Eastern Cooperative Oncology Group; EORTC= European Orga nization for Research and Treatment of 
Cancer ; FCBP = female of childbearing potential; EOT = End of Treatment; HI = hematologic improvement; HRQoL = Health -related Quality of Life; 
HSCT = hematopoietic stem cell transplantation ; ICF = informed consent for m; IDH2 = isocitrate dehydrogenase isoform 2 ; IP = investigational product; 
IVRS = Inte ractive Voice Response System ; IWG =International Working Group;  PB=peripheral blood ; PD = progressive disease; 
SOC = standard of care; UGT1A1 =uridine diphosphate -glucuronosyltransf erase 1 family, polypeptide A1.
aStudy Treatment is to be initiated on Day 1 of each treatment cycle.  Onetreatment cycle (one month) is considered as 28 days (ie, 4 weeks).  Unless noted 
otherwise, a n administrativ e window of± 3daysis permitted for all subsequent visits after the start of study treatment in the Treatment P hase.  Day 1 of 
Cycles 2 and beyond may be delay ed from Day 28 of the prior cycle in order for subjects to recover from t oxicity and meet crite ria for initiating each treatment 
cycle ( Section 7.2).  The study visit window for EOT or monthly-scheduled survival follow -upis ± 7days.   
bSee Section 6.2.[ADDRESS_539451] should start study treatment (ie, Day 1 of Cycle 1) within [ADDRESS_539452] should continue to be eligible for study  entry  prior to the start of study treatment on Day 1 of Cycle 1.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
43 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539453] may be eligible for randomization with approval by [CONTACT_1689].
hAll prior medications (prescription and non -prescription) taken and treatment procedures received from the 4-week period (ie, 28days) prior to starti ng study  
treatment (i ncluding those prior to the start of study treatment on Day 1 of Cycle 1
),and all prior anticancer therapi[INVESTIGATOR_014], regardless of discontinuation date of 
treatment.
iDocumentation of CCR treatment option selected by [CONTACT_426844] .
jSource documented only.
kThe BSA calculation is per the Dubois & Dubois formula: BSA (m2) = weight (kg)0 425x height (cm)0 725/139.2.   Where applicable, t he dose should be 
calculated on Day 1 ofeach treatment cycle .
lThese assess ments will be done locally .
mThe screening ECHO does not need to be repeated i f a prior ECHO or multi-gated acquisition (MUGA) scan hasbeen performed within [ADDRESS_539454] is required for all FCBPs ( see Section 4.2forthe definition).  Serum β -hCG pregnancy test (sensitivity of at least 25 mIU/mL) will be performed
centrally  at screening.  For FCBP subjects, a local serum or urine ( investigator’s discretion under local regulations) β-hCGpregnancy test (sensitivity of at 
least 25 mIU/mL) is to be done within 72 hours prior to study treatment administration on Day 1 of ever y treatment cycle in the Treatment Phase and at the 
EOT visit.  N egative results are required for study treatment administratio n.
oThese assessments will be done centrally .  Fasting is recommended , particularly for subjects who experience clinical lymeaningful elevations of lipi[INVESTIGATOR_805] , per the 
investigator’s assessment .
pA local serum or urine ( investigator’s discretion under local regulations) pregnancy test (sensitivity of at least 25 mIU/mL) is to be done within 72 hours prior 
to the start of study  treatment inthe Treatment Phase for FCBP only (note that the screening central serum pregnancy test can be used as the test prior to the 
start of study  treatment in the Treatment Phase if it is performed within the 72 -hour timeframe).
qWhenever response /disea se status isassessed in the Follow -up P hase (ie, every 12 weeks [ ± 28 days]).  See Section 6.3for details.
rDay 1 (± 14days) of e very 3rdcycle (eg, Cy cles 3, 6, 9, etc )or more frequent lyper standard institutional practice. Not necess ary for the EOT visit if last 
performed within 1 4 days.
sDay 1 of Cy cle 3 and Day 1 (± 28days) of ever y 6thcycle (eg, Cycles 6, 12, 18, etc) or more frequent lyper standard institutional practice.   Not necessary for 
the EOT visit if last performed within 28 days .
uIncluding type, number of units, reasons and date of transfusions taken ≤ [ADDRESS_539455] .  
vIn addition to the frequency specified in the table, samples will also be collected if clinically indicated (eg, confirmation of CR/CRi/CRp , morphologic relapse 
after CR/CRi/CRp or PD by a repeated bo ne marrow assessment at least 1 month later ) or required for toxicity assessment .
wWithin 7 days prior to study treatment administration on Day 1 of Cycle 2.
xWithin 7 days prior to study treatment administration on Day 1 of Cycle 3.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
44 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017yWithin 7 days prior to study treatment administration on Day 1 of Cycle 5 and Day 1 of ever y 2ndcycle thereafter (eg, Cycles 7, 9, etc).
zNotnecessary for the EOT visit if last performed within [ADDRESS_539456] be collected if 
adequate aspi[INVESTIGATOR_291970] .
eeIfthebone marrow aspi[INVESTIGATOR_426793]/CRi/CRp, morphologic relapse after CR/CRi/CRp or PD, a sample of the bone marrow aspi[INVESTIGATOR_426794] (for sites without local analysis capability) for standard meta phase preparation and analysis of a minimum 
of 20 metaphase cells.  A bone marrow biopsy can be used for cytogenetics testing if adequate aspi[INVESTIGATOR_291970] (note that specific handling of the 
biopsy is required for cytogenetics testing).
jjIncluding diary cards , if utilized .  See Section 7.6for details.
kkCycle 2 only .
llEvery 4weeks (± 7days)for survival follow -up until death, lost to follow -up, withdrawal of consent for further data collection or the End of Trial, whichever 
occurs first.  Subsequent AML therapi[INVESTIGATOR_426795] -assessed response /disease status to subsequent AML therapi[INVESTIGATOR_426796] .  See Section 6.3for details.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
45 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539457] been obtained
:
Registration o f screening in IVRS
Inclusio n and exclusio n criteria
Dem ographics ( age, sex, race, and ethnicit y)
Inform ation supporting the init ial diagnosis of AMLby[CONTACT_426845] , including reports of bone marrow aspi[INVESTIGATOR_6706]/or biopsy , 
peripheral  blood sm ear, cytogeneti csand other tests if pert inent
Prior AML therapi [INVESTIGATOR_184597] , radi ation, systemic or any  other therapy  for 
the subject’s AML disease , particularly induction /re-induct ion/salvage
chemotherapi[INVESTIGATOR_014], consolidat ionor maintenance therapi [INVESTIGATOR_014], HSCT, low-intensity AML 
therapi [INVESTIGATOR_426797], decitabine or LDAC , or other m edicat ions considered 
supportive care for AML , regardl ess of di scont inuation date of treatment
Inform ation supporting CR/CRi/CRp attained during prior AML therapi[INVESTIGATOR_426798], incl uding reports of bone m arrow aspi[INVESTIGATOR_6706]/or 
biopsy, peripheral  blood sm ear, cyt ogenetics, and other pertinent tests
AML d isease status at screening determined by  [CONTACT_426846] .  Therefore, bone ma rrow 
aspi[INVESTIGATOR_337] (or bi opsy if adequate aspi[INVESTIGATOR_291970] )must be collected at 
screening so slides of bone marrow aspi[INVESTIGATOR_337] (and/or biopsy ) and peripheral  blood 
smear are available for both the local and the central  pathol ogy reviewers.   A bone 
marrow bi opsy  can be collected in conjunct ion with an aspi [INVESTIGATOR_426799] i t is standard 
institutional pract ice.  Whenever a bone marrow sample is collected, a peripheral
blood sm ear is to be prepared.  In addition, a sample ofthe screening bone m arrow 
aspi[INVESTIGATOR_426800]  (for sites wi thout 
local analysis capabilit y)for standard meta phase preparati on and analysis o f a 
minimum o f 20 metaphase cells .  A bone m arrow bi opsy can be used for cytogenet ics 
testing if adequate aspi[INVESTIGATOR_291970] (note that specific handling o f the biopsy 
is required for cy togeneti cs testing).
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
46 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017The retrospective central  review o f screening bone marrow a spi[INVESTIGATOR_26631]/or bi opsies, 
peripheral blood sm ears and cy togeneti cs will  be conducted by  [CONTACT_426847]. The central assessments will be used to confirm AML disease status 
at screening . If central review and l ocal review disagree on AML disease status of a 
subject at screening , a thi rd party reviewer will a djudi cate and make the final 
assessment.   If the subject was centrally confirmed to be ineligible for the study , the 
subject will be allowed to remain in the study , but will be excluded fro m the modified 
intent-to-treat ( mITT)populat ion (Secti on9.2.2 ).
Instructi ons for submissio n slides of bone m arrow aspi[INVESTIGATOR_337] (and/or biopsy) and 
peripheral  blood sm ear, and pertinent reports for central review are provi ded in the 
Study  Reference and /orStudy  Central  Laboratory  Manual .
Subject has IDH2 gene mutations tested centrally in samples of bone marrow aspi[INVESTIGATOR_426801] , and confirmed posit ive in bone marrow aspi[INVESTIGATOR_6706]/or
peripheral  blood . (Note: in the event that the central laboratory result is delayed and 
precl udes acute clinical management of a subject who has confirmed IDH2 gene 
mutati onby [CONTACT_426837], the subject may be eligible for randomizat ion with 
approval  by [CONTACT_386102].)  
The detecti on and identificat ion of IDH2 mutation s(if present) will be assessed by 
[CONTACT_426848]2 using a parti ally autom ated sy stem  entailing extracti on and 
amplificat ion of deoxy ribonucleic acid ( DNA )with specific primers and probes. The 
device (test) has been developed by [CONTACT_426849]. and is used to detect and 
ident ify IDH2 mutations in subjects’ bone marrow aspi[INVESTIGATOR_426802]. The co mmercial t est, which has been approved by  [CONTACT_8415], is equivalent to 
the invest igational test in the study . 
Refer to the Study  Reference and/or Study  Laboratory  Manual for sample collection, 
processing, storage, and shipment procedures .
Medical history including all relevant current medical condi tionsand medical 
condi tionsdiagnosed / occurri ng prior to screening
Prior medicat ions including those taken ≤ 28 days prior to the start of study  treatm ent
and all prior anticancer therapi[INVESTIGATOR_014] , regardl ess of discontinuat ion date of treatm ent
Prior procedures including thoseoccurri ng ≤ 28 days prior to the start of study  
treatm entand all prior ant i-cancer procedures, regardless of discont inuat ion date of 
treatm ent
Docum entati on of  the CCR treatm ent opti on selected by  [CONTACT_426850]
ECOG p erform ance status
Physical exami nation: information about the screening physical examinat ion must be 
present in the subject’s source documentation.  Significant findings must be included 
on the appropriate eCRF page .
Vital signs including temperature, blood pressure, pulse rate and respi [INVESTIGATOR_426803]
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
47 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Height (only collected once at screening)
Body  weight
Body  surface area (BSA) calculat ion per the Dubo is & Dubo is formula: 
BSA (m2) =weight (kg)0.425x height (cm)0.725/139.2
The fo llowing laboratory  assessments will be done locally :
-ECHO (notrequired if a prior ECHO or MUGA scan hasbeen performed 
within 28 days prior to the start of study  treatm ent)
-12-lead ECG will be assess ed by  a physician trained in ECG interpretation as 
norm al, abnorm al -not clinically significant, or abnormal -clinically 
significant .  Intervals including PR, QRS, QT and RR will be collected , 
as 
well as heart rate and rhy thm.  Abnorm al finding(s) will be report edon the 
appropriate eCRF page .  For a given subject, ECG interpretations should be 
conducted by  [CONTACT_426851] , 
with a consistent approach for the QT interval analysis (eg , pre-cordial leads 
and lead II) .
The fo llowing l
aboratory  assessments will be done centrally :
-Serum  β-hCG pregnancy test (sensit ivity of at least 25 m IU/mL) is required
for all FCBPs ( see Secti on4.2forthe definit ion)
-Urinalysis including examinat ion by a standard dipstick test for specific 
gravit y, glucose, ketones, blood, pH, and protein ,andmicroscopic analysis if 
indicated
-Coagulat ion test including prothrombin time (PT) with internat ional 
norm alized rati o (INR) and partial thrombopl astin time (PTT)
-Hem atology panel  including c omplete bl ood count (CBC) wi th different ial, 
including red blood cell (RBC) count, hemoglobin, hematocrit , mean 
corpuscular vo lume (MCV) , mean corpuscular hemoglo bin (MCH), mean 
corpus cular hemoglo bin concentration (MCHC), white blood cell ( WBC) 
count ( with different ial), abso lute neutrophil count (ANC) and platel et count
-Chemistry  panel including sodium, potas sium, calcium , magnesium, chloride, 
phosphorus, CO 2, bicarbonate, blood urea nitrogen (BUN), creatinine, 
glucose, albumin, total protein, alkaline phosphat ase (ALP) , bilirubin (total  
and direct), uric acid, lactate dehy drogenase (LDH ), AST/SGOT, ALT/SGPT , 
gamma glutamyl transpept idase (GGT), amylase and lipase
-UGT1A1 gene mutation testperformed on peripheral blood samples for 
diagnosis of Gilbert’s syndro me (refer to the inclusio n criterion regarding
serum  total  bilirubin in Section4.2)
Assessing AEs  start when the subject signs the ICF
Transfusio n history  including the type, number of units, reason, and date of
transfusio ns for the 8weeks prior to the start of study  treatm ent
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
48 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539458]’s source 
docum ents and appropr iate eCRF(s).
Randomization
Eligible subjects will be rando mized in a central IVRS in a 1:[ADDRESS_539459] igator.  Randomizat ion will be 
stratified by [CONTACT_426852] (y es versus no), primary refractory  (yesversus no), 
and prior allogeneic HSCT for AML (yes versus no ).  
The study  treatm ent shoul d be ini tiated within [ADDRESS_539460] should continue to be eligible for study entry prior to the start of study treatment on 
Day 1 of Cycle 1.  Study  Treatm ent is to be init iated on Day  1 of each treatm ent cy cle.  One 
treatm ent cycle (one month) is considered as 28 days (ie, 4 wee ks).  Unless noted otherwise , an 
administrative window of± 3daysis permitted for all subsequent visits after the start of study  
treatm ent in the Treatm ent Phase .  Day 1 of Cycles 2 and beyo ndmay be delayed fro m Day 28 
of the pri or cy cle in order for subjects to recover from t oxicity and m eet cri teria for ini tiating 
each treatm ent cy cle (see Secti on7.2for details).
The fo llowing evaluations will be performed during study  treatm ent at the frequency  specified in
the Tabl e of Events ,Table 3, or more frequent lyif clinically indicated. The evaluat ions should 
be perform ed pri or to dosing on scheduled clinical visit day , unless otherwi se specified .  
For 
each evaluation, the same parameters as required at screening or on Day 1 of Cycle 1 shoul d be 
evaluated.
Registratio n of the start of each treatment cy cle in IVRS (where applicable)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
49 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017HRQoL ( EORTC QLQ -C30 and EQ -ED-5L questionnaires ; Sect ion 6.9)
Treatment accountabilit y(where applicable; also refer to Secti on7.5)
ECOG performance status
Physical examinat ion, vital signs and body  weight .  Significant findings are to be 
reported on the appropriate eCRF page .
Body  surface area calculat ion.  Where applicable, the dose shoul d be calculated on 
Day 1 of each treatm ent cy cle.
The fo llowing laboratory  assessments will be done locally :
-ECHO i f clinically  indicated
-12-lead ECG .  Abnorm al finding(s) will be report edon the appropriate eCRF
page .
-A serum  or urine ( invest igator’s discret ion under local regulations) β -hCG 
pregnancy test (sensit ivity of at least 25 m IU/mL) is to be done within 
72hours prior to study  treatm ent administration on Day 1of each treatm ent 
cycle (for FCBPs only; note that th e central serum  pregnancy test at screening 
can be used as the test prior to the start of study  treatment in the Treatm ent
Phase if it is performed wit hin the 72 -hour timeframe).  The subject may  not 
receive study  treatm ent unt il the invest igator has verif ied that the result of the 
pregnancy test is negat ive.
The fo llowing laboratory  assessments will be done centrally :
-Urinalysis and /orcoagulation test if clinically  indicated
-Hem atology panel
-Chemistry  panel
-Cardi ac marker troponin I
-Fasting(pref erred) lipid panel including total cholesterol, low -densit y 
lipoprotein cho lesterol (LDL -C), hi gh-densit y lipoprotein cho lesterol  (HDL -
C), tri glyceri des.  Fast ing is recommended , parti cularly for subjects who 
experience clinical lymeaningful elevat ions of lipi[INVESTIGATOR_805] , per the invest igator’s 
assessment .
Continuous evaluations of AEs,  conco mitant 
medicat ions and procedures, and transfusio ns
Bone m arrow aspi [INVESTIGATOR_337] (or bi opsy  if adequate aspi[INVESTIGATOR_291970]) samples will 
be collected for assessing response during study  treatm ent.  As specified in the Table 
of Events ,Table 3, the frequency  is within 7days pri or to study treatment 
administration on Cycles 2 and 3, every 2ndcycle thereafter (eg, Cycles 5, 7, 9, etc), 
and if clinically  indicated (eg, confirmation of CR/CRi/CRp, morpho logic relapse 
after CR/CRi /CRp or PD by a repeated bo ne marrow assessment at least 1 mont
h 
later) or required for toxicit y assessment .  A bone marrow biopsy can be collected in 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
50 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539461] ice or if clinical 
indicated (eg, evaluat ion of bone marrow cellularit y).  Whenever a bone marrow 
sample i s collected, a peri pheral blood sm ear is to be prepared.   In addit ion, whenever 
a bone marrow aspi[INVESTIGATOR_426793]/CRi/CRp, morphologic relapse 
after CR/CRi /CRp or PD, a sam ple of the bone marrow aspi[INVESTIGATOR_426804]  (for sites wi thout local analysis capabilit y)for 
standard m etaphase preparation and analysis of a minimum o f 20 metaphase cells.  A 
bone marrow bi opsy  can be used for cytogeneti cs testing if adequate aspi[INVESTIGATOR_291965] (note that specific handling o f the biopsy is required for cy togenetics 
testing ).  Bone marrow aspi[INVESTIGATOR_6706]/or biopsy , peripheral  blood sm ear and 
cytogeneti cs collected after the start of study  treatment for response assessment must 
be available for both local and central  review .  Instructions for submissio n slides of 
bone marrow aspi[INVESTIGATOR_337] (and/or biopsy) and periphera l blood smear, and pertinent 
reports for central review are provided in the Study  Reference and Study  Central  
Laboratory  Manual s
Response to treatment and HI will be assessed whenever bone marrow samples are 
collected for response assessment (see above)
 
Treatment dispensing and administration (where applicable; refer to Section 7)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
51 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539462] recent 
screening results prior to the start of study  treatm ent on Day  1 of Cycle 1 will be considered the 
baseline values.   Transfusio ns history  includes the type, number of unit s, reason, and date of
transfusio ns for the 8weeks prior to the start of study  treatm enton Day  1 of Cycle 1 .  
EORTC 
QLQ -30and EQ - 5 D are to be completed prior to the start of study  treatm ent on Day  1 of Cycle 1
and prior to i nteracti on wi th study  personnel.
6.2.2. Unscheduled Visits
Shoul d it becom e necessary  to repea t an evaluat ion (eg,laboratory  tests or ECG ), the results of 
the repeat evaluation sshoul d be entered as appropriate in additional unscheduled visit page sof 
the eCRF.
6.2.3. End of Treatment
An EOT evaluation willbe perform ed for subjects who are withdrawn fro m study  treatm ent for 
any reason as soon as possible after the decision to permanently disco ntinue study  treatment has 
been made.  A n administrative window of ± [ADDRESS_539463] is discont inued during a regularly -scheduled visit, all EOT evaluat ions 
shoul d be completed at that visit.
The fo llowing evaluations will be performed as specified in the Table of Events ,Table 3.  For 
each evaluation, the same param eters as requi red at screening or on Day  1 of Cycle 1 shoul d be 
evaluated.
Registration o f treatm ent discont inuat ion in IVRS
HRQoL (EORTC QLQ -C30 and EQ -ED- 5L questionnaires )
Treatment accountabilit y (where applicable; refer to Secti on7.5)
ECOG performance status 
Physical examinat ion, vit al signs and body  weight .  Significant findings are to be 
reported on the appropriate eCRF page.
The fo llowing l
aboratory  assessments will b e done locally :
-ECHO if clinically indicated
-12-lead ECG
-Aserum  or urine ( invest igator’s discret ionunder local regulations) β -hCG 
pregnancy test (sensit ivity of at least 25 m IU/mL) (for FBCPs only )
The fo llowing l
aboratory  assessments will be done centrally :
-Urinalysis and/orcoagulation test if clinically indicated
-Hem atology panel
-Chemistry  panel
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
52 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017-Cardiac marker (notnecessary for the EOT visit if itwas last performed 
within 14 days unless clinically indicated )
-Fasting (pref erred) lipid panel ( not necessary  for the EOT visi t if itwas last 
perform ed wi thin 28 days unless clinically indicated )
Evaluat ions of AEs,  concomitant medicat ions, 
concomitant procedures and transfusio ns (monitored through [ADDRESS_539464] 
study  treatm ent or until the EOT visit, whichever is longer)
Bone marrow aspi[INVESTIGATOR_6706]/or biopsy, peripheral blood sm earand, ifapplicable, 
cytogeneti cs, for response assessment (
not necessary  for the EOT visit if itwas l ast 
perform ed wi thin 28days unless clinically indicated )
Response to treatment and HI will be assessed if bone m arrow samples are collected 
for assessing response at the EOT visit (see above)
6.3. Follow -up P hase
All subjects di scont inued fro m study  treatm ent for any reason other than withdrawal of consent 
for follow-
upwill continue to have the fo llowing ass essments in the Follow -up Phase :
AEs,  conco mitant medi cations, concomitant 
procedures and transfusio ns for 28days after the last study  treatment or the EOT
visit, whichever is lo nger.  
Thereafter, SAEs made known to the invest igator at any  time that are suspected of 
being related to study  treatm ent, as described in Secti on10.1.  
Transfusio ns will continue to be collected until the
initat ion of the first subsequent AML therapy after di scont inuat ion from study  
treatm ent, death, lost to fo llow-up, wi thdrawal of consent for further data collect ion, 
or the End of Trial, whichever o ccurs first .
Bone marrow aspi[INVESTIGATOR_6706]/or biopsy, peripheral blood sm earand, if applicable, 
cytogeneti cs,available for both local and central  review for assessing response or 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
53 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017disease status, every 12weeks (± 28days) ormore frequent if clinically indicated
until PD, the initation of  the first subsequent AML therapy after discont inuat ion of 
study  treatm ent, death, lost to follow- up, withdrawal  of consent for further data 
collect ion, or the End of Trial, whichever occurs first .  
Response/disease status and HIwillbe assessed whenever bone marrow samples are 
collected for assessing response or disease status (see above)
Survival follow-up every  4 weeks (± 7 days )until death, lost to fo llow-up, 
withdrawal  of consent for further data collect ion, or the End of Trial, whichever 
occurs first.  Subsequent AML therapi[INVESTIGATOR_426805]-up.
Invest igator -assessed response / disease status to subsequent AML the rapi[INVESTIGATOR_426806]
. Specifically, the best response to a subsequent AML therapy  and the first 
date achieving the best response, and progressive disease /relapse date during or after 
a respective subsequent AML therapy  shoul d be reported.  
Survival fo llow-up, s ubsequent AML therapi[INVESTIGATOR_014] , and response / disease status to 
subsequent AML therapi[INVESTIGATOR_426807] (including public 
records) and/or telephone contact [CONTACT_1155], family, or the subject’s treating 
physician .
Females of chil dbearing potential shoul d avoi d becoming pregnant for [ADDRESS_539465] study  treatm ent([ADDRESS_539466] dose of cy tarabine) , and male subjects 
and their partners shoul d avo id concept ionfor [ADDRESS_539467] study  treatm ent
([ADDRESS_539468] dose of cy tarabine; [ADDRESS_539469] dose of azacit idine
in Canada ).
6.4. Safety Assessment
Safety assessments include physical  examinat ion, vital signs, ECG, hem atology, serum  
chemistry , cardi ac marker s, fasting(pref erred) lipid pa nel, pregnancy  testing (for FCBP subjects 
only), AEs, concomitant medications and procedures, and transfusions , will  be perform ed at the 
frequency  specified in Table 3or more frequent lyif clinically indicated.   After screening, 
ECHO, urinalysis and coagulat ion will be performed if clinically indicated .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
54 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539470] igator Notificat ions.  Refer to United Kingdo m ([LOCATION_006]) 
Summary  of Product Characteristics (SmPC) for i nform ationabout commo n side effects already 
known about cytarabine.  This informat ion about commo n side effects will als o be included in 
the subject ICF and should be discussed with the subject as needed during the study .
6.4.2. U rinal ysis, C oagulation , Hema tology, Serum C hemistry, Cardiac Markers and
Fasting (Preferred) Lipid Panel
All samples should be sent to the central laboratory.  In the event that an immediate laboratory 
assessment i s requi red to acutely manage a subject (eg, monitoring ALT increases of ≥ [ADDRESS_539471]; 
Appendix P ), local laboratory  tests m ay be used.  In addition to collecting the local laboratory  
sample, a second sample should be collected and sent to the central  laboratory .
Refer to Section 10.[ADDRESS_539472] 
resul ts consti tute an AE .
6.5. Efficacy Assessment
6.5.1. Disease Status or Response to Study Treatment
Bone m arrow aspi [INVESTIGATOR_337] (or biopsy if adequate aspi[INVESTIGATOR_291970]) samples will be collected 
for assessing disease status orresponse to study  treatm ent at the frequency specified in Table [ADDRESS_539473] iceor if clinical indicated (eg, evaluat ion of bone marrow cellularit y).  
Wheneve r a bone m arrow sam ple is collected, a periphera lblood sm ear is to be prepared.   
In addit ion, whenever a bone marrow aspi[INVESTIGATOR_426793]/CRi/CRp , 
morphol ogic relapse after CR/CRi /CRp or PD, a sam ple ofthe bone m arrow aspi[INVESTIGATOR_337] i s to be sent 
to the local or central  cytogenetics laboratory  (for sites wi thout local analysis capabilit y)for 
standard m etaphase preparation and analysis of a minimum o f [ADDRESS_539474] ingif adequate aspi[INVESTIGATOR_291970] (note 
that specific handli ng of  the bi opsy  is required for cy togeneti cs testing ).  
Bone m arrow aspi[INVESTIGATOR_6706]/ or biopsy , peri pheral blood sm ear and cy togeneti cs collected 
throughout study must be available for both local and central  review .  A retrospective central 
review of all bone marrow aspir ates and/or bi opsies, peripheral blood smears and cy togeneti cs 
collected throughout study will be conducted by  [CONTACT_426853].  The 
central  cytogeneti c review will provide standardized analysis and reporting for all subjects, 
regardl ess of the l aboratory  performing th e initial analysis (local or central).  The central 
assessments will be used in the statist ical analyses .  Disagreement between central and local 
assessments will be adjudicated by a third party  reviewer and t headjudicated assessment will be 
used in the statist ical analyses .
Response to studytreatm ent will be assessed by [CONTACT_426854] a 
blinded IRAC according to modified IWG AML response criteria (Appendix F ) through 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
55 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539475] ion of central hematol ogy parameters , central assessments of bone marrow aspir ates 
and/or biopsies, peripheral blood sm ears and cy togeneti cs, and results of other pertinent tests.
Instructi ons for submissio n slides of bone m arrow aspi[INVESTIGATOR_337] (and/or biopsy )and peripheral  blood 
smear, and pertinent re ports for central review are provi dedin the Study  Reference and Study  
Central  Laboratory  Manual s.
In addit ion, investigator -assessed response/ disease status to subsequent AML therapi[INVESTIGATOR_188130] (see the details in Section6.3). 
6.5.2. Hematologic Improvement
Hem atologic improvement will be assessed by [CONTACT_426855] a blinded
IRAC according to IWG MDS HI criteria (Appendix H ) through collect ion of transfusio n 
records and central hematol ogy param eters .
6.5.3. Survival
Refer to Section 6.3forsurvival follow-up.
 
 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
56 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539476] ionnaire (EORTC QLQ -C30) and EuroQoL Group EQ -5D, will be used for HRQoL.  
The EORTC QLQ -30 (Aaronson, 1993
) is avalidated quali ty of life measure applicable to 
subjects wi th any cancer diagnosis.  It is co mposed of [ADDRESS_539477] com pletes all assessments of EORTC QLQ -30and EQ - 5 D at 
every specified time po int, prior to dosing and prior to i nteracti on wi th study  personnel, to 
minimize the amount of missing data .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
57 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
58 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539478](s)
7.1.1. AG-[ADDRESS_539479] ( IP)for 
this study .
Celgene Corporati on will supply  AG-221 50-, 100-, 150- and200-mg free-base equivalent 
strength tablets for oral  administrati on.  Each tablet is formulated using excipi[INVESTIGATOR_426808] .
All tablets will be packaged in high de nsity polyethylene (HDPE) bottles wit h a d esiccant (silica 
gel) canister and child resistant closures wit h heat induct ion seal .  All  tablets shoul d be 
swallowed who le, and should not be broken or chewed.
Bottl es of  AG-[ADDRESS_539480] (NIP) may have cytarabine sourced locally by [CONTACT_977].  
Subjects rando mized to LDAC treatment a nd located i n countries where LDAC is designated as 
IP willhave cytarabine supplied a nd packaged by  [CONTACT_426856].  
Please refer to the [LOCATION_006] Sm PCfor more details on available formulat ions, preparation of SC 
cytarabine , storage condi tions (eg, refrigeration), the approved indicat ions, known precautions, 
warnings, and ad verse reactions of cytarabine .
7.1.4. Intermediate -dose Cytarabine
Subjects rando mized to IDAC treatment a nd located i n countries where I DAC is designated as 
NIP may have cytarabine sourced locally by [CONTACT_977].  Subjects randomized to IDAC 
treatm ent a nd located i n countries where I DAC is designated as IP willhave cytarabine supplied 
and packaged by  [CONTACT_426856].
Please refer to the [LOCATION_006] Sm PC for moredetails on available formulat ions, preparation of IV 
cytarabine , storage condi tions (eg, refrigeration), the approved indicat ions, known precautions, 
warnings, and ad verse reactions of cytarabine .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
59 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539481] Supportive Care Only
Refer to Section 8for details regarding BSC .Please refer to local prescribing information and 
local therapeut ic guidelines for more details on available formulat ions, preparation, storage 
condi tions (eg, refrigeration), the approved indicat ions, known precautions, warnings, and 
adverse reactions of BSC (see the current version of prescribing i nformat ion).
7.2. Treatment Administration and Schedule
Study  treatm ent is to be init iated on Day  [ADDRESS_539482] been co mpleted and all 
doses of study  treatm ent from the prior treatm ent cycle are accounted for (where applicable).  
For FCBP subjects, a serum  or urine ( investigator’s discret ion under local regul ations) β -hCG 
pregnancy test (sensit ivity of atleast 25 mIU/mL) must be performed within 72 hours prior to 
study  treatm entadministration on Day 1 of each treatment cy cleand verified negative .
No crossover between any  of the treatm ent options, including the CCR treatment options, will be 
permitted during the course of study  treatm ent. Any AML therapy other than the study -
prescribed treatment isprohibited during the course of study  treatment .
S
ubjects will be monitored fo r hem atologic toxi city and non -hematol ogictoxicity with the 
National Cancer Institute (NCI)Commo n Termino logy Criteria for Adverse Events 
(CTCAE, Versi on 4.0 3) used as a guide f or the grading of severit y.  Dosing interruptions or 
delays, or dose m odificati onsmay occur for managing toxi cities and/or augmenting treatm ent 
response during study  treatm ent.
Overdose , as defined for this protocol, refers to AG -221, azacit idine andcytarabine dosing only .
On a per dose basis, an overdose is defined as the following amount over the protocol -specif ied 
dose of AG -221, azacit idine andcytarabine assigned to a given subject , regardl ess of any 
associ ated adverse events or sequelae .
PO:any amount over the protocol -specified dose
IV: 10% over the protocol -specified dose 
SC:10% over the protocol -specified dose
On a schedule or frequency  basis, an overdose i s defined as any thing more frequent than the 
protocol  requi red schedule or frequency .
Com plete data about drug administration, including any  overdose, regardl ess of whether the 
overdose was accident al or intent ional, shoul d be reported in the eCRF .  See Section 10for the 
reporting of AEs associ ated wi th overdose.
Subjects can cont inue to recei ve study treatm ent pro vided that they benefit fro m study treatm ent 
and all protocol -specified criteria for continuing study treatm entare m et.  Study  treatm ent will
be discont inued if the invest igator has alternat ive therapi[INVESTIGATOR_014] ( eg, HSCT ) and /or considers study  
treatm ent to be no l onger beneficial to the subject, or the rapi[INVESTIGATOR_193107] y of change o f disease state 
renders it unacceptable for further study  treatm ent in the judgment of the investigator .  
Refer to Section 11.[ADDRESS_539483] 
from study  treatm ent.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
60 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539484] 6 cycles or as 
long as subjects continue to benefit fro m the treatment until the End of Trial. Subjects m ay be 
discontinued fro m the treatm ent for any  of the reasons detailed in Section11.1.
[IP_ADDRESS]. Dispensation and Administration of AG -[ADDRESS_539485] (subjects should be instructed to return 
any tablet not totally intact to the clinic ).    
Subjects should be instructed to take their daily dose at approx imately the same t ime each day .  
Each dose should be taken with a glass of water and consumed ov er as short a time as possible.  
Subjects should be instructed to swallow tablets who le and to not chew the tablets .  
All efforts shoul d be made to administer AG- [ADDRESS_539486] sho uld continue wi th the dosing schedule on the next day  and 
inform  the investi gator about the vomitingevent at the next visit.
[IP_ADDRESS]. Dose Modification s for AG -[ADDRESS_539487] the Medical Monitor for guidance on AG -221 dose m odificati on, 
if needed .
Dose modification due to toxicities
If a certain level of toxicit y (eg, Secti on7.2.1.3 )is observed after init iation of AG-[ADDRESS_539488] who is unable to tolerate 50 m g QD 
of AG-221 shoul d be discontinued fro m study treatment .
If treatm ent is modified during the course of the study  and benefit is demonstrated with a 
reduced l evel of dose , then that dose level should be maintained during the subsequent treatm ent 
cycles that are given unless toxicit y develops.  However, once reduced, if there is a need for 
augmenting treatment response as de fined below , the AG-221 dose m ay be subseq uently 
re-escalated back to the starting dose (ie, 100 mgQD), provided that the starting dose is tolerable.
  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
61 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Dose escalation for augmenting treatment responses
The AG -221 dose for the subsequent treatment cy cles that are given may be increased from 
100mg QD to 200 mg QD if the fo llowing occurs :
ANC < 0. 5 x 109/L after being on AG-[ADDRESS_539489] cyclewithout ≥Grade [ADDRESS_539490] igator to be related to AG -221; or
no partial remissio n (PR)achieved after being on AG -[ADDRESS_539491] 2 cycles without 
≥Grade [ADDRESS_539492] igator to be related to AG -221; or
evidence of morpho logic relapse or PD
If benefit is demo nstrated with a nincreased level of do se, then that dose level shoul d be 
maintained during the subsequent treatm entcycles that are given.  However, once increase d, the 
AG-221 dose may  be reduced if a certain level o f toxicity(eg, Secti on7.2.1.3 )is observed and 
considered as possibly  or probably related to AG -[ADDRESS_539493] who is 
unable to tolerate 50 m g QD of AG -221 shoul d be di scontinued fro m study treatm ent.
[IP_ADDRESS]. Reference Toxicities During AG -221 Treatment
Hematologic toxicities
Hem atologic toxici ties incl ude clinically significant hematologic toxicit ies of cytopenia (> 50% 
decrease fro m baseline [ defined in Section6.2.1 ])and/or marrow cellularit y <5% on Day  28 or 
later from the start of AG -221 treatm ent in a treatment cy cle without evi dence of leukemia .
Non-hematologic toxicities
Non-hematol ogic toxi cities include a ll clinically significant non -hematol ogic toxi cities of 
≥Grade 3 with the exception of ≥Grade 3blood bilirubin increases in s ubjects wi th a UGT1A1 
mutati on.  In subjects with a UGT1A1 mutation, blood bilirubin increases o f > 5 × ULN may be 
considered clinically significant .
QT P rolongati on
Subjects who experience prolongat ion of the h eartrate-corrected QT interval , Fridericia’s
correcti on(QTcF) to > 480 msec ( Grade ≥2) while treated with AG -221, shoul d be prom ptly 
evaluated for causalit y of the QTc prol ongat ionand managed according to the fo llowing 
guidelines:
Levels of electroly tes (potassi um, calcium  and magnesium ) shoul d be checked and 
supplementati on given to correct any  values outsi de the norm al range.
Concomitant therapi[INVESTIGATOR_426809].
If no other cause is ident ified and the investigator b elieves i t is appropri ate, 
particularly if QTc remains elevated (after above measures have been implemented, 
or as determined by  [CONTACT_3170]), AG-221 treatm entmay be interrupted, and an 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
62 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539494] weekly (eg , at every  scheduled visit) for 2 weeks following 
QTc reduction ≤480 m sec.
-If Grade 2 (QTcF > 480 and ≤ 500 msec) , the dose of AG -221 m ay be reduced 
without interruption of dosing. The AG -221 dose may be re -escalated to the 
prior dose in ≥14 day s after QT prol ongati on has decreased to ≤ Grade 1.
If this is the second occurrence of QT prolongat ion, administration of 
AG-221 shoul d continue at a reduced dose ( ie,the dose may not be re -
escalated) .
-If Grade 3 (QTcF > 500 m sec), hospi[INVESTIGATOR_426810] a cardi ologist shoul d both be considered.   
Dosing wit h AG -221 will be interrupted. If QTc returns to within 30 msec of 
baseline or < 450 m sec wit hin 14 days, treatment may be resumed at a 
reduced dose .  The AG -221 dose cannot be re -escalated fo llowing dose 
reducti on for Grade 3 QTcF prolongat ion unless the prolongat ion was 
associ ated wi th an electroly te abnorm ality or conco mitant m edicati on.
-If Grade 4 (QTcF > 500 m sec or > 60 msec change fro m baseline with torsade 
de pointes or polymorphic ventricular tachy cardia or si gns/symptom s of 
serious arrhy thmia) , subjects shoul d be admitted to the hospi [INVESTIGATOR_426811] m onitoring and di scharged only after review by  a cardi ologist.   Dosing 
with AG-[ADDRESS_539495] s treated with AG-221 ( enasidenib )have experienced symptoms of different iation 
syndro me, which can be fatal if not treated. Symptoms may include fever, dy spnea, acute 
respi [INVESTIGATOR_36645], pulmo nary infiltrates, pl eural  or peri cardial  effusi ons, rapi d weight gain or 
peripheral  edema, lymp haden opathy , bone pain, and hepat ic or renal  dysfunct ion. If 
different iation syndrome is suspected, init iate corticosteroid therapy and hemodynamic 
monitoring until symptom reso lution.
If different iation syndrome is suspected, init iate oral or intravenous corticosteroids (eg, 
dexamethasone 10 mg every 12 hours) and hemodynamic mo nitoring unt il improvement.  Taper 
corticosteroi ds only  after resol ution of symptoms.  Symptoms of different iation syndro me may 
recur with premature discont inuat ion of corticosteroi d treatm ent.  If severe pulmo nary symptom s 
requi ring intubation or ventilator support, and/or renal dysfunct ion persist for more than 48 hours 
after ini tiation of corticosteroids, interrupt enasidenib unt il signs and symptoms are no longer 
severe.  Hospi[INVESTIGATOR_426812] m onitoring of pat ients with pulm onary and/or 
renal manifestation is reco mmended. Enasidenib can be resumed when signs and symptoms 
improve to Grade 2 or lower.
Further informat ion on diagnosis and treatm ent of IDH differe ntiation s yndro me can be found in 
the current version of IDH different iation syndrome guidance docum ents. 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
63 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539496] ious leukocy tosis (defined as WBC greater than 
30x 109/L) pri or to the init iation o f enasidenib and monitored at a minimum of every [ADDRESS_539497] ices. Interrupt 
enasidenib if leukocy tosis is not improved with hydroxy urea, and then resume enasi denib at 
100mg daily when WBC is less than 30 x 109/L. 
Tumor Lysis Syndrom e
Subject s with hematol ogic malignancies treated with enasidenib may  experi ence tum or lysis 
syndro me.  Manage any abnormalit ies prom ptly.  If enasidenib -related toxicity is Grade 3 or 
more,interrupt enasidenib until toxicit y resolves.
Gastrointestinal Disorders
Appropriate monitoring and management of GI disorders, such as diarrhea, nausea, and 
vomiting, is requi red.
Elevated Serum Bilirubin
Hyperbili rubinemia is induced by [CONTACT_426857]1A1, the enzyme responsible for 
the metabo lism o f bilirubin (a condit ion similar to Gilbert’s syndrome). 
Patients wi th Gilbert ’ssyndrome genoty pe treated wi th enasidenib experienced earlier onset of 
bilirubin elevat ion following treatm ent init iation, as compared to patients with normal UGT1A1 
genotype.  Wi th continuing treatment, maximum severit y of bilirubin elevation was similar in 
patients wi th Gilbert ’ssyndro me and pat ients with norm al UGT1A1 genoty pe. Reference 
toxicities of hyper bilirubin emia during AG -221 treatm ent is described in Section [IP_ADDRESS] , and
dose m odificat ion due to hyper bilirubin emia Sect ion7.2.1.2 . 
[IP_ADDRESS]. Initiation of Eac h AG -[ADDRESS_539498] ion prior to starting each AG -221 treatm entcycle (including Cycle 1).
In order to proceed to the next AG -[ADDRESS_539499] recovery  of 
hematol o
gic and non-hematol ogic toxi cities (seeSecti on [IP_ADDRESS] ).  If the subject does not meet 
these cri teria, the start of the next cycle will be delay ed, BSC init iated and the subject evaluated 
regul arly per standard inst itutional pract iceand as deem ed necessary by [CONTACT_3170] .  If there 
is a delay  of more than 2 8 day s (ie, 4weeks) in the start of the next AG -221 treatment cy cle, the
Medical Monitor should be consulted forthe risks and benefits of continuing AG -221 treatm ent.  
Subjects who experience persistent Grade ≥[ADDRESS_539500] is experiencing clinical benefit fro m AG-221 treatm ent.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
64 AG-221-AML -004 Amendment 2.0 Final :30 Nov [ZIP_CODE].2.2. Azacitidine Treatment
Subjects rando mized t otheazacit idine treatment option will receive continuous 28- day cycles of 
azacit idine 75 m g/m2/day SCfor 7days until the End of Trial, unless they  are discont inued fro m 
the study  treatm ent for any  of the reasons detailed in Secti on11.1.  In addit ion, subjects may 
receive BSC per standard inst itutional pract iceand as deem ed necessary by [CONTACT_3170] .  In 
the event 2 or few erdoses are missed (eg, ski ppi[INVESTIGATOR_426813]), dosing shoul d continue so the subject receives the full [ADDRESS_539501] the Medical Monitor and a decisio n on dosing 
will be made on a case -by-case basis. The dose of azacit idine shoul d be calculated on Day  1 of 
each treatment cy cle.  The dose during a treatment cy cle should not be am ended.
[IP_ADDRESS]. Dose Modifications for Azacitidine
The first treatm entcycle of azacit idine should always be given at 100% of the dose, ie, 75 mg/m2
SC, regardl ess of the subject’s laboratory  values (provi ded that the subject is allowed to enroll in 
the study  based on the inclusio n and exclusio n criteria).  
Subjects sh ouldbe monitored for hem atologic toxici ty and renal toxicit y; a delay in starting the 
next treatm ent cycle or dose reduction as describe d bel ow m ay be necessary .  If the dose of 
azacit idine is modified during the course of the study  (see bel ow) and benefit is demonstrated at 
a dose l ower than 75 mg/m2, that dose should be maintained during subsequent cy cles that are 
given (unless toxicit y devel ops).  The i nvestigator should contact [CONTACT_426858], if needed.
Azacitidine dose modifications due to nonhematological toxicity
Following recei pt of  any dose of azacit idine, subsequent treatm ent cycles m ay be delayed if a 
certain level o f toxicity occurs after the previous dose.  Any subject who experiences a non -
hemat ologi cal AE of Grade 3 or 4 that is an escala tion from his or her status at b aseline (defined 
in Secti on6.2.1 )should have azacit idine tem porarily  discontinued unt il the toxicit y grade returns 
to less than Grade 3.  Azacit idine shoul d be permanent ly discont inued if the non -hematol ogical 
toxicity pers ists as Grade [ADDRESS_539502] 2 cy cles.  Com plete bl ood counts shoul d be perform ed as specified in
Table 3and as needed to monitor response and toxicit y.
Recovery  is defined as an increase of cell line(s) where hematological toxicit y was observed of 
at least half o f the difference of nadir and the baseline count plus the nadir count (ie, blood coun t 
at recovery  ≥ Nadir Count + (0.5 x [Baseline count –Nadir count]).
Subjects with out reduced baseline blood counts (ie, WBC ≥3.0 x 109/L, 
ANC ≥1.5 x 109/L, and platelets ≥75.0 x 109/L) prior to the first treatment
If hematol ogical toxicity is observed fo llowing azaci tidine treatm ent, the next cy cle of 
azacit idine therapy shoul d be delayed unt il the platelet count and the ANC have recovered.  If 
recovery  is achieved within 14 days, no dose adjustment is necessary .  However, if recovery has 
not been achieved within 14 days, the dose should be reduced according to the follow ing table.  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
65 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Following dose m odificat ions, the cy cle durati on shoul d return to 28 days.  The reduced dose 
shoul d be maintained during subsequent cy cles that are given (unless toxicit y devel ops).  A fl ow 
diagram  for the determinati on of  azaci tidine dose adj ustment in subjects without reduced 
baseline blood counts is provided in Appendix L.
Nadir Counts% Dose in the next course if 
recoveryais not achieved in next 14 
days
Absolute Neutrophil Count (x109/L) 
≤ 1.0
> 1.0Platelets (x109/L) 
≤ 50.0
> 50.050%
100%
aRecover y = counts ≥ nadir count + (0.5 x [baseline count –nadir count])
Subjects with reduced baseline blood counts (ie, WBC count < 3.0 x 109/L or 
ANC <1.5x 109/L or platelets < 75.0 x 109/L) prior to the first treatment
Following azacit idine treatm ent, if the decrease in WBC or ANC or platelets fro m that pri or to 
treatm ent is l ess than 50%, or greater than 50% but with an improvement in any cell line 
different iation, the next cy cle shoul d not be del ayed and no d ose adjust ment made.
If the decrease in WBC or ANC or platelets is greater than 50% from that prior to treatment, with 
noimprovement in cell line different iation, the next cy cle of azacit idine therapy  shoul d be 
delayed unt il the platel et count and the ANC have recovered. If recovery  is achieved wit hin 
14days, no dose adjust ment is necessary . However, if recovery  has not been achieved within 
14days, bone marrow cellularit y shoul d be determined. If the bone marrow cellularit y is > 50%, 
no dose adj ustments shoul dbe made. If bone marrow cellularit y is ≤ 50%, treatm ent shoul d be 
delayed and the dose reduced according to the fo llowing table:
Bone Marrow Cellularity% Dose in the next course if recoverya
is not achieved in next 14 days
Recovery ≤ 21 days Recovery > 21 days
15 – 50%
< 15%100%
100%50%
33%
aRecover y = counts ≥ nadir count + (0.5 x [baseline count –nadir count])
Following dose m odificat ions, the cy cle durati on shoul d return to 28 days.   The reduced dose 
shoul d be maintained during subsequent cy cles that are given (unless toxicit y devel ops).  A fl ow 
diagram  for the determinati on of  azaci tidine dose adj ustment in subjects with reduced baseline 
blood coun ts is provi ded in Appendix M.
Renal d ysfunction during azacitidine t herapy
In previous studies, r enal abnormalit ies ranging from elevated serum creatinine to renal failure 
and death were reported rarely  in subjects treated wi th intravenous azacit idine in co mbina tion 
with other chemotherapeut ic agents.  In addit ion, renal tubular acidosis, defined as a fall in serum 
bicarbonate to < 20 mmo l/L in association wit h an alkaline urine and hypokalemia (serum 
potassi um < 3 mm ol/L) devel oped in 5 subjects with CML treated with azacit idine and 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
66 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539503] ions in serum bicarbonate (< 20 mmo l/L) occur, the dose should 
be reduced by 50% on the next course.  Similarly, if unexplained elevat ions in serum creat inine 
or BUN to ≥ 2-fold abo ve baseline values a nd above upper limit normal occur, the next cycle 
shoul d be delayed unt il values return to normal or baseline and the dose should be reduced by 
50% on the next treatment cy cle.  The reduced dose should be maintained during subsequent 
cycles that are given (unless toxi city devel ops).
Necrotiz ing fasciitis during azacitidine therapy
Necroti zing fasciit is, including fatal case s, have been reported in subjects treated with 
intravenous azacit idine. Azacitidine therapy  should be discontinued in subjects who develop 
necroti zing fasciit is, and appropriate treatment should be promptly init iated.
7.2.3. Low -dose Cytarabine Treatment
Subjects rando mized to the LDAC treatm ent opti on will receive continuous [ADDRESS_539504] adequate 
platelet and neutrophil recovery ( ie, platelets and neutrophils should return approximately to 
baseline levels ).  Indivi dual patients differ considerably regarding their abilit y to regenerate bone 
marrow cellularit y after chem otherapy .  In case of myelotoxi city with unacceptable cy topenia 
and poor regen eration [ADDRESS_539505] dose of LDAC , the start of the next treatment cycle 
can be delayed up to 2 weeks.  In the event of prol onged ( ie, more than 2 weeks ) and severe
(ie,Grade 4) neutropenia or thrombocy topeni a, complicated by  a Grade [ADDRESS_539506] igator s’ 
discreti on.  The i nvest igator should contact [CONTACT_426859], if needed.
7.2.4. Intermediate -dose Cytarabin eTreatment
Subjects rando mized to IDAC treatm ent opti on will receive 28-day cycles of cytarabine 0.5 to 
1.5g/
m2/day IVfor 3to [ADDRESS_539507] ice.  
(Note: any local standard regimen different from the above specificat ion will need review and 
approval  by [CONTACT_1689] .)
The dose of cytarabine shoul d be calculated on Day  [ADDRESS_539508] the 
Medical Monitor for guidance on IDAC modificat ion, if needed.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
67 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539509] igator’s assessment .  Thus the invest igator should evaluate 
prior to randomizat ion whether a subject has any potential contraindicat ions to any  of the CCR
treatm entoptions based on the azacit idine IB and cytarabine [LOCATION_006] Sm PC, and which CCR 
treatm ent option woul d be th e most sui table for the subject.  If, in the i nvest igator’s opi[INVESTIGATOR_3078] n, the 
subject is contraindicated to receive AG -[ADDRESS_539510] is not to be randomized.   
Following the sel ection of a CCR treatm ent opti on, subjects will be rando mized centrally  in a 1:1 
ratiotoreceive either the AG -221 treatm ent or the CCR treatment option pre -selected by [CONTACT_1275].  Randomizat ion will be stratified by [CONTACT_426832] (y es ver sus 
no), primary refractory (yesversus no), and pri or allogeneic HSCT for AML (y es versus no ).
No crossover between any  of the treatm ent options, including the CCR treatment options, will be 
permitted during the course of study treatment .
7.4. Packaging and L abeling
This is an open -label study .  The label(s) for IP will include S ponsor name, address and 
telephone number, the protocol number, IP name, dosage form and strength (where applicable), 
amount of IP per container, lot number, expi[INVESTIGATOR_11313] (where applicable), medicat ion 
ident ificat ion/kit number, dosing instructions, storage condi tions, and required caut ion 
statements and/or regulatory  statem ents as applicable. Addit ional information may  be included 
on the l abel as applicable per local regulati ons.
7.5. Investigational Product Accountability and Disposal 
The invest igator(s) or desi gnee (s)is responsible for taking an inventory of each shipment of IP
received, and co mpar ing it with the accom panying IP accountabilit y form.  The investigator(s) or 
designee (s)will verify  the accuracy of the information on the form, sign and dat e it, retain a copy  
in the study  file, and return a copy  to Cel gene .  
At the study  site, all IPs will be stored according to the storage conditions described on the IP 
packaging label in a locked, safe area to prevent unauthorized access .  The IPmust be stored at 
controlled temperature and a temperature log must be maintained in the source documents.
Invest igational product (and comparator product in countries where comparator is designated as 
NIP) accountabilit yis the responsibilit y of the investi gator and designee.  Applicable 
inform ation such as lot number , tabl etor vial count , and expi[INVESTIGATOR_426814] d be collected, as 
well as informat ion provi ded by [CONTACT_27701] (eg, subject dosing diary).  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
68 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539511] igator (s) or designee(s) is responsible for accounting for all IPs received at the site and 
issued to and returned by  [CONTACT_426860].   
Invest igational product (and comparator product in countries where comparator is designated as 
NIP) issued to and returned by [CONTACT_426861] .  This should occur as soon as possible after subjects 
have co mpleted all schedul ed doses of study  treatment .
Any unused IP must be returned by a study subject and retained by [CONTACT_426862] y to be conducted by  a Cel gene representative (or designee).  If any IPis lost or 
damaged, i ts disposi tion shoul d be doc umented .  At the periodic monitoring visit s, a Cel gene 
representative (or designee) will conduct IP (and comparator product in countri es where 
comparator i s desi gnated as NIP) accountabilit y and address any discrepancies.  Upon 
satisfactory  reconciliat ion of all IP s (and co mparator product in countries where comparator is 
designated as NIP ), the Cel gene representative (or designee) will authorize for the product to be 
either returned or destroy ed at the si te.  At the concl usion of  the study  a final  reconcil iation will 
be conducted and all remaining IPwill be counted, and reconciled wit h dispensing records , 
destruction records , returns and other documents .  The Celgene representative (or designee) will 
ensure that a final drug accountabilit y to the uni t dose level (ie, tablet or vial) is conducted.  
Docum entati on of  this accountabilit y and any discrepancies will be prepared and placed in both 
the invest igator study file and the central clinical study file .
Celgene (or designee) will review wit h the i nvest igator and rel evant si te personnel the process 
for IP(and comparator product in countries where comparator is designated as NIP )return, 
disposal , and/or destructi on including responsibilit ies for the site versus Celgene (or designee).   
If IPis to be destro yed via the site’s process, a copy of the site’s s tandard o perating procedure 
(SOP) for drug destruction will be collected by [CONTACT_1034] (or designee).  Any site without a 
Sponsor (or designee) approved destruction SOP and process will be required to retu rn IP (and 
comparator product in countries where comparator is designated as NIP )to Cel gene .  
Any 
revisio ns to a site’s destruction process must be provided and approved by [CONTACT_1034] (or 
designee) prior to implementation on this protocol .
7.6. Investigational Product Compliance
Study  treatm ent on scheduled clinic visit days will be administered in the clinic by [CONTACT_426863] -dose assessments (Secti on6.2)have been completed .  
Subject swill self -administer all other AG -[ADDRESS_539512] (or legally authorized representative) .  If study  specific 
diary cards are utilized, subjects (or legally authorized representative) will be asked to 
record AG-221 dosing information and to bring the diary car d and unused tablets in 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
69 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017the bottle (or the bottle if it isempt y)with them  to all clinic visit s.  A diary card and 
tabletcompliance check will be performed by [CONTACT_426864] .  Diary cards, if ut ilized, must be saved and kept with the source 
docum entati on.  Study  site personnel will perform a nAG-[ADDRESS_539513]’s source documentation 
and on the appropriate eCRF page.
Administrati on of  all other doses of azacit idine, LDAC, IDAC or BSC in the 
Treatment Phase is per standard inst itutional pract ice.    
Accurate recordi ng of study  treatm ent administration (including preparation, dosing and any  
changes in dosage administration such as interruption or reduction in dosing due to an AE) will 
be made in the appropriate section of the subject’s eCRF and source documents.  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
70 AG-221-AML -004 Amendment 2.0 Final :30 Nov [ZIP_CODE]. CONCOMITANT MEDICATI ONS AND PROCEDURES
All prior and conco mitant m edicati ons (pres cription and non -prescript ion) taken and treatment 
procedures receiv edfrom the 4-week period ( ie, 28days) pri or to starti ng study  treatm entup to 
[ADDRESS_539514] be recorded on the appropriate eCRF page(s).   
Parti cularly, all prior anti -cancer treatm ents shoul d be recorded regardless of discont inuat ion 
date of treatment.
For informat ion regarding other drugs that may int eract wit
h study  treatm entand affect its 
metabo lism,  or excretion, see the respective IBsand/or Cytarabine [LOCATION_006] SmPC .
8.1. Permitted Concomitant Medications and Procedures
Supportive c are may be used per standard institutional practice and as deemed necessary by [CONTACT_1275] .  Supportive care includes prophylact ic ant ibiotics, ant ifungal and /orantiviral 
agents, analgesics, ant iemetics, ant ipyretics, RBC transfusio ns (packed RBC or whole blood), 
single donor or pooled donor platelet transfusio nsand nutrit ional support .  
The use of erythropoi esis stimulat ing agents ( ESA s)is permitted according to the American 
Society of Clinical  Oncol ogy Guidelines (Rizzo, 2010 ).  
The use of myelo id growth factors (granulocyte -colony stimulating factor [G-CSF] and 
granulocy te-macrophage colony -stimulat ing factor [GM -CSF]) may be given to support subj ects 
who have developed Grade 4 neutropenia or Grade 3 neutropenia with fever and/or infect ion. 
Treatment with hydroxyurea is allowed af terthe start of study  treatm entfor the control  of 
leukocy tosis and/or if subject s experi ence IDH Differentiation S yndrome (Section7.2.1.3 ) 
during the course of study  treatm ent.  However, hydroxy urea should not be given within the 
72hours prior to and after azacitidine administration .  
Steroi ds are allowed for the tre atment of IDH Different iation Syndro me, if warranted , as 
standard of care . The use of chronic low -dose steroids to treat an underlying medical condit ion 
that is not a malignancy is permitted during the course of study  treatm ent.
It is recommended that an ant iemetic med ication such as a serotonin 5- HT 3receptor antagonist 
(eg, ondansetron) be taken 30 minutes prior to azacit idine administration during Cycle 1. If 
nausea/vo miting is not si gnificant, further ant iemetic prophylaxis may not be needed.  
Pretreatment or posttreatment with a serotonin [ADDRESS_539515]’s eCRF.   Treatment with ant idiarrheal medicat ions 
is reco mmended at the first sign of  diarrhea. Premedicat ion with antidiarrheal medication for 
subsequent doses of azacit idine may be appropriate. Pretreatm entand posttreatment with 
antidiarrheal medicat ion will be considered concomitant treatment and should be recorded on the 
appropriate subject’s eCRF .
8.2. Prohibited Concomitant Medications and Procedures
Systemic ant i-cancer therapy (excluding hydroxyurea) is not permitted during the course of study  
treatm ent.  Hydroxyurea isallowed after the start of study  treatm entfor the control of 
leukocy tosis and/or if subject s experi ence IDH Differentiation S yndrome during the course of 
study  treatm ent.  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
71 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539516]’s AML disease, the subject shoul dbe discont inued fro m study treatm ent.  
The fo llowing therapi [INVESTIGATOR_426815]:
Oral retino ids (topi[INVESTIGATOR_426816])
The following therapi [INVESTIGATOR_426817] -221 trea tment:
Corti costeroi ds, wi th the except ion of topi[INVESTIGATOR_426818], ophthalmic, na sal, and 
inhalat ional steroi ds.  Note that s hort course steroid therapy will be permitted to treat 
co-morbidities such as IDH D ifferent iation Syndrome .  The use of a stable dose of 
oral steroi ds post HSCT and/or topi[INVESTIGATOR_426789] .
The fo llowing m edicat ions that are known to prolong QT interval: amiodarone, 
arsenic trioxide, astemizo le, azithro mycin, bepridil, chloroquine, chlorpromazine, 
cisapride, citalopram, clarit hromycin, disopy ramide, dofet ilide, domperidone, 
droperido l, erythromycin, escitalopram, flecainide, halo fantrine, haloperido l, 
ibutilide, levo methadyl, mesoridazine, methadone, moxiflo xacin, pentamidine, 
pi[INVESTIGATOR_3924], probucol, pr ocainamide, quinidine, sevoflurane, sotalo l, sparflo xacin, 
terfenadi ne, thi oridazine, or vandetanib
Sensit ive CYP substrate medicat ions that have a narrow therapeutic range : paclitaxel 
and docetaxel (CYP2C8), pheny toin (CYP2C9), S -mephenyto in (CYP2C19), 
thioridazine (CYP2D6), theophylline and t izanidine (CYP1A2)
The BCRP transporter -sensit ive substr aterosuvastatin
The fo llowing therapi [INVESTIGATOR_426819]:
5-Flurocy tosine (the antifungal efficacy o f 5-Fluorocytosin e has been shown to be 
abolished during cytarabine therapy)
Live or live -attenuated vaccines (
Administrati on of these vaccines may result in 
serious or fatal  infect ions. Killed or inact ivated vaccines may be administered; 
however, the response to such vac cines m ay be diminished .)
8.3. Restricted Concomitant Medications and Procedures
The fo llowing therapi [INVESTIGATOR_426820] -221 treatm ent:
Coadministration of CYP2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2B6, CYP 3A4, 
and CYP 1A2 substrates other than those listed in Section 8.2shoul d be used only if 
medically necessary (refer to Appendix Nfor a list of CY P substrates)
Coadministration o f P-gp or BCRP substrates, OAT, OATP1B and OCT2 substrates 
other than those listed in Secti on 8.2shoul d be used only if medically necessary (refer 
to Appendix Ofor a list of transporter substrates)
Given the so lubility profile of AG -221, the exposure can be much lower for subjects 
with elevated gastri c pH. Thus antacids, H 2blockers, or proton pump inhibitors
shoul d be used only  if medically necessary and wi that least 4 hours of elapsed t ime
after AG -221 administration .  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
72 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017As an inhibitor of UGT1A1, AG-[ADDRESS_539517] ive products .
8.4. Required Concomitant Medications and Procedures
Not a pplicable.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
73 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539518] ical analysis p lan
(SAP) .
9.1. Overview
This is an international, mult icenter, open -label, rando mized, Phase [ADDRESS_539519]-line AML therapy and positive for an IDH2 mutation .
All data will be summarized by [CONTACT_1570].  In addit ion, where appropriate, a total co lumn 
will be included to sum marize subjects across treatment groups.  Summaries of cont inuous 
variables will present the number of subjects included in the analysis (N), the mean and standard 
deviat ion (SDev) of the mean , the m edian, the minimum, and the maximum statist ics.  Counts 
and percentages will be presented in summaries of categorical variables.  The deno minator for 
each percentage will be the number of subjects in the populat ion treatment group unless 
otherwi se specified.  In general, missing data will not be imputed unless o therwise specified.
All statistical analyses specified in this protocol will be conducted using SAS®Versi on 9.2 or 
higher unless otherwise specified.
9.2. Study Population Definitions
9.2.1. Intent -to-Treat Population
The intent -to-treat (ITT) populat ion includes all subjects who are randomized to treatment, 
regardl ess of whether they  received treatm ent or not.
9.2.2. Modified Intent -to-Treat Population
The modified intent -to-treat ( mITT)populat ion includes all subjects who h ave met all eligibilit y 
criteria and experienced no major protocol deviations during the study , received at least one dose 
of study treatm entand had at least one treatm ent response assessment performed .  This definit ion 
will be further clarified and detailed in the final SAPprior to database lock.
9.2.3. Safety Population
The safet y popul ation includes all rando mized subjects who received at least [ADDRESS_539520] -randomization assessment.  
The safet y popul ation wil l be used for all safet y analyse s.  Subjects will be analyzed according t o 
the treatment actually received.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
74 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539521]. Subjects will be rando mized to receive AG -221 
treatm ent or a CCR treatment option pre -selected by  [CONTACT_426865] a 1:1 ratio.  Assuming a 
median OS of 5.6months in the CCR treatm ent arm(Roboz, 2014 ),a median OS of 8 months in 
the AG -
221 treatm ent arm ( 42.9% improvement), and a drop-out rate of approximately 9%, this 
design requires 250deaths and 316subjects ( 158per treatment arm) to be rando mized in order to 
achieve 80% power to detect a co nstant hazard ratio (HR) of 0. 7and demonstrate a statist ically 
significant difference in OS at a Type I error rate of 0. 05 (two -sided).   
It is assumed that the OS 
distribut ion is exponent ial with a constan t failure rate and that accrual rate is 3subjects per 
month for the first 12 months and 9subjects per month afterwards. The interim analysis for 
superi ority will be condu cted at 65% informat ion (ie, 163deaths) based on Lan-DeMets versio n 
of the O’Brien -Fleming alpha spending funct ion
.
9.4. Background and Demographic Charact eristics
Dem ographic and baseline disease characterist ics will be summarized by  [CONTACT_426866], m ITT andsafet y popul ations.  Subjects’ age, height, weight, and continuous baseline 
characterist ics will be summarized using descript ive statistics(N, m ean, SD ev, median, 
minimum, maximum) , while age group, gender, race and other categorical variables will be 
provi ded using frequency  tabulat ions(count, percent) by [CONTACT_1570].
9.5. Subject Disposition
Subject disposit ion (analysis population allocat ion, entered, di scont inued, along wit h primary  
reason for discont inuat ion) will be summarized using frequency and percent for both treatment 
and fo llow-up phases.  A summary  of subjects enrolled by [CONTACT_176458] b y country  will be provi ded. 
Protocol  deviat ions/violationswill be summarized using frequency  tabulat ions
.  Supportive 
corresponding subject list ings will also be provided .
9.6. Efficacy Analysis
All efficacy analyse s will be perform ed on the ITT population.  Key secondary  efficacy  analysis 
will be performed on the mITT populat ion as supportive evidence and to assess the robustness of 
the efficacy  findings.  Subjects will be analyzed according to randomized treatment group. Refer 
to Section 2for the primary and secondary efficacy endpo ints, respectively .
In order to perform hypothesis testing on mult iple endpo ints while controlling the overall Type I 
error rate, a closed, sequent ial testing approach is proposed with the endpo ints to be tested in a 
pre-specified order.  The primary efficacy endpo int of OS will be tested first at a two -sided 
significance l evel of 0.05.  If superiorit y of AG-221 is dem onstrated in OS, then each of the key  
secondary  endpoints of overall response rate (ORR )and e vent-free survival (EFS) , in the pre -
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
75 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539522] ratio and a 95% confidenc e 
interval .
The assumpt ion of proportional hazards will be tested by  a time -dependent Cox mo del with the 
interact ion of treatm ent and time. A significant interaction indicates that the proportional hazard 
assumpt ion is vio lated. Under such circumstance, r estricted mean survival t ime and pi[INVESTIGATOR_426821]. Generalized Wilcoxon test will be 
utilized as a sensit ivity analysis when treatment difference occurs early rat her than late during 
the Follow -up peri od.
In order to assess the impact of subsequent enasidenib treatment in the CCR arm, sensit ivity 
analyses o f OS will be conducted fo llowing ICH E9 (R1) addendum, in which strategies to 
address intercurrent events are described. To be specific, Hy potheti cal S trategy , eg, regression -
based imputation method ( Luo, 2016 ) and Rank Preserve Struct ure Failure Time model 
(Robins, 1991), Principal Stratum Strategy , eg, Inverse Probabilit y of Censoring Weighted 
method ( Robins, 2000
), and While on Treatment Strategy  to censor subj ects at the time of 
crossover will be adopted to provide supporting evidence when appropriate. In addition,to asse ss 
the impact of subsequent transplantation, a sensit ivity analysis of OS will be conducted in which 
subject s who have subsequent transplantation will be censored at the time of transplantation after 
study  treatm ents.
9.6.2. Secondary Efficacy Analyses
The time -to-event secondary  efficacy variables will be analyzed similarly  to the primary  efficacy 
variable with or without stratificat ion when appropriate.  Kaplan -Meier (KM) methods will be 
used to estimate time -to-event curves , unless otherwise specified.  Counts and percentages will 
be used to describe ca tegori cal secondary  variables.
[IP_ADDRESS]. Key Secondary Efficacy Analyses
The key  secon dary efficacy  endpoints include ORR and EFS assessed by a blinded IRAC 
according to modified IWG AML response criteria ( Appendix F).  Overall response rate will be 
compared by  [CONTACT_125427] -Mantel -Haenszel test.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
76 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Overall response rate is defined as the r ate of morphologic leukemia -free state ( MLFS )+ CR + 
CRi + CRp + PR according to modified IWG AML resp onse cri teria (Appendix F ).
Event -free survival is defined as the interval fro m the date of rando mizat ion to the date of 
docum ented morphologic relapse after CR/CRi/CRp ,PD or death fro m any cause, whichever 
occurs first.  Subjects who are alive wit hout any  of these events will be censored at the date of 
their last response assessment.
[IP_ADDRESS]. Additional Secondary Efficacy Analyses
The other secondary  endpoints i nclude durati on of response, time to res ponse, rates of overall 
remission, CR and HI assessed by [CONTACT_426867] g to m odified IWG AML response criteria
(Appendix F )and IWG MDS HIcriteria ( Appendix H ), treatm ent m ortali ty at [ADDRESS_539523] docum ented MLFS/ CR/CRi/CRp
/PRto
docum ented morphologic relapse after CR/CRi/CRp /PD or death dueto any cause, whichever 
occurs fir st.  Subjects without morphologic relapse , PD or death due to any cause will be 
censored at the date of the last response assessment.
Time to response is defined as time from randomization to first documented MLFS/CR/CRi/CRp /
/PR.  Subje cts wi thout a MLFS/CR/CRi /CRp /PRwill be censored at the date of the last response 
assessment .
Treatment mortality at 30 and 60 daysis defined as rate of death from any cause within 30 or 
60days of initiation of study treatment .
One-year survival is defined as the probabilit y of survival at 1year from rando mizat ion.
Overall remission rate is defined as rate of CR + CRi + CRp according to m odified IWG AML 
response criteria (Appendix F ).
Complete remission rate is defined as rate of CR according to modified IWG AML response 
criteria (Appendix F ).
Hematologic improvement rate is defined as r ate of neutrophil response ( hematol ogic 
improve ment neutrophil response [HI-N]) + platelet response ( hematol ogic improve ment platelet 
response [ HI-P]) + erythroidresponse ( hematol ogic improve ment ery throid response [ HI-E]) 
according to IWG MDS HI criteria (Appendix H ).
Rate of H SCT is defined as rate of bridge -to-HSCT through study treatment.
Time to treatment failure is defined as time from randomizat ion to discontinuation o f study  
treatm ent due to any  cause.
The rate of CR/CR wi th parti al hematol ogic recovery  (CRh;Appendix F )and duration of 
CR/CRh will  be analyzed using the statist ical methods m entioned above or other statist ical 
methods as appropriate.   Note: CRh is not available for the investigator’s assessment and will be 
assessed by[CONTACT_426868] l aboratory  dataset.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
77 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539524] ionary for Regul atory  Activities
(MedDRA )system  organ cl ass and preferred term.   Treatment -emergent AEs leading to death, 
TEAEs l eading to di scont inuat ion from treatm ent, CTCAE Grade [ADDRESS_539525] rocardi ogram swill be analyzed for QTc intervals, QTc > 480and > 500, increase > 30 and 
>60 msec .
9.8. Interim Analysis
The interim analysis for superiorit y will be performed when approximately 65% of the expected 
number of deaths (ie, 163 deaths) have been reported.  The interim efficacy analysi s will  be 
perform ed by  [CONTACT_426869] .  The interim results will be provided to the DMC who will
review and give advice to the S ponsor regarding the study  conduct. The analysis result s will not 
be disseminated among invest igators and those directly invo lved with the study  conduct.
The T ype I error rate will be controlled at the overall one -sided 0.0 25 level by[CONTACT_426870] O’Brien -
Fleming monitoring b oundary  with a Lan -DeMets al pha spending function. The decisio n rules 
are as fo llows: 
65% of expected events
Stop for superiorit y if one -
sided p -value ≤0.005 5(HR ≤ 0.6715)
100% of expected events 
Claim success if one
-sided p -value ≤0.0233 (HR ≤ 0.7775)
The actual  levels used will depend on the actual number of events observed at the interim and the 
final analyses.   
Based on the study  assumpti ons, the superi ority interim is pro jected to occur 
approximately  37months after the fir st subject is rando mized and 256subjects have been 
accrued.
At the time of the interim analysis, the overall death rate will be evaluated relat ive to the study  
assumpt ions and enrollment into the study  may be increased to ensure that the required number 
of 
250deaths can be reached in a reasonable time period.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
78 AG-221-AML -004 Amendment 2.0 Final :30 Nov [ZIP_CODE].9. Other Topi[INVESTIGATOR_1102]
9.9.1. Data Monitoring Committee
An external DMC will be convened that will include medical hematol ogists/oncologists with 
experience in treating subjects with AML and a stati stician, all of who m are not otherwise 
involved in the study  conduct. During the course of the study , the DMC will review the safet y 
data regularly as well as safet y and efficacy data in accordance with the guidelines fo r the 
prepl anned interi m analysi s.  An independent third party  will prepare the reports of aggregate 
data summaries and individual subject data list ings, as appropriate, to the DMC members for 
each scheduled meeting. Operati onal details for the DMC will be detailed in the DMC c harter.
9.9.2. Steering Committee
The conduct of this trial will be overseen by a steering c ommittee , presi ded over by [CONTACT_426871].  The steering committee will serve in an advisory  capaci ty to 
the Sponsor.   Operational details for the steering committee will be detailed in a separate steering 
committee charter.   
Note: The steering co mmit teeis separate from the DMC.
9.9.3. Health -Related Qual ity-of-Life
Two instruments, the EORTC QLQ -C30 and EuroQoL Group EQ -5D, will be used for HRQoL.  
Scoring for EORTC QLQ -C30 and EQ -5D, and methods to address missing values will be 
accomplished according to direct ions provided by [CONTACT_426872] .  Detailed analysis 
plans will  be described in the subject -reported outcome statist ical plan .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
79 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
80 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539526]’s healt h, including 
laboratory  test val ues (as specified by  [CONTACT_81677]10.3), regardl ess of eti ology. Any 
worsening (ie, any  clinically significant adverse change in the frequency  or intensi ty of a pre -
exist ing condit ion) should be considered an AE.  A diagnosis or s yndro me should be recorded on 
the AE page of the e CRF rather than the individual signs or symptom s of the di agnosis or 
syndro me. 
Abuse, wi thdrawal , sensi tivity or toxi city to IPshoul d be reported as an AE. Overdose, 
accidental  or intent ional, whether or not it is associated with an AE should be reported on the 
overdose eCRF.   See Section 7.2for the definit ion of overdose. Any sequela of an accide ntal or 
intentional overdose of study  treatm entshoul d be reported as an AE on the AE eCRF. If the 
sequela of an overdose is an SAE, then the sequela must be reported on an SAE report form and 
on the AE eCRF. The overdose result ing in the SAE should be i dentified as the cause o f the 
event on the SAE report form and eCRF but should not be reported as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary .  There i s no kno wn specific ant idote for overdose of IP. 
Actual  treatm ent shoul d depend on the severit y of the clinical situation and the judgment and 
experience o f the treating physician.
All subjects will be mo nitored for AEs during the study.  Assessments may include m onitoring 
of any or all o f the following param eters:  the subject’s clinical symptoms, laboratory , 
pathol ogical, radi ological or surgical  findings, physical examinat ion findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by [CONTACT_414489] [ADDRESS_539527] ’s 
source documents.  All SAEs must be reported to Celgene Drug Safet ywithin 24 hours of the 
investi gator’s knowl edge of the event by  [CONTACT_6972], or other appropriate method, using the SAE 
Report F orm, or approved equivalent form.  
10.2. Evaluation of Adverse Events
A qualified i nvestigator will evaluate all AEs as to: 
10.2.1. Seriousness 
An SAE is any  AE occurring at any  dose that:
Results in death;
Is life -threaten ing (ie, in the opi[INVESTIGATOR_3078] n of the i nvest igator, the subject is at immediate 
risk of death fro m the AE);
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
81 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Requi res in patienthospi [INVESTIGATOR_24508] 
(hospi [INVESTIGATOR_426822] n, regardl ess of l ength o f stay);
Results in persistent or significant disabilit y/incapacit y (a substant ial disrupt ion of the 
subject’s abilit y to conduct normal life functions);
Is a congenital ano maly/birth defect;
Const itutes an important medical event.
Important m edical events are defined as those occurrences that may not be immediately life -
threatening or result in death, hospi[INVESTIGATOR_3094], or disabilit y, but may  jeopardi ze the subject or 
requi re medical or surgi cal intervent ion to prevent one of the other outcomes listed above.   
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospi[INVESTIGATOR_208839]:
astandard procedure for protocol therapy administration.  However, hospi[INVESTIGATOR_208840] a com plicat ion of therapy  administrati on will be 
reported as an SAE. 
routine treatm ent or m onitoring of the studied indication not associated with any  
deteri oration in condit ion.
the administration o f blood or pl atelet transfusio n as routine treatment of studied 
indicat ion.  However, hospi[INVESTIGATOR_414444] a complication 
of such transfusion remains a reportable SAE.
aprocedure for protocol/disease -related invest igations (eg, surgery , scans, endo scopy , 
sampling for laboratory  tests, bone m arrow sam pling).  However, hospi[INVESTIGATOR_208840] a com plicat ion of such procedures remains a reportable 
SAE.
hospi[INVESTIGATOR_372085] , practical ,or social 
reasons, in absence of an AE.
aprocedure that is planned (ie, planned prior to start of treatment on study); must be 
docum ented in the source document and the eCRF.   Hospi[INVESTIGATOR_208842] a com plicati on remains a repo rtable SAE.
an elect ive treatment of or an elect ive procedure for a pre -exist ing condit ion, 
unrelated to the studied indicat ion, that has not worsened fro m baseline. 
emergency out patient treatm ent or observat ion that does not result in admissio n, 
unless f ulfilling other seriousness criteria above.
If an AE i s considered serious, both the AE page/screen of the eCRF and the SAE Report Form 
must be completed.
For each SAE, the i nvestigator will provide information on severit y, start and stop dates, 
relationship to the IP, acti on taken regarding the IP, and outcome.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
82 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201710.2.2. Severity/Intensity
For both AEs and SAEs, the i nvestigator must assess the severit y/ intensity of the event. 
The se verity/intensity of AEs will  be grade d based upon the subject’s symptoms according to the 
current active minor versio n of the Commo n Termino logy Criteria for Adverse Events ( CTCAE, 
Versi on 4.0 3);
AEs that are not defined in the CTCAE shoul d be evaluated for severit y/intensity according to 
the following scale:
Grade 1 = Mild –transi ent or mild disco mfort; no limitat ion in act ivity; no m edical  
intervent ion/therapy  requi red
Grade 2 = Moderate –mild to moderate limitat ion in activity, som e assistance may  be 
needed; no or minimal medical intervent ion/therapy  required
Grade 3 = Severe –marked limitat ion in act ivity, som e assistance usually required; 
medical intervention/therapy required, hospi[INVESTIGATOR_5186] n is possible
Grade 4 =Life-threatening
–extreme limitation in activit y, significant assistance 
requi red; significant medical intervent ion/therapy  requi red, hospi [INVESTIGATOR_372087]
Grade 5 =Death -the event results in death
The term  “severe” is often used to describ e the intensit y of a specific event (as in mild, moderate 
or severe myocardial infarct ion); the event itself, however, may be of relat ively minor medical 
significance (such as severe headache).  This criterio n is notthe same as “serious” which is 
based on subject/event outcome or action criteria associ ated wi th events that pose a threat to a 
subject’s life or funct ioning.  
Seriousness, not severit y, serves as a gui de for defining regul atory  obligat ions.
10.2.3. Causality
The i nvest igator must determine the relat ionshi p between the administration o f the IPand the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected: a causal relat ionship of the AEto IPadministration is unlikely 
or remote , or other m edicat ions, therapeutic intervent ions, or 
underlying condit ions provide a sufficient explanatio n for the 
observed event.
Suspected: there is a reasonable possibility that the administration of IP
caused the AE.  ‘Reasonable possibilit y’ means there is 
evidence to suggest a causal relat ionship between the IPand the 
AE.
Causalit y shoul d be assessed and provided for every  AE/SAE based on currently available 
inform ation.  Causalit y is to be reassessed and provide d as addi tional information beco mes 
available.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
83 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539528] igator will report the action taken with study  treatm entas a result of an AE or SAE, as 
applicable (eg, d iscont inuat ion, interruption, or dose reduction of IP, as appropriate) and report if 
concomitant and/or addit ional treatments were given for the event. 
10.2.6. Outcome
The i nvest igator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discont inuatio n of the subject’s participat ion in the study  
must be fo llowed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE ).
10.3. Abnormal Laboratory Values
An abnormal laboratory  value is considered to be an AE ifthe abnorm ality:
resul ts in discont inuat ion from the study;
requi res treatm ent, m odificat ion/ interruption of IPdose, or any other therapeutic 
intervent ion; or
is judged to be of significant clinic al importance, eg, one that indicates a new disease 
process and/or organ toxicit y, or is an exacerbat ion or worsening of an exist ing 
condi tion.
Regardless of severit y grade , only  laboratory  abnorm alities that fulfill a seriousness criterion 
need to be docu mented as a SAE .
If a laboratory  abnorm ality is one com ponent of a di agnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the eCRF.  If the abnormalit y was not 
a part of a diagnosis or syndrome, then the labo ratory  abnorm ality should be recorded as the AE. 
If possible, the laboratory  abnorm ality should be recorded as a medical term and not simply  as an 
abnorm al laboratory  resul t (eg, record thrombocy topeni a rather than decreased platelets).
10.4. Pregnancy
All pregn ancies or suspected pregnancies occurring in eit her a female subject of childbearing 
potenti al or partner of childbearing potential of a male subject are immediately reportable events .  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
84 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201710.4.1. Females of Childbearing Potential
Pregnancies and suspected pregnanci es (incl uding el evated β-hCG or posi tive pregnancy test in a 
female subject of childbearing potential regardless of disease state) occu rring while the subject is 
on IP, or wi thin [ADDRESS_539529] ’s last dose of IP (6months fo llowing the last dose of 
cytarabine) , are consi dered immediately reportable events.  Invest igational product is to be 
discontinued immediately and the subject instructed to return any  unused porti on of  the IP to the 
investi gator .The pregnanc y, suspected pregnancy , or posi tive pregnancy  test m ust be reported to 
Celgene Drug Safet y immediately  by [CONTACT_6968] , phone or facsimile, or other appropriate method, 
using the Pregnancy Init ial Report Form , or approved equivalent form.  
The female subject sho uld be referred to an obstetrician -gyneco logist, preferably  one 
experienced in reproductive toxicit y for further eval uation and counseling.
The i nvest igator will fo llow the female subject until co mpletion of the pregnancy , and m ust 
notify Celgene Drug Safe ty immediately  about the outcom e of the pregnancy  (either norm al or 
abnorm al outcom e) using the Pregnancy  Follow-up Report Form , or approved equivalent form.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the invest igator 
shoul d report the abnormal outcome as an AE.  If the abnormal outcome meets any  of the seri ous 
criteria, i t must be reported as an SAE to Celgene Drug Safet y by [CONTACT_6972], or other appropriate 
method, within 24 hours of the i nvestigator’s knowledge o f the event using the SAE Report 
Form , or approved equivalent form .
All neonatal  deaths that occur within [ADDRESS_539530] igator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form .
10.4.2. Male Subjects
Ifa female partner of a m ale subject taking IPbecomes pregnant while the male subject is on IP, 
or wi thin [ADDRESS_539531] ’s last dose of IP (6months following the last dose of 
cytarabine; 6months following the l ast dose of azaci tidine in Canada) , the m alesubject taking IP
shoul d notify the i nvest igator, and the pregnant female partner should be advised to call their 
healt hcare provider immediately .  Where applicable, the IPmay need to be discont inued in the 
male subject, but may  be resum ed later at the discretion of the investigator and the Medical 
Monitor.
10.5. Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the complet ion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the eCRF.  All SAEs must be reported to 
Celgene Drug Safety within [ADDRESS_539532] igator ’s knowledge of the event by [CONTACT_6972], 
or other appropriate method (eg, via email), using the SAE Report Form, or approved equivalent 
form.  This instruction pertai ns to i nitial SAE reports as well as any  follow-up reports.
The i nvest igator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relat ionship to IP) that occur during the study
(from the time the subject signs informed conse nt until [ADDRESS_539533] study  treatm entor 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
85 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017until the EOT visit, whichever is longer ) or any  SAE m ade known to the invest igator at any time 
thereafter that are suspected of being related to IP.  Serious AEs occurring prior to treatment 
(after signing the ICF) will be captured.
The SAE report should provide a detailed descript ion of the SAE and include a concise summary 
of hospi [INVESTIGATOR_27598].  If a subject died and an autopsy  has been 
perform ed, copi [INVESTIGATOR_348863].  Any fo llow-up data should be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to C elgene Drug Safet y.  
Where requ ired by  [CONTACT_81689], the i nvest igator is responsible for informing the Inst itutional 
Review Board/Ethics Co mmittee (IRB/EC) of the SAE and providing them wit h all relevant 
initial and fo llow-up informati on about the event. The invest igator must keep copi[INVESTIGATOR_208843] h Celgene and the IRB/EC.
10.5.1. Safety Queries
Queri es pertaining to SAEs will be co mmunicated fro m Celgene Drug Safet y to the si te via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) bus iness 
days.  Urgent queries (eg, missing causalit y assessment) m ay be handled by [CONTACT_648].
10.6. Expedited Reporting of Adverse Events
For the purpose of regulatory  reporting, Cel gene Drug Safet y will determine the expectedness of 
events suspected of being related to AG-221 or azacit idine based on AG-221 (enasidenib) IBor 
Azacitidine IB, respectively .
In the US, all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) will be reported in an 
expedited manner in accordance wit h 21 CFR 312.32.
For countri eswithin the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory  Authori ties and Ethi cs 
Committees concerned, S[LOCATION_003]Rs in accordance with Direct ive 2001/20/EC and the Detailed 
Guidance on col lection, verificat ion and presentation of adverse react ion reports arising from 
clinical trials on IPsfor hum an use (ENTR/CT3) and also in accordance with country -specific 
requi rements.   
For the purpose of regulatory  reporting in the EEA, Celgene Drug Sa fety will determine the 
expectedness of events suspected o f being related to the other IP, specifically, the Cytarabine [LOCATION_006]
SmPC.
Events of disease progressi on for the di sease under study  (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as AEs and will not 
be reported as expedited safet y reports to regulatory  authori ties.
Celgene or i ts authori zed repr esentative shall notify  the i nvestigator of the fo llowing inform ation
(In Japan, Celgene KK shall notify the Heads of the Institutes in addit ion to the i nvestigators):
Any AE suspected of being related to the use of IPin this study  or in other studi es 
that is both serious and unexpected (ie, S[LOCATION_003]R);
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
86 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Any finding fro m tests i n laboratory  animals that s uggests a si gnificant risk for 
human subjects including reports of mutagenicit y, teratogeni city, or carcinogenicit y.
In Japan, measures taken in foreign countries to ensure subject safet y, study  reports 
that indicate potential risk of cancer, etc, or biann ual SAE report accordi ng to the 
local regulati ons.
Where requ ired by  [CONTACT_81689], the i nvest igator shall notify his/her IRB/EC promptly o f 
these new serious and unexpected AE(s) or significant risks to subjects.
The invest igator must keep copi[INVESTIGATOR_1309] a ll pert inent safet y information on file including 
correspondence with Celgene and the IRB/EC.  (See Section 14.[ADDRESS_539534] retention 
inform ation.)
Celgene Drug Safety Contact [CONTACT_7171]:
For Celgene Drug Safet y contact i nformat ion, please refer to the Serious Adverse Event Report 
Form  Com pletion Guidelines or to the Pregnancy  Report F orm Com pletion Guidelines.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
87 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539535] from study  
treatm ent:
Adverse e vent
Progressive disease ( Appendix F )
Withdrawal by [CONTACT_426873]
Death
Lost to fo llow-up
Allogeneic HSCT
Pregnancy
Other (to be specified on the eCRF)
Although progressive disease is considered a sufficient reason f or discont inuing a subject from 
study  treatm ent, the investigator may consider continuing study  treatm entuntil the investigator 
has al ternat ive therapi[INVESTIGATOR_014] (eg, allogeneic HSCT) and/or considers study  treatm ent to be no l onger 
beneficial to the subject, or the rapi[INVESTIGATOR_426823] i nvesti gator .
The decisio n to di scont inue a subject fro m treatm ent rem ains the responsibilit y of the treating 
physician, which will no t be del ayed or refused by [CONTACT_941] S ponsor.  However, prior to discont inuing 
a subject forprogressive disease , or any other reason if not listed above , the i nvest igator may 
contact [CONTACT_426874] n.  The reason for discont inuat ion ofstudy treatm ent shoul d be recorded in the eCRF 
and in the sour ce docum ents.   
Discontinued subjects will not be replaced .
11.2. Study Discontinuation
Discontinuati on from study  treatm ent shoul d be considered dist inct fro m discont inuation fro m 
the study .  All subjects discont inued from study treatment for any  reasonother than wit hdrawal 
of consent for fo llow-up, death or lost to fo llow -upwill be fo llowed in the Fo llow-up Phase of 
the study  (Secti on6.3).  Every attempt should be made to collect all data during the Follow -up 
Phase unless subjects discontinue from the study .
The fo llowing events are considered sufficient reasons for discont inuing a subject from the 
study :
Screen failure
-IDH2 m utation negat ive
-Other
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
88 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Adverse event
Withdrawal by [CONTACT_426875]
Death
Lost to follow -up
Other (to be specified on the eCRF)
The reason for study  discont inuat ion shoul d be recorded in the e CRF and in the source 
docum ents.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
89 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539536] the responsible Clinical Research 
Physician/Medical Monitor or designee by [CONTACT_27722](s) listed on the Emergency 
Contact [CONTACT_372158] (after title page).
In the unlikely  event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact [CONTACT_426876] y Contact [CONTACT_27723] (after tit le page). This global 
Emergency  Call Center i s available 24 hours a day and 7 day s a week. The representatives are 
responsible for obtaining y our call -back informat ion and contact[CONTACT_81694] -call Celgene/ contract 
research organizat ion Medical Monitor, who will then contact y ou prom ptly.
Note: The back -up [ADDRESS_539537] call  center shoul d only  be used if y ou are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or des ignee for 
emergency calls . 
12.2. Emergency Identification of Investigational Products
This is an open -label study; therefore, IP will be identified on the package labeling.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
90 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539538] igator abide by [CONTACT_27727], as described in ICH Guideline E6 and in accordance with the 
general ethical p rinciples outlined in the Declaration of Helsinki. The study  will receive approval  
from an IRB /EC pri or to commencement. The i nvestigator will conduct all aspects of this study  
in accordance wit h applicable nat ional, state, and local laws o f the pertinent regul atory  
authori ties.
13.2. Investigator Responsibilities
Invest igator responsibilit ies are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulat ions.  Celgene staff or an authorized representative will evaluate and approve all 
investigators who i n turn will select their staff.
The i nvest igator should ensure that all persons assisting wit h the study  are adequately  informed 
about the protocol, amendments, study  treatm ents, as well as study -related duti es and funct ions, 
including obliga tions of  confident iality of Celgene informat ion. The i nvest igator should maintain 
a list of Sub -invest igators and other appropriately qualified persons to whom he or she has 
delegated si gnificant study -related duti es.
The i nvest igator is responsible for ke epi[INVESTIGATOR_007] a record of all subjects who sign an ICFandare 
screened for entry  into the study .  Subj ects who fail screening must have the reason(s) recorded 
in the subject’s source documents.
The i nvest igator, or a desi gnated m ember of the i nvestigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow dire ct access to subject records (e g, 
medical records, office charts, hospi[INVESTIGATOR_1332], and study -related charts) for source data 
verification.  The i nvestigator must ensu re timely and accurate completion of eCRFs and queries.
The informat ion contained in the protocol and amendments (with the except ion of the 
inform ation provi ded by  [CONTACT_348953]) i s considered Celgene confident ial 
inform ation.  Only  information that i s previ ously  discl osed by  [CONTACT_184690] a public registry  
website may be freely disclosed by [CONTACT_941] i nvestigator or its institution, or as outlined in the Clinical 
Trial Agreement.   Celgene protocol ,amendment and IB informat ion is not to be made publicly 
available (for example on the i nvest igator’s or their inst itution’s website) without express written 
approval  from Celgene.  Inform ation proposed for posting on the i nvest igator’s or their 
institution’s website must b e submitted to Celgene for review and approval, providing at least [ADDRESS_539539] and/or their caregiver as agreed by [CONTACT_1560] .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
91 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539540] and/or a subject’s legal representative 
prior to any  study  related procedures.
Docum entati on that inform ed consent occurred prior to the study  subject’s entry  into the study  
and of the informed consent process should be recorded in the study  subject’s source documents 
including the date.  The original ICF signed and dated by  [CONTACT_414493]’s entry into the study, must be m aintained 
in the i nvest igator’s study  files and a copy  given to the study  subject. In addit ion, if a protocol is 
amended and i t impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participat ing in the study  when the am ended protocol is implemented must be re -
consented with the revised versio n of the ICF.  The revised ICF signed and dated by [CONTACT_372161] m ust be m aintained in the i nvest igator’s 
study  files and a copy  given to the study  subject.
13.4. Confidentiality
Celgene affi rms the subject's ri ght to pr otecti on against invasio n of privacy  and to be in 
compliance wi th ICH and other l ocal regul ations (whichever i s most st ringent). Celgene requires 
the invest igator to permit Celgene's representatives and, when necessary, representatives from 
regul atory  auth orities, to review and/or copy  any medical records relevant to the study  in 
accordance with local laws.
Shoul d direct access to m edical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibilit y of the i nvest igator to obtain such permissio n in 
writing fro m the appropri ate individual.
13.5. Protocol Amendments
Any amendment to this protocol must be approved by  [CONTACT_184693]/Medical Monitor.  Amendments will be submitted to the IRB/EC for wri tten approval .  
Written approval  must be obtained before implementation of the amended versio n occurs.  The 
written si gned approval  from the IRB/EC shoul d specific ally reference the i nvest igator name, 
protocol  number, study  title and amendment number(s) th at is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for inform ation purposes.
13.6. Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of th e study , the study  protocol , ICF, and any  other appropri ate docum ents will 
be submitted to the IRB/EC with a cover letter or a form list ing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for w hich approval is 
sought. If applicable , the docum ents will  also be submitted to the authorit ies in accordance with 
local legal  requirements.
Invest igational product can only be supplied to an i nvesti gator by  [CONTACT_339132] i ts authori zed 
representative after d ocum entati on on all  ethical  and legal  requirements for starti ng the study  has 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
92 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539541] of the members of the IRB/EC and their occupation and qualificat ions. If th e IRB/EC will 
not disclose the names, occupations and qualificat ions of the committee members, it should be 
asked to i ssue a statement confirming that the composit ion of the committee is in accordance 
with GCP. For exam ple, the IRB General Assurance Number may be accepted as a subst itute for 
this list. Form al approval  by [CONTACT_1201]/EC shoul d ment ion the protocol tit le, number, amendment 
number (if applicable), study  site (or regi on or area of jurisdiction, as applicable), and any other 
docum ents reviewed. It m ust m ention the date on which the decisio n was made and must be 
officially signed by  a commi ttee m ember. Before the first subject is enrolled in the study , all 
ethical and l egal requi rements m ust be m et.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance wit h local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICFshoul d also be revised.
The i nvest igator must keep a record of all co mmunicat ion with the IRB/EC and, if applicable, 
between a Coordinat ing Invest igator and the IRB/EC. This statement also applies to any  
communicat ion betw een the i nvestigator (or Coordinat ing Investi gator, if applicable) and 
regul atory  authori ties.
Any advertisements used to recruit subjects for the study  must be reviewed by [CONTACT_27734]/EC prior to use.  
13.7. Ongoing Information for Institutional Review Board/ Ethics 
Committee
If required by [CONTACT_81704]/EC, the i nvestigator must submit to the IRB/EC:
Inform ation on serious or unexpected AEs as soon as possible; 
Periodic reports on the progress of the study;
Deviat ions from  the protocol  or any thing that may  involve added risk to s ubjects.
13.8. Termination of the Study
Celgene reserves the ri ght to terminate this study  prem aturely  at any  time for reasonable medical 
or administrative reasons. Any premature discont inuat ionwill be appropriately documented 
according to l ocal requi rements ( eg, IRB/EC, regulatory  authori ties, etc).
The Sponsor may  end the tri al when all key  endpoints and object ives of the study have been 
analyzed, and the availabilit y of a roll-over or extensio nprotocol  exists into whi ch any subjects
who remain on study  maybe consented  and continue to receive access to AG-221.  Such a 
protocol  woul d be wri tten for a com pound that woul d not y et be commercially  available .
In addit ion, the i nvest igator or Celgene has the right to discont inue a single site at any  time 
during t he study for medical or administrative reasons such as:
Unsat isfactory  enro llment;
GCP nonco mpliance ;
Inaccurate or inco mplete data collect ion;
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
93 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Falsificat ion of records;
Failure to adhere to the study  protocol .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
94 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201714. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645] 
14.1. Data/Docume nts
The i nvest igator must ensure that the records and documents pertaining to the conduct of the 
study  and the di stribut ion of the invest igational product are complete, accurate, filed and 
retained.  Examples of source documents include: hospi[INVESTIGATOR_1097]; clinic and office charts; 
laboratory  notes; m emoranda; subject’s di aries or evaluat ion checklists; dispensing records; 
recorded data from automated instruments; copi[INVESTIGATOR_348867]; micro fiche; x -ray film and reports; and records kept at the pharmacy , and 
the laboratories, as well as copi[INVESTIGATOR_81648] -ROM.
14.2. Data Management
Data will be co llected via eCRF and entered into the clinical database per Celgene standard 
operating procedures ( SOPs ). Thisdata will be electronically  verified through use of 
programmed edit checks specified by [CONTACT_6098].  Discrepancies in the data will be brought 
to the attention of the clinical team, and invest igational site personnel, if necessary.  Reso lutions 
to these issues will be reflected in the database.  An audit trail wit hin the system will track all 
changes made to the data.
14.3. Record Retention
Essential doc uments m ust be retained by  [CONTACT_941] i nvestigator according to the period of time outlined 
in the clinical tr ial agreement . The i nvest igator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is lo nger. Essent ial 
docum ents include, but are not limited to, the follo wing:
Signed ICFs for all  subjects;
Subject identificat ion code list, screening log (if applicable), and enrollment log;
Record of all commu nicati ons between the i nvestigator and the IRB/EC;
Com position of  the IRB/EC;
Record of all co mmu nicati ons between the i nvestigator, Celgene, and their authorized 
representative(s);
List of Sub -invest igators and other appropriately qualified persons to whom the 
investi gator has del egated si gnificant study -related duti es, together wi th their roles in 
the study , curri culum vi tae, and thei r signatu res;
Copi [INVESTIGATOR_348868] (if paper) and of documentation of corrections for all subjects;
IP accoun tabilit y records;
Record of any body  fluids or ti ssue samples retained;
All other source documents (subject records, hospi[INVESTIGATOR_1097], laboratory  records, 
etc.); 
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
95 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017All other documents as listed in Secti on8 of the ICH consolidated guideline on GCP 
(Essent ial Docum ents for the Conduct of a Clinical Trial).
The i nvest igator must notify Celgene if he/she wishes to assign the essent ial docum ents to 
someone else, remove them to another l ocati on or is unable to retain the m for a specified period.  
The i nvest igator must obtain approval in writ ing from Celgene pri or to dest ruction of any 
records. If the i nvest igator is unable to meet thi s obligat ion, the i nvest igator must as k Cel gene 
for permissio n to m ake al ternative arrangements. Details of these arrangements should be 
docum ented. 
All study  docum ents shoul d be made available if required b y relevant healt h authorities. The 
investi gator or institution shoul d take measures to prevent accidental or premature destruction of 
these documents.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
96 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539542] igator and the staff at a study
initiation visit and/or at an i nvestigators’ Meeting.  Prior to enrolling subjects into the study , a 
Celgene representati ve will review the protocol, eCRFs, procedures for ob taining informed 
consent, record keepi[INVESTIGATOR_007], and reporting of AEs/SA Es with the i nvest igator.  Monitoring will 
include on -site visi ts with the i nvest igator and his/her staff as well as any appropriate 
communicat ions by [CONTACT_2319], email, fax, or telephone.  During mo nitoring visits, the facilit ies, 
investigat ional product storag e area, eCRFs, subject’s source documents, and all other study  
docum entati on will be inspected/reviewed by  [CONTACT_348957] h the 
Study  Moni toring Pl an.
Accuracy  will be checked by [CONTACT_81706] i s a di rect com parison of 
the entries made onto the eCRFs against the appropriate source documentation.  Any result ing 
discrepan cies will be reviewed with the i nvest igator and/or his/her staff.  Any necessary 
correcti ons will be made direct ly to the eCRFs or via queri es by [CONTACT_941] i nvest igator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusio n/exclusion 
criteria and docum entati on of  SAEs and their proper recording be verified.  Addit ional 
monitoring act ivities may be out lined in a study -specific m onitoring pl an.
15.2. Audits and Inspections
In addit ion to the routine monitoring procedures, a Good Clinical Pract ice Qualit y Assurance 
unit exists wit hin Celgene.  Representatives of this unit will conduct audi ts of clinical researc h 
activit ies in accordance with Celgene SOPs  to evaluate compliance with Good Clinical Pract ice 
guidelines and regulations.
The i nvest igator is required to permit direct access to the facilit ies where the study  took place, 
source documents, eCRFs and appl icable supporting records of study  subject parti cipat ion for 
audits and inspect ions by [CONTACT_1744]/ ECs, regul atory authori ties (e g,Food and Drug Administration
[FDA ], 
European Medicines Agency [EMA] , Health Canada) and com pany auth orized 
representatives.  The i nvest igator should make every  effort to be available for the audi ts and/or 
inspections.  If the i nvest igator is contact[CONTACT_348958], 
he/she shoul d contact [CONTACT_27740].
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
97 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539543] authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recrui tment, data qualit y, parti cipat ion in data analysis, participation in study  steering co mmittee 
(when applicable) and contribut ion to abstract, presentation and/or publicat ion developmen t.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
98 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201717. REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ ,et al. The European
Organizat ion for Research and Treatment for Cancer QLQ- C30: a qualit y-of-life instrument for 
use in internat ional clinical trials in onco logy. J Natl  Cancer Inst . 1993;85(5) :365- 76.
American Heart Associat ion [ADDRESS_539544] ive Assessment of Patien ts Wi th Diseases of the Heart. Amer ican Heart Associat ion 
website. Available at: 
http://my.americanheart.org/professio nal/Statem entsGui delines/By[CONTACT_146967] c/Topi [INVESTIGATOR_426824]-H/Funct ional-
Capacit y-and-Obj-Assessment -of-Patients-With-Diseases -of-the-
Heart_UCM_424309_Articl e.jsp. Accessed 05 Aug 2015.
.  
Cheson BD, Bennett JM, Kopecky  KJ, Büchner T, Willman CL, Estey  EH, et al . Revised 
recommendat ions of the International Working Group for diagnosis, standardizat ion of response 
criteria, treatm ent outcom es, and reporti ng standards for therapeutic trials in acute myeloid 
leukemia. J Clin Onco l. 2003;21(24):[ADDRESS_539545], Bennett JM, Lowenberg B, Wijermans PW, Nimer SD ,et al.  
Clinical applicat ion and proposal for modificat ion of the International Working Group (IWG) 
response criteria in myelodysplasia. Blood 2006; 108(2):419-25.
Commo n Termino logy Criteria f or Adverse Events (CTCAE ), versi on 4.0 3. 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -
06-14_QuickReference_8.5x11.pdf .
Accessed 05 Aug 2015.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
99 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Food and Drug Administration D rug Development and Drug Interactions Website: Table 7.  
Examples of Sensi tive In Vivo CYP Substrates and CYP Substra tes wi th Narrow Therapeutic 
Range (7/28/2011) .  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio
nsLabeling/ucm080499.htm .Accessed 05 Aug 2015.
Food and Drug Administration
Drug Development and Drug Interactions Websi te: Table 13.  
Examples of In Vivo Substrat
es for Selected Transporters (7/28/2011) .  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractio
nsLabeling/ucm080499.htm .Accessed 05 Aug 2015.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
100 AG-221-AML -004 Amendment 2.0 Final :[ADDRESS_539546] ic syndro mes[published erratum appe ars in 
Blood 1998;91(3):1100] . Blood1997;89(6) :[ADDRESS_539547] in survival analysis. J Bi
opharm  Stat 2016;26(4) : 790-800.
Managan JK, Luger SM. Salvage therapy for relapsed or refractory acu te myel oid leukemia. 
Ther Adv Hematol. 2011; 2(2):73 -
82.
Oken MM, Creech RH, Tormey DC, Horton J, D avisTE, McFadden ET, et al. Toxicit y and 
response criteria of the Eastern Cooperative Onco logy Group. 
AmJClin Onco l.
1982;5(6):649 - 55.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
101 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Rizzo JD, Brouwers M, Hurley  P, Sei denfeld J, Arcasoy  MO, Spi[INVESTIGATOR_92316], et al . American Society  
of Hematol ogy/American Soci ety of Clinical  Oncol ogy clinical  pract ice guideline update on the 
use of epoeti n and darbepoetin in adult patients with cancer. Bl ood 2010; 116(20):4045 -59.
Robins JM , Tsiatis AA. Correcting for non -
compliance in rando mized trials using rank 
preserving structural failure t ime models. Commun Stat Theory  Methods 1991;20 (8):2609 -31.
Robins JM, Finkelstein DM. Correcting for non compliance and dependent censoring in an AIDS 
clinical trial with inverse probabilit y of censoring weighted (IPCW) long -rank test s. 
Biometrics2000
;56(3): [ADDRESS_539548] igator choice in pat ients with 
relapsed/refractory  acute myel oid leukemia. J Clin Onco l. 
2014;32(18):1919 - 26.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
102 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Swerdl ow, SH, Cam po, E, Harri s, NL, Jaffe, ES, Pi[INVESTIGATOR_12348], SA, Stein, H, et al. editors. WHO 
Classificat ion of Tum ors of  Haem atopoi etic and Lympho id Tiss ues. 4th ed. Ly on, [LOCATION_009]: 
IARC Press; 2008;109-39.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2 008 
revisio n of the World Healt h Organizat ion (WHO) cl assificat ion of myelo id neoplasms and acute 
leukemia: r ationale and important changes. Blood 2009;114(5):937-
51.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
103 AG-221-AML -004 Amendment 2.0 Final :30 Nov 201718. APPENDICES
Appendix A:  Table of Abbreviations
Table 4: Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term Expl anation
ACS Acute coronary syndrome
AE Adverse event
ALP Alkaline phosphatase
ALT Alanine aminotransferase (SGPT)
AML Acute myeloid leukemia
ANC Absolute neutrophil count
AST Aspartate aminotransferase (SGOT)
BCRP Breast cancer resistance protein
β-hCG β-subunit of human chorionic gonadotropin
BID Twice a day
BP Blood pressure
BMA Bone marrow aspi[INVESTIGATOR_426825] 2 Carbon dioxide
CR Morphologic complete remission
CRh Morphologic complete remission with partial hematologic recovery
CRi Morphologic complete remission with incomplete neutrophil recovery
CRp Morphologic complete remission with incomplete platelet recovery
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
104 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 4:Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Expla
nation
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of variation
CYP Cytochrome
DNA Deoxyribonucleic acid
DMC Data Monitoring Committee
EBV Epstein -Barr virus
EC Ethics Committee
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form
EEA European Economic Area
EFS Event -free survival
EMA European Medicines Agency
EORTC European Organization for Research and Treatment of Cancer
EOT End of treatment
FCBP Fema le of childbearing potential
FDA Food and Drug Administration
GCP Good Clinical Practice
G-CSF Granulocyte -colony stimulating factor
GFR Glomerular filtration rate
GGT Gamma glutamyl transpeptidase
GI Gastrointestinal
GM-CSF Granulocyte macrophage colony -stimulating factor
GVHD Graft -versus -host disease
HBV Hepatitis B virus
HCV Hepatitis C virus
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
105 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 4:Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
HDPE High density polyethylene
HI Hematologic improvement
HI-E Hematologic improve ment erythroid response
HI-N Hematologic improve ment neutrophil response
HI-P Hematologic improve ment platelet response
HIV Hum an immunodeficiency virus
HR Hazard ratio
HRQoL Health-related Quality -of-Life
HSCT Hematopoietic stem cell transplantation
IB Investigator’s Brochure
ICF Infor med consent form
ICH International Council on Harmonisation
IDAC Inter mediate -dose cytarabine
IDH Isocitrate dehydrogenase
IDH2 Isocitrate dehydrogenase [ADDRESS_539549]
ITT Intent -to-treat
IV Intravenous ly
IVRS Interactive voice response system
IWG International Working Group
KM Kaplan -Meier
LDAC Low-dose cytarabine
LDL -C Low-density lipoprotein cholesterol
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
106 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 4:Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
LDH Lactate dehydrogenase
LVEF Left ventricular ejection fraction
MDS Myelodysplastic syndromes
MCH Mean corpuscular h emoglobin
MCHC Mean c orpus cular hemoglobin c oncentration
MCV Mean corpuscular v olume
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary for Regulatory Activities
mITT Modified intent -to-treat
MLFS Morphologic leukemia -free state
MPN Myeloproliferative neoplasm
MUGA Multi -gated acquisition
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
NIP Non-investigation product
NYHA [LOCATION_001] Heart Association
OAT Organic anion transporter 
ORR Overall response rate
OS Overall survival
PCR Polymerase chain reaction
PD Progressive disease
P-gp P-glycoprotein
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
107 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 4:Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
PO Orally
PR Partial remission
PT Prothrombin time
PTT Partial thromboplastin time
QD Once a day
QTc Heart rate -corrected QT
QTcF QTc with Fridericia’s correction
RBC Red blood cell
SAE Serious adverse event
SAP Statistical analysis plan
SC Subcutaneous
SD Stable disease
SDev Standard deviation
SGOT Serum glutamic oxaloacetic transaminase 
SGPT Serum glutamic pyruvic transaminase
SmPC Summary of Product Characteristics
SOP Standard operating procedure
S[LOCATION_003]R Suspected unexpected serious adverse reaction
UDP Uridine diphosphate
UGT1A1 UDP -glucuronosyltransferase [ADDRESS_539550] Upper limit of normal
US [LOCATION_002]
WBC White blood cell
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
108 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Table 4:Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term Explanation
WHO World Health Organization
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
109 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix B :  World Health Organization Classification of Acute Myeloid 
Leukemia
Acute myeloid leukemia with recurrent genetic abnormalities
Acute myelo id leukemia wi th t(8;21)(q22;q22); (RUNX1 -RUNX1T1)
Acute myelo id leukemia wi th inv(16)(p13.1q22) or t(16;16)(p13.1;q22); 
(CBFB -MYH11)
Acute promyelocy tic leukemia wi th t(15;17)(q22;q12); (PML -RARA)
Acute myel oid leukemia wi th t(9;11)(p22;q23); MLLT3 -MLL
Acute myelo id leukemia wi th t(6;9)(p23q34); DEK -NUP214
Acute myelo id leukemia wi th inv(3)(q21q26.2) or t(3;3)(q26.2); RPN1 -EVI1
Acute myelo id leukemia (megakary oblast ic) with t(1;22)(p13;q13); RBM15 -MKL1
Acute myelo id leukemia wi th gene m utations
Acute myeloid leukemia with myelodysplasia -related changes
Therapy -related myeloid neoplasma
Acute myeloid leukemia, not otherwise categorized
Acute myelo id leukemia wi th minimal differentiation
Acute m yeloid leukemia wi thout m aturati on
Acute myelo id leukemia wi th maturati on
Acute myelo monocy tic leukemia
Acute m onoblast ic and monocyt ic leukemia
Acute ery throid leukemia (ery throid/myel oid and pure ery throleukemia)
Acute m egakary oblast ic leukemia
Acute bas ophilic leukemia
Acute panmyelosis wit h myelo fibrosis
Source: Swerdlow, 2008.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
110 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix C :  Acute Myeloid L eukemia Risk Status
Risk Status Cytogenetics Molecular Abnormalitiesa
Better -risk inv(16)b, c
t(16;16)b
t(8;21)b
t(15;17)Normal cytogenetics:
NPM1 mutation in the absence of 
FLT3 -ITD or isolated biallelic 
CEBPA mutation 
Inter mediate -risk Normal cytogenetics
+8
t(9;11)
Other non -definedt(8;21), inv(16), t(16;16):
with c -KIT dmutation
Poor-risk Complex ( ≥ 3 clonal chromosomal 
abnor malities)
Monosomal karyotype
-5, 5q -, -7, 7q-
11q23 -non t(9;11)
inv(3), t(3;3)
t(6;9)
t(9;22)eNormal cytogenetics:
with FLT3 -ITD mutation f
aThe molecular abnormalities included in this table reflect those for which validated assays are available in 
standardized commercial laboratories.  Given the rapi[INVESTIGATOR_426826], risk stratification should be modified 
based on continuous evaluation of r esearch data.  Other novel genetic mutations have been identified that may 
have prognostic significance.  
bOther cy togenetic abnormalities in addition to these finding do not alter risk status.
cPaschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corb acioglu A, et al. Secondary genetic lesions in acute 
myeloid leukemia with inv(16) or t(16;16): a study of the German -Austrian AML study group (AMLSG). 
Blood 2013; 121:170-177.
dEmerging data indicates the presence of c -KIT mutation in subject s with t(8;21), and to a lesser extent, inv( 16), 
confers a high risk of relapse.  These subject s should be considered for clinical trials, if available .
eFor Philadelphia+ acute myeloid leukemia (AML) t(9;22), manage as myeloid blast crisis in chronic myeloid 
leukemia (CML), with addition of tyrosine kinase inhibitors.  These subjects are excluded from study entry .
fFLT3 -ITD mutations are considered to confer a significant poor outcome in subject s with no rmal karyotype, and 
these subject s should be considered fo r clinical trials where available.  There is controversy as whether FLT3 -TKD 
mutations carry equally poor prognosis
Source:  
Natio nal Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia. 
Natio nal Comprehensive Cancer Network website.  Available at 
http://www nccn.org/professionals/physician_gls/PDF/aml.pdf .  Accessed 05 Aug 2015 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
111 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix D:  Eastern Cooperative Oncology Group (ECOG) Performance 
Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Grade ECOG
0 Fully  active, able to carry on all pre -disease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary  nature, eg, light house work, office work.
2 Ambulatory and capable of all selfcare but unable to carry out any work activities.  Up and about 
more than 50% of waking hours.
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.
4 Completely disabled.  Cannot carry on any selfcare.  Totally confined to bed or chair.
5 Dead.
Source :  Oken,1982 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
112 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix E:  [LOCATION_001] Heart Association Classification for Congestive Heart 
Failure
Functional Capacity
Class I.   Subjects with cardiac disease but without resulting limitation of physical activity.  Ordinary 
physical activity does not cause undue fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class II.   Subjects with cardiac disease resulting in slight limitation of physical activity.  They are 
comfortable at rest.  Ordinary physical activity results in fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class III.   Subjects with cardiac disease resulting in marked limitation of physical activity.  They are 
comfortable at rest.  Less than ordinary activity causes fatigue, palpi[INVESTIGATOR_332], dyspnea, or anginal pain.
Class IV.   Subjects with cardiac disease resulting in i nability to carry on any physical activity without 
discomfort.  Symptoms of heart failure or the anginal syndrome may be present even at rest.  If any 
physical activity is undertaken, discomfort is increased.
Source: Ameri canHeart Association, 1994 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
113 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix F :  International Worki ng Group Acute Myeloid Leukemia 
Response Criteria
Hematologic Response According to modified IWG Criteria for AML
Category Definition
Morphologic Complete Remission (CR) Defined as less than 5% blasts in a BM aspi[INVESTIGATOR_426827] a count of at least 200 nucleated cells. There should be no blasts with 
Auer rods and absence of extramedullary disease.  Plus, all the following 
conditions should be met:
 ANC ≥ 1 x 109/L (1,000/μL)
 Platelet count ≥ 100 x 109/L (100,000/μL)
 Independent of red cell transfusions for ≥ 1 week immediately 
before each response assessment
Morphologic Complete Remission with 
Incomplete Neutrophil Recovery (CRi)aDefined as all criteria of CR except the following:
 ANC < 1 x 109/L (1,000/μL)
Morphologic Complete Remission with 
Incomplete Platelet Recovery (CRp)aDefined as all criteria of CR except the following:
 Platelet count < 100 x 109/L (100,000/μL)
Morphologic Complete Re mission with 
Partial H ematologic Recovery ( CRh )aDefined as all criteria of CR except the following:
 ANC > 0.5 x 109/L (500 /μL); and
 Platelet count > 50 x 109/L (50 ,000/μL)
Morphologic Leukemia -free State 
(MLFS)Defined as less than 5% blasts in a BM aspi[INVESTIGATOR_426827] a count of at least 200 nucleated cells. There should be no blasts with 
Auer rods and absence of extramedullary disease
Partial Remission (PR) Defined as all hematologic criteria of CR with a > 50% decrease in the 
percentage of BM blasts to 5% to 25% (a blast count value of < 5% may also 
be considered a partial remission if Auer rods are present) b
Cytogenetic Complete Remission (CRc) Defined as CR/CRi/CRp with a reversion to a normal karyotype in cases with 
an abnormal karyotype at baseline, based on evaluating ≥ 20 metaphase BM 
cells
Morphologic Relapse after CR/CRi/CRpaDefined as one of the following conditions:
 Reappearance of ≥5% blasts in the BM not attributable to any other 
cause (eg, BM regeneration after consolidation therapy); or 
 Development of extramedullary disease
Not evaluable (NE)aDefined as without a post treatment response assessment
Stable Disease (SD)aDefined as failure to meet any of the above criteria and not meeting the 
criteria of progressive disease (see below)
Progressive Disease (PD)aDefined as one of the following conditions:
 For subjects with 5 to 70% BM blasts at baseline: a > 50% increase 
of BM blast count percentage from baseline to ≥ 20%; or
 For subjects with > 70% BM blasts at baseline: a doubling of 
absolute blast count in peripheral blood from baseline to ≥ 10 x 
109/L (10,000/μL); or
 Development of new extramedullary disease since last respo nse 
assessment
Progressive disease is to be confirmed by [ADDRESS_539551] date that one of three conditions listed above was met.
AML = Acute Myeloid Leukemia ; ANC= Absolute Neutrophil Count; BM= Bone M arrow; IWG= International Working Group .
aModification to IWG response criteria.   Note :CRh is not available for the investigator’s assessment and will be assessed by [CONTACT_426877] .
bIf the pre -treatment bone marrow blast percentage was 50% to 100%, the percentage of blasts must decrease to a value between
5% and 25%; if the pre -treatment blast percentage was 20% to less than 49%, they must decrease by [CONTACT_426878] a value of 
more than 5% .
Notes:  Deletions to the IWG response criteria are not shown.  
Source: Cheson, 2003 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
114 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix G : Definitions of Prior Line of AML Therapy
A line o f AML therapy  is defined as cy totoxic chem otherapy  or low-intensit y therapy, single 
agent or in combinat ion, delivered with the intent to induce remissio nand/or prolong survival.   
If remissio n is not induced by [CONTACT_426879] (eg, cytarabine 100 -200 m g/m2continuous infusio n 
for 7 days ), the second cycle is modified (eg,cytarabine 1 to 3g/m2every 12 hours for 3 to 
7days) wi th the intent to induce remissio n, then the subject has received two different lines of 
AML therapy .  Treatment modifications wit h the intent to manage toxicit y arenot counted as 
separate lines.   
The line used for re -induct ion for first relapse is also regarded as a second line even if the same 
drugs are given at the same doses as for the first remissio n induct ion, since the disea se 
characterist ics have changed from diagnosis to relapse.
Post-remissio n strategi es(regimens) such as c onsolidat ion or maintenance are not coun ted as 
separate line s.
Transplantation is considered as a line if gi ven wi th the intent to induce remissio n.  However, 
transpl antati onas a post- remissio n strategy  is not considered a separate line as it is regarded as 
conso lidation.
Hydroxyurea is not counted as a separate line.
Note that, for subjects having AML secondary to prior higher risk (Intermediate -2 or High risk 
according to the International Prognostic Scoring Sy stem  [see bel ow]) MDS treated wi th a 
hypo methylat ing agent [eg, azacitidine or decitabine], the hypo methylat ing therapy can be 
counted as a line if there is disease progression to AML during o r shortly (eg, within 60 days) 
after the hypom ethylat ing therapy.
International Prognostic Scoring System  for MDS
Prognostic VariableScore Value
0 0.5 1.0 1.5 2.0
Bone Marrow Blasts (%) < 5 5-10 - 11-20 21-30
KaryotypeaGood Intermediate Poor - -
Cytopeniasb0 or 1 2 or 3 - - -
aGood :  normal, -Y, del(5q), del(20q); Poor :  complex ( 3 abnormalities) or chromosome 7 anomalies; 
Intermediate :  other abnormalities.
bDefined as :  Hemoglobin < 100 g/L, absolute neutrophil count < 1. 5x 109/L, and platelet count < 100 x 109/L.
Note :  Scores for risk groups are as follows :  Low = 0; INT -1 = 0.5 -1.0; I NT-2 = 1.5-2.0; and High :  2.5.
Source : Greenberg, 1997 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
115 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix H :  Hematologic Improvement According to the International 
Working Group f or Myelodysplastic Syndromes
Hematologic Improvement According to IWG Criteria
Hematologic improvementaResponse criteria (responses must last at least 8 week)b
Erythroid Response (HI -E) 
(pre-treatment, <11 g/dL) Hemoglobin increase by ≥1.5 g/dL
Relevant Reduction in units of RBC transfusions by [CONTACT_51244] 4 RBC transfusions/8 w eek compared with the pretreatment 
transfusion number in the previous 8 w eek
Note: Only RBC transfusions given for a hemoglobin of ≤9.0 g/dL on treatment 
will count in the RBC transfusion response evaluationb
Platelet Response  (HI -P)
(pre-treatment, <100 X 
109/L) Absolute increase of ≥30 X109/L for subjects starting with >20 X
109/L platelets 
Increase from < 20 X 109/L to >20 X 109/L and by [CONTACT_2669] 100%b  
Neutrophil Response (HI -N)
(pre-treatment, <1.0 X
109/L) At least 100% increase and an absolute increase >0.5 X 109/Lb  
Progression or Relapse After 
HIcAt least 1 of the following:
At least 50% decrease from maximum response levels in granulocytes 
or platelets
Reduction in hemoglobin by ≥1.5 g/dL
Transfusion dependence
HI-E = hematologic improvement erythroid response; HI -N = hematologic improvement neutrophil response; HI -P= 
hematologic improvement platelet response; IWG = International Working Group; RBC = red blood cell.
aPre-treatment counts averages of at least 2 measurements (not influenced by [CONTACT_27752], ie, no RBC transfusions for 2 weeks 
and no platelet transfusions for 1 week) ≥1 week apart (modification).  
bModification to IWG (2000) response criteria.
cIn the absence of another explanation, such as acute infection, repeated courses of chemotherapy (modification), 
gastrointestinal bleeding, hemolysis, and so forth.  It is recommended that the 2 kinds of erythroid and platelet responses be 
reported overall as well as by [CONTACT_27753].
Note:  Deletions to the IWG response criteria are not shown.  To convert hemoglobin levels from grams per deciliter to grams per 
liter, multiply grams per deciliter by 10.  
Source:  Cheson, 2006 .
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221-AML -004 Celgene Corporati on
116 AG-221 -AML -004 Amendment 2.0 Final :30 Nov 2017Appendix I: European Organi zation for R esearch and Treatment of Cancer 
Quality -of-Life questionnaire (Version 3.0)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221-AML -004 Celgene Corporati on
117 AG-221 -AML -004 Amendment 2.0 Final :30 Nov 2017Appendix I:  European Organization for Research and Treatment of Cancer
Quality -of-Life questionnaire (Version 3.0) ( Continued)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221-AML -004 Celgene Corporati on
118 AG-221 -AML -004 Amendment 2.0 Final :30 Nov 2017Appendix J:  EQ-5D-5L Health Questionnaire (English Version for the [LOCATION_006])
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221-AML -004 Celgene Corporati on
119 AG-221 -AML -004 Amendment 2.0 Final :30 Nov 2017Appendix J:  EQ -5D-5L Health Questionnaire (English Version for the [LOCATION_006])
(
Continued)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
120 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix K: Subcutaneous Preparation and Administration of Azacitidine
Recommendations for Safe Handling 
Azacit idineis a cy totoxi c medicinal product and, as with other potentially toxic compounds, 
cauti onshoul d be exercised when handling and preparing azacit idine suspensio ns. Procedures 
for proper handling and disposal o f anticancer medicinal products should be appli ed.  If 
reconstituted azacit idine co mes into contact [CONTACT_426880], immediately  and thoroughly wash 
withsoap and water. If it com es into contact [CONTACT_426881], flush thoroughly wit h 
water.
Overview of Two Methods for Preparing Injection 
Azacit idine de grade s rapi [INVESTIGATOR_426828]; therefore the 
azacit idine suspension should be prepared immediately before use (Method A) or should be 
refrigerated immediately  after reconsti tution (Method B). 
Method A: The total time fr om reconst itution to administration should be no greater than 
45minutes (60 minutes in the US):
1.Reconst itute (see next page for instructions).  Record time of reconst itution. 
2.Prior to administrati on to the subject, the nurse/doctor must check the time o f
reconstitution.  If elapsed time is greater than 45 minutes (60 minutes in the US), the dose 
shoul d be discarded appropriately and a new dose prepared.
3.Nurse or doctor must administer dose to subject and record time of administration. 
Method B: If the product must be reconstituted in advance of the dose, it should be prepared as 
follows: 
1.Reconst itute.  Record time of reconst itution.
2.Place in refrigerator (2°C to 8°C
[36°F to 46°F] )immediately .  Record time of placement 
in refrigerator.  If the suspensio n is prepared using water for inject ions that has not been 
refrigerated (2°C to 8°C [36°F to 46°F]), the suspensio nmay be held under refrigerat ed
condi tions for a m aximum  of 8hours (22hours if the suspensio n is prepared using 
refrigerated water for inject ions).
3.When ready  to administer, rem ove from  refrigerator.  Record time.  If elapsed time held 
in refrigerator is over the m aximum hours as defined above , the suspensio n shoul d be 
discarded appropri ately  and a new dose prepared. 
4.The sy ringe fil led wit h reconst ituted suspension should be allowed, up to 30 minutes 
prior to administration, to reach a temperature of approximately  20°C to 25°C (68°F to 
77°F).
5.Prior to administrati on to the subject, the nurse/doctor must check the time o f removal 
fromthe refrigerator.  If el apsed time is more than [ADDRESS_539552] time of administration.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
121 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix K:  Subcutaneous Preparation and A dministration of Azacitidine
(Continued)
Preparing the suspension for subcutaneous administration:
1.Assemble the fo llowing supplies:
Vial(s) of azacit idine; 
Vial(s) of sterile water for injection;
Nonsterile surgical glo ves;
Alcoho l wipes;
5 mL syringe(s) with 18-gauge needle(s); and
Addit ional 25 -gauge needle(s) for subcutaneous inject ion.
2.Docum ent the sequence number of vial(s) on the source document.
3.Wash and dry  hands and put on gloves.
4.Remove the sy ringe from  its protecti ve wrapper by [CONTACT_426882].
5.Remove the pl astic cover from the sterile water vial and use an alcoho l wipe to cl ean the 
rubber top.  Do not touch the rubber top after it is cleaned.
6.Remove the pl astic cover from the azacit idine vial, shake the vial to break up the 
lyophilized cake, and use a fresh alcohol wipe to clean the rubber top.  Do not touch the 
rubber top after it is cleaned. 
7.Remove the pl astic cap fro m the 18-gauge needle an d attach to the sy ringe.  Never touch 
the needle.
8.Pull the plunger back to the [ADDRESS_539553] the needle/syringe in the v ial and turn the vial upside down.  Make sure the needle 
tip is below the level o f the liquid.  Pull  the pl unger back to draw 4 mL of sterile water 
into the sy ringe, m aking sure to purge any  air trapped wi thin the syringe. 
11.Pull the needle/syringe out of t he vial and set the vial down.
12.Insert the needle of the syringe with sterile water through the rubber top of the azacit idine 
vial and slowly inject the [ADDRESS_539554] time in the pharmacy  and other 
applicable records.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
122 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix K:  Subcutaneous Preparation and Administration of Azacitidine 
(Continued)
13.Remove the sy ringe and needle.  The vial should be vigorously  shaken unt il a uniform 
cloudy  suspensi on is achieved.  The reconstituted product is a ho mogeneous, cloudy  
suspension, free of agglo merates.  The product should be discarded if it contains large 
particles or aggl omerates.  Do not filter the suspension after reconstitution since this 
could rem ove the act ive substance.  It must be taken into account that filters are present 
in some adapters, spi[INVESTIGATOR_2988], and closed systems; therefore such systems should not be used 
for adm inistrati on of  the drug after reconstitution.   After reconstitution each milliliter of 
suspension will contain 25 mg of azacit idine (100 mg/4 mL).
14.Using an alcoho l wipe, clean the rubber top and insert a new needle and syringe.  Turn 
the vial upside down. Make sure the needle tip is below the level o f the liquid.  Pull the 
plunger back to withdraw the amount of drug required for the proper dose, making sure to 
purge any  air trapped wi thin the syringe. 
15. Pull the needle/syringe out of the vial.  Properly dis pose of the needle according to local 
pharmacy standard operating procedures and other applicable guidelines.
16.Remove a fresh subcutaneous needle (recommended 25 -gauge) for inject ion from its 
paper wrapper and firmly attach it to the sy ringe, being careful to not touch the ti p of the 
syringe.
17.If needed (doses over 100 mg) repeat all the above steps for preparation of the 
suspension.  For doses greater than 100 mg (4 mL), the dose should be equally divided 
into 2 sy ringes (eg, dose 150 mg = 6 mL, 2 sy ringes w ith 3 m L in each sy ringe).  All 
syringes shoul d be prepared pri or to starting administration.
The contents of the dosing syringe must be re -suspended immediately prior to administration.  
The tem perature of the suspensio n at the time of inject ion shoul d be approximately  20°C to 25°C 
(68°F to 77°F).  To re -suspend, vigorously ro ll the syringe between the palms unt il a uniform , 
cloudy  suspensi on is achieved.  The product should be discarded if it contains large particles or 
agglomerates.  Azacit idine is suppl ied in single -use vials that cannot be used more than once. 
After rem oving the dose needed, dispose of all used sterile water vials and needles appropriately. 
All partially used and empt y vials should not be retained, but d isposed of in accordance wit h 
local requi rements . Each vial number and amount used per subject should be carefully 
docum ented in the applicable site and pharmacy records. 
Subcutaneous injection of suspension
1.Select the si te(s) for inject ion: either of the upper arms, thigh, or abdomen .  Injection si tes 
within an inject ion area must be different from [ADDRESS_539555] astic cap fro m the subcutaneous needle, being careful to not touch the 
needle. 
4.Pi[INVESTIGATOR_820] a 2 -inch fold of skin at the injection site between your thumb and forefinger.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
123 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix K:  Subcutaneous Preparation and Administration of Azacitidine 
(Continued)
5.Insert the needle at a 90 angle unt il it is completely inserted.
6.Pull back on the plunger slight ly to check for blood.  If blood appears in the syringe, 
withdraw the sy ringe and select another site, then repeat steps 2, 4, 5, and 6.
7.If no bl ood appears in the sy ringe, push the plunger forward and inject the drug.
8.Withdraw the sy ringe an d swab the area with alcoho l.
9.If needed (doses over 100 mg) repeat all the above steps for subcutaneous inject ion of the 
suspension.  A new location should be selected for administration of each part of the 
dose.  Document location(s) of dose(s) administer ed.
10.New inject ions should be given at least [ADDRESS_539556](s).  
When doses exceed 100 mg and/or more than 1 injection is administered, the “time of 
subcutaneous inject ion” shoul d be recorded as the time of completion o f the last 
inject ion.
12.Appropriately dispose of all needles and sy ringes in accordance wit h local requi rements.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
124 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix L:  Azacitidine Dose Modifications due to Hematologic Toxicity –
Subjects without Reduced Baseline Blood Counts
Hematological toxicity 
observed in a given cycle
Delay the next cycle 
until platelet count 
and ANC have 
recoveredSubjects witho utreduced baseline blood counts*
Reduce doseNo dose
adjustment needed
Nadir counts % dose to give in next cycle
ANC (x 109/L) Platelets (x 109/L)
1 50 50%
> 1 > 50 100%
* White blood cells (W BC) ≥ 3.0 x 109/L and a bsolute neutrophil count (ANC) ≥ 1.5 x 109/L and platelets ≥ 75.0 x 109/L prior to the first treatment
** Recovery = counts nadir count + ( 0.5 x [ Baseline count –nadir count])
Following dose adjustments, cycle duration should return to 28 daysRecovery** not achieved within 14 days Recovery** achieved within 14 days
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
125 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix M :  Azacitidine Dose Modifications due to Hematologic Toxicity –
Subjects with Reduced Baseline Blood Counts
Delay the next cycle 
until platelet count 
and ANC have 
recoveredSubjects withreduced baseline blood counts*
Delay treatment 
and adjust doseDetermine bone
marrow cellularity
Bone marrow 
cellularity% dose to give in next cycle
Recovery** 21 days Recovery** > 21 days
15-50% 100% 50%
< 15% 100% 33%
* White blood cells (W BC) < 3.0 x 109/L or absolute neutrophil count (ANC) < 1.5 x 109/L or platelets < 75.0 x 109/L prior to the first treatment
** R   t   i  t  ( 0 5  [ B li  t i  t])
Following dose adjustments, cycle duration sho uld return to 28 daysReduction in W BC/ ANC/ platelets
from that prior to treatment > 50%,
with no improvement 
in cell line differentiation
Recovery** achieved within 14 days
No dose
adjustment neededHematological 
toxicity observed in 
a given cycle
No dose
adjustment neededNo delay or dose
adjustment neededReduction in W BC/ ANC/ platelets
from that prior to treatment < 50%,
or > 50%, with improvement 
in cell line differentiation
Recovery** not achieved within 14 days
≤50%>50%
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
126 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appe ndix N :  Cytochrome Sensitive Substrates
From Food and Drug Administration (FDA ) Drug Development and Drug Interactions Website: 
Table 7. Examples aof Sensitive In Vivo Cytochrome ( CYP )Substrates and CYP Substrates with 
Narrow Therapeutic Range (7/28/2011)
CYP 
EnzymesSensitive substrates bSubstrates with narrow therapeutic rang e c
CYP1A2 Alosetron, caffeine, Theophylline, tizanidine
duloxetine, melatonin, ramelteon,
tacrine, tizanidine
CYP2B6 dBupropi[INVESTIGATOR_2394], efavirenz
CYP2C8 Repaglinide ePaclitaxel
CYP2C9 Celecoxib Warfarin, phenytoin
CYP2C19 Lansoprazole, omeprazole, 
S-mephenytoinS-mephenytoin
CYP3A fAlfentanil, aprepi[INVESTIGATOR_053], budesonide, 
buspi[INVESTIGATOR_5331], conivaptan, darifenacin, 
darunavir, dasatinib, dronedarone, 
eletriptan, eplerenone, everolimus, 
felodipi[INVESTIGATOR_050], indinavir, fluticasone, 
lopi[INVESTIGATOR_054], lovastatin, lurasidone, 
maraviroc, midazolam, nisoldipi[INVESTIGATOR_050], 
quetiapi[INVESTIGATOR_050], saquinavir, sildenafil, 
simvastatin, sirolimus, tolvap tan, 
tipranavir, triazolam, vardenafil , 
grapefruit juiceAlfentanil, astemizole g, cisapride g,
cyclosporine, dihydroergotamine, ergotamine, 
fentanyl, pi[INVESTIGATOR_3924], quinidine, sirolimus, 
tacrolimus, terfenadineg
CYP2D6 Atomoxetine, desipramine, 
dextromethorphan, metoprolol, 
nebivolol, perphenazine, tolterodine, 
VenlafaxineThioridazine
aNote that this is not an exhaustive list . For an updated list, see the following link : 
http://www fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/uc
m080499.htm .  Accessed [ADDRESS_539557] been shown to increase 5 -fold or higher 
when co -administered with a known CYP inhibitor.
cCYP substrates with narrow therapeutic range refers to drugs whose exposure -response relationship indicates 
that small increases in their exposure levels by [CONTACT_119586] (e.g., Torsades de Pointes).
dThe AUC of these substrates were not increased by [ADDRESS_539558] sensitive substrates studied with available inhibitors evaluated to date.
eRepag linide is also a substrate for OATP1B1, and it is only suitable as a CYP2C8 substrate if the inhibition of 
OATP1B1 by [CONTACT_135719].
fBecause a number of CYP3A substrates (e.g., darunavir, maraviroc) are also substrates of P -gp, the observed 
increase in exposure could be due to inhibition of both CYP3A and P -gp.
gWithdrawn from the [LOCATION_002] market because of safety reasons.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
127 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix O :  Transporter Sensitive Substrates
From Food and Drug Administration (FDA ) Drug Development and Drug Interactions Website : 
Table 13. Examples of In Vivo Substrat es for Selected Transporters a(7/28/2011)
Transporter Gene Substrate
P-gp ABCB1 Aliskiren, ambrisentan, colchicine, dabigatran 
etexilate, digoxin, everolimus, fexofenadine, 
imatinib, lapatinib, maraviroc, nilotinib, 
posaconazole, ranolazine, saxagliptin, 
sirolimus, sitagliptin, talinolol, tolvaptan, 
topotecan
BCRP ABCG2 Methotrexate, mitoxantrone, imatinib, 
irinotecan, lapatinib, rosuvastatin, 
sulfasalazine, to potecan
OATP1B1 SLCO1B1 Atrasentan, atorvastatin, bosentan, ezetimibe, 
fluvastatin, glyburide, SN -38 (active 
metabolite of irinotecan), rosuvastatin, 
simvastatin acid, pi[INVESTIGATOR_2830], pravastatin, 
repaglinide, rifampin, valsartan, olmesartan
OATP1B3 SLCO1B3 Atorvastatin, rosuvastati n, pi[INVESTIGATOR_2830], 
telmisartan b,valsartan, olmesartan
OCT2 SLC22A2 Ama ntadine, amiloride, cimetidine, dopamine, 
famotidine, memantine, metformin, pi[INVESTIGATOR_8405], 
procainamide, ranitidine, varenicline, 
oxaliplatin
OAT1 SLC22A6 Adefovir, captopril, furosemide, lamivudine, 
methotrexate, oseltamivir, tenofovir, 
zalcitabine, zidovudine
OAT3 SLC22A8 Acyclovir, bumetanide, ciprofloxacin, 
famotidine, furosemide, methotrexate, 
zidovudine, oseltamivir acid, (the active 
metabolite of oseltamivir), penicillin G, 
pravastatin, rosuvastatin, sitagliptin
aPlease note this is not an exhaustive list . For  an updated list, see the following link : 
http://www fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/uc
m080499 htm .  Accessed 05 Aug 2015.
bSelective for OATP1B3.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Protocol  AG-221- AML - 004 Celgene Corporati on
128 AG-221-AML -004 Amendment 2.0 Final :30 Nov 2017Appendix P:  Monitoring of Liver Function
Subjects with ALT increases of ≥ [ADDRESS_539559] will be monitored as fo llows:
Liver function tests (ie, ALP, ALT, AST, total bilirubin and GGT) should be repeated 
within 3 days of the init ial ALT finding, 2 to 3 times weekly  until  ALT levelis stable , 
and weekly thereafter 
Addit ional diagnost ic follow-ups incl ude: 
Focused medical history , including detailed review of prior history  of liver and/or 
biliary  disorders, concurrent symptoms, all concomitant medications (eg, 
acetaminophen -containing medicat ions, over -the-counter o r herbal medicat ions, 
nutritional supplements) including any changes in medicat ions, and alcohol use 
Hepati tis serol ogy (anti-HAV antibody , HBsAg , HBcAb , HBsAb , anti-HCV 
antibody , HCV RNA)
Profiling of EBV , CMV and autoantibodies (eg, ANAs, ant i-smooth m uscle 
antibodies) 
Com plete physical  examinat ion
Liver ul trasound and other imaging fo llow
-ups as appropriate
Addit ional evaluat ions as appropri ate (eg, PT with INR and PTT )
Key: ALP = alkaline phosphatase ; ALT = alanine aminotransferase ; ANA = antinuclear antibody ; AST = aspartate 
aminotransferase; CMV = Cytomegalovirus ; EBV = Epstein -Barr virus; GGT = gamma glutamyl transpeptidase ; 
HAV = hepatitis A virus; HBV = hepatitis B Virus; HBcAb = anti-HBV core antibody ; HBsAb = anti-HBV 
surface antibody ; HBsAg = HBV surface antigen ; HCV = hepatitis C virus; INR = international normalized ratio; 
PT=prothrombin time; PTT = partial thromboplastin time; RNA = ribonucleic acid ; ULN = upper limit of  
normal .
Approved
1.0
v
EDMS Doc. Number: 
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature [CONTACT_81712] a nd procedures.
UserName: 
[CONTACT_1641]:  
Date: Friday, 01 December 2017, 08:46 AM   Eastern Daylight Time
Meaning: Approved, no changes necessary.
 ================================================
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Changes AG-221- AML - 004 Celgene Corporati on
3 AG-221-AML -004 Amendment 2.0 Final: 30 Nov [ZIP_CODE]. JUSTIFICATION FOR AM ENDMENT
Significant changes included in this amendment are summarized below:
Sample size was increased and statistical considerations were updated .
AG-221 (enasidenib) was approved by [CONTACT_2165] (FDA) in the United 
States (US) for the treatment of adul t pati ents wi th relapsed or refractory  AML wi th an isocitrate 
dehydrogenase 2 ( IDH2) mutation as detected by  [CONTACT_426883] -approved test.  This approval may 
allow subjects in the convent ionalcare regimen arm to receive commercially available AG-221 
(enasidenib) , leading to statistical power loss in detecting the treatment effect on overall survival.  
To rem edy this stati stical power loss , Study  AG-221-AML -004 increased sample size from 280 
to 316 subjects and updated statistical considerations (eg, event si ze was increased from 193 to 
250deaths , etc) .(Refer to the Protoco l Summary , Secti on 3.1.1, Fi gure 1, Secti on 4.1, and 
Secti ons 9.3, 9.6.1, and 9.8.)
Study duration was updated .
The expected duration of this study  was changed from approximately [ADDRESS_539560] Marketing Requirements by [CONTACT_1622] ( NDA 209606 APPROVAL 1-Aug- 2017 
Reference ID: 4132874). Accordingly, the definit ion of t he End of Trial has been updated as 
either the date of [ADDRESS_539561] is available for survival fo llow-up, whichever
is the later date .(Refer to the Protocol Summary, Table 2, Sections 3.2 and 3.3 .)
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Changes AG-221- AML - 004 Celgene Corporati on
4 AG-221-AML -004 Amendment 2.0 Final: 30 Nov 2017Fasting (preferred) lipid panel was added at 2more timepoints .
Fasting(pref erred) lipid panel was added on Day  1 of Cycles 2 and 3 to allow for monitoring 
lipid changes during early  cycles of study  treatm ent.(Refer to Table 3 .)
The fasting requirement for lipid panel was updated.
The most recent European guideline indicates that non -fasting bl oodsamples are sufficient for 
assessing plasma lipid profiles (Nordestgaard ,2016) .  Thus, the fasting requi rement for lipid 
panel was updated, particularly  for subjects who experience clinical lymeaningful elevat ions of 
lipi[INVESTIGATOR_805], per the investigator’s assessment . (Refer to Table 3 and Section 6.2.)
Frequency of assessing disease status in the follow -up phase was reduced.
The frequency for disease status assessment was reduced from every 8 weeks to every 12 weeks
to reduce subjects’ burden during fo llow-up.   (Refer to Section 6.3 .)
Data collection of i nvestigator -assessed response/ disease status to subsequent AML 
therapi[INVESTIGATOR_014] w as added. 
This will allow for evaluate of disease response to subsequent AML therapi [INVESTIGATOR_426829].  For example, subjects who had refractory disease status before the 
study  treatm ent might achieve good disease control fro m subsequent AML therapy  after 
exposure to AG -221. Thi s would provi de scient ifically meaningful data regarding the sensitivity 
tosubsequent AML therapy after exposure to study  treatm ent, and general disease status after 
study  treatm ent.  (Refer to Table 3 and Secti on 6.3 .
)
Fasting requirement for taking AG -[ADDRESS_539562] study  (Study  AG221 -C-002) and two Phase 1/2 dose escalation studies (A G221 -C-001 and 
AG221 -C-003) which showed that the increase of AG -221 exposure by  [CONTACT_426884]. Accordingly , as reco mmended by [CONTACT_1622], the US prescribing 
inform ation does not include a fasting requirement for AG -221 administration . (Ref er to 
Secti on7.2.1.1 .)
Reference toxicities during AG- 221 therapy were updated .
These changes were made based on the current AG -221 IB. (Refer to Section [IP_ADDRESS] .)
Restricted concomitant medications during AG -221 therapy were updated.
Restricted concomitant medicat ions during AG- 221 therapy  were updated based on the current 
AG-221 IB. (Refer to Section 8.3 .)
The amendment also includes several other minor clarifications and corrections:
Celgene therapeuti c area head signature [CONTACT_3264] w asupdated on page 3.   
Three new references were cited in Section 9.6.1 (Primary Efficacy Analysis) and 
have been included in Sect ion 17.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Changes AG-221- AML - 004 Celgene Corporati on
5 AG-221-AML -004 Amendment 2.0 Final: 30 Nov 2017The commercial test to detect IDH2 m utations has been approved by [CONTACT_426885] 2017 . The explanation was added in Secti on 6.1. 
Other clarificat ions, correcti onsofminor typographical errors and incidental 
formatting changes were m ade throughout the document.
2. REFERENCES
Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al.  Fasting is not 
routi nely required for determination o f a lipid profile: clinical and laboratory  implicat ions 
including flagging at desirable concentration cut -points -a joint consensus statement from the 
European Atherosclerosis Society  and European Federati on of  Clinical  Chemistry  and 
Laboratory  Medicine .  Eur Heart J. 2016 Jul 1;37(25):1944-58.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Cha nges AG-221- AML - 004 Celgene Corporati on
3 AG-221-AML -004 Amendment 1.0 Final: 11Oct [ZIP_CODE]. JUSTIFICATION FOR AM ENDMENT
Significant changes included in this amendment are summarized below:
Best supportive care was clarified to be given according to local prescribing 
information and local therapeutic guidelines .
This clarificat ion was at the request of the French National Agency for Medicines and Healt h 
Products Safet y (ANSM ).  (Refer to the Protocol  Summary , Sect ions3.1.1 and 7.1.5.)
A special condition of allowing confirmation of  isocitrate dehydrogenase (IDH) 
gene mutation locally was added
In the event that the central laboratory  resul t is delay ed and precl udes acute clinical management 
of a subject who has confirmed IDH2 gene mutation by [CONTACT_426837], the subject may  be 
eligible for randomizat ion with approval  by [CONTACT_208558] .  (Refer to Protocol Summary, 
Secti ons 3.1.1 and 4.2 [inclusio n criterion #7].)
Management of d ifferentiation syndrome during AG -[ADDRESS_539563] ionary for Regulatory  Activities(MedDRA), the 
preferred term of different iation syndrome associated with therapy  of mutant i socitrate 
dehydrogenase (IDH) inhibit ion will  be IDH Diffe rentiation Syndrome.  Thus the term  for 
different iation syndrome during AG -221 therapy  was chang ed from “Different iation-like 
Syndrome ”to “IDH Different iation Syndro me".  Diagnosis and treatm ent of IDH Different iation 
Syndrome during AG -221 therapy  was also updated with a reference to a supplemental guidance 
docum ent.  (Refer to Protocol Summary, Sections 3.1.1, [IP_ADDRESS] and 8. )
A note wa s added to clarify the intermediate -dose cytarabine (IDAC) regimen
Any local standard regimen different from the IDAC regimen specified in the protocol will need 
review and approval by  [CONTACT_426886].  (Refer to Protocol Summary, Sections 3.1.1 and 
7.2.4 .)
For subjects having acute myeloid leukemia ( AML )secondary to prior higher risk 
(Intermediate -2 or High risk according to the International Prognostic Scoring 
System) myelodysplastic syndromes ( MDS ) treated with a hypomethylating agent 
(eg, azaciti dine or decitabine), the hypomethylating therapy can be counted as a 
line/regimen if there is disease progression to AML during or shortly (eg, within 60 
days) after the hypomethylating therapy.
As hypomethylat ing therapy isapproved for higher risk (Inter mediate-2 or High risk according 
to the International Prognostic Scoring Sy stem ) MDS and AML (approvals vary by [CONTACT_1606] ), and 
secondary  AML wi th prior MDS treated with hy pomethylat ing therapy has the median overall 
survival only about [ADDRESS_539564]-line AML 
therapy , this amendment will count the hypo methylat ing therapy for higher risk MDS as a 
line/regimen if there is disease progression to AML d uring or shortly (eg, within 60 days) after 
the hypomethylat ing therapy.  (Ref er to Secti ons 4.2 [inclusio n criterion #9] and 17 , and 
Appendix G.)  
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Cha nges AG-221- AML - 004 Celgene Corporati on
4 AG-221-AML -004 Amendment 1.0 Final: 11Oct 2016 
Caution of AG -221 phototoxicity was removed.
AG-221 does not possess phototoxicit y potenti al based on i ts exposure to BALB/c -3T3 m ouse 
fibroblasts in the presence of ultravio let(UV) radiation.  Thus caution of AG -221 phototoxi city 
was rem oved. (Refer to Sections [IP_ADDRESS].)
A new response criterion, morphologic co mplete remission with partial hematologic 
recovery (CRh) was added .
The new response criterion, CRh is defined as all criteria of morphologic CR except that absolute 
neutrophil count ( ANC )
>0.5x 109/L (5 00/μL) and platel et count > 50 x 109/L (50,000/μL).  
This criterion will be assessed by [CONTACT_426887] .  (Refer to 
Table 2, Section 9.6.2 .2, and Appendix F.)
The formula for creatinine clearance calculation was updated
The Cockcroft -Gault formula was repl aced by t he Modificat ion of Diet in Renal Disease
(MDRD ) glomerular fil tration rate (GFR) .  (Refer to Section 4.2 [ inclusio n criteria #8])
The requirement for cytarabine pregnancy prevention was updated for female 
subjec ts and male subjects with their partners.
These updates were made at the request of healt h authorities in reference to the contraceptive 
recommendat ions in the summary o f product characterist ics (Sm PC) of c ytarabine (ie, effect ive 
contraception during trea tment and up to 6 m onths after stoppi[INVESTIGATOR_309901] ).(Refer to Sections 3.1.3, 4.2 
[inclusio n criteria #9 and #10], 6.3 , 
and 10.4.)
The requirement for the minimum number of treatment cycles was clarified for 
subjects refractory to ,or relapsed after ,second -or third -line/regimen of intensive 
therapy for AML .
This clarificat ionwas made at the request of the ANSM.  Intensive therapy  as the second -or 
third-line/regimen for AML subjects 60 y ears or older (as required by [CONTACT_1758] ) woul d need 
extensive customizat ion which could be best achieved through the treating physician ’s 
assessment.  Thus ,the protocol does not specify the minimum number of treatment cycles 
requi red to define refractory  or rel apsed disease after intensive therapy  as the second -or thi rd-
line/regimen for AML . (Refer to Section 4.2 [i nclusion criterion #4a ].)
The eligibility of subjects to the conventional care regimen ( CCR) treatment option 
was further clarified that subjects with degenerative and toxic encephalopathy
should not receive cytarabine.
This addit ion was made at the request of the ANSM in reference to the secti on of  
Contraindicat ions in the SmPC of cy tarabine. (Refer to Section 4 .2 [inclusio n criterion #5 ].)
The definition of  females of childbearing potential (FCBPs) was updated
.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Cha nges AG-221- AML - 004 Celgene Corporati on
5 AG-221-AML -004 Amendment 1.0 Final: 11Oct 2016This update was made in reference to “ Reco mmendations related to contraception and pregnancy 
testing in clinical trials ”by [CONTACT_426888] (CTFG). (Refer to Section 4.2 
[inclusio n criterion#9].)
Effective contraceptive methods were clarified .
This clarificat ion was made in reference to “Recommendat ions re lated to contraception and 
pregnancy testing in clinical trials” by [CONTACT_426889] . (Secti on 4.2 [i nclusio n criteria #9 and #10] .)
True abstinence was incorporated into the requirement for pregnancy prevention .
This update was made at the request of Medicines and Healthcare products Regul atory Agency 
(MHRA). ( Refer to Section 4.2 [i nclusio n criteria #9 and #10])
Management of leukocytosis with hydroxyurea was updated.
The thresho ld of white blood cell (WBC) count was removed to allow control  of leukocy tosis 
with hydroxyurea per standard inst itutional practice. (Refer to Section s4.2 [e xclusio n 
criterion#4], [IP_ADDRESS] and 8.)
Exclusion of subjects taking specific medications known to prolong QT interval 
was clarified
Subject staking specific medications that are known to prolong QT interval will be excluded 
unless the subject scan be transferred to other medications at least 5 half -lives prior to the start of 
study  treatm ent.  (Refer to Section 4. 3 [exclusio n #18].)
A guideline for monitoring liver function was added
The gui deline was added as an example of acute clinical management.  (Refer to Section 6.4.2 
and Appendix P.)
Management of gastrointestinal disorders during AG-
[ADDRESS_539565] of the ANSM in reference to the current AG -221 IB and in 
line with the IB. (Refer to Section [IP_ADDRESS] .)
A recommendation of the minimum number of AG- 221 treatment cycles was added .
Preliminary data from the Phase 1/2 study  (ie, AG -221-C- 001) showed that response to treatment 
with AG
-[ADDRESS_539566] 
6cycles o f AG-221 t reatment in order to optimally benefit fro m the treatment. (Refer to 
Secti on7.2.1.)
Definitions of hematologic toxicities were clarified.
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Cha nges AG-221- AML - 004 Celgene Corporati on
6 AG-221-AML -004 Amendment 1.0 Final: 11Oct 2016These clarifications were made to allow cont inuous AG -221 treatm ent cy cles wit hout delay s due 
to disease -related hematol ogic toxi cities.  (Refer to Secti on [IP_ADDRESS].)
Criteria for initiating subsequent AG-221 treatment cycle was updated.
This update was made to allow continuous AG -221 treatm ent cy cles wi thout delays due to 
disease -related adverse events. (Refer to Section [IP_ADDRESS] .)
The definition of subjects without reduced baseline blood counts was updated.
These updates were made at the request of the ANSM in reference to the current Azacit idine IB 
and in line with the IB. (Refer to Secti on [IP_ADDRESS] and Appendix L .)
Management of nec rotizing fasciitis during azacitidin etherapy was added .
This addit ion was made at the request of the ANSM in reference to the azacit idine Sm PC. (Refer 
to Section [IP_ADDRESS].)
Guidelines of concomitant treatment of gastrointestinal side effects during 
azacitidine treatment were added.
Reco mmended conco mitant treatm ent of nausea, vomit ing and/or diarrhea d uring azacit idine 
treatm ent was added. (Refer to Section 8.1.)
Administration of live or live -attenuated vaccine s was added as a prohibited 
concomitant medication during the course of cytarabine therapy .
This addit ion was made at the request of the ANSM in reference to the s ection “Special warnings 
and precaut ions for use ”in the cutarabine SmPC . (Refer to Section 8 .2.)
Administration of 5-Fluorocytosine was added as a prohibited concomitant 
medication during the course of cytarabine therapy .
This addit ion was made at the request of the ANSM in reference to the section of Interaction 
with medicinal products and forms of interaction in the cytarabine SmPC . (Refer to Section 8.2.)
The amendment also includes several other minor clarifications and corrections:
Medical monitor contact [CONTACT_426890] s 2and 3 .
Citations of  AG-221 and azacit idine IBswere removed in Section 17 and the links to 
these citations (in the Protocol Summary, and Secti ons  10.6) were abolished 
to allow reference to the current IBs.   
Approved
1.0
v
EDMS Doc. Number: AG-221 (CC -[ZIP_CODE])
Summary  of Cha nges AG-221- AML - 004 Celgene Corporati on
7 AG-221-AML -004 Amendment 1.0 Final: 11Oct 2016Multi-gated acqui sition(MUGA) scan was rem oved as an assessment during 
screening and/or treatment.  However, a prior MUGA scan performed wit hin 28 days 
prior to the start of study  treatm ent can be used for study  entry .  These changes were 
reflected in the Protocol Summary , Table 3, and Sections 6.1, 6.2, and 6.4.
The window for bone marrow aspi[INVESTIGATOR_6706]/or biopsy , peri pheral bl ood sm earand, if 
applicable, cy togeneti cs, during the Treatm ent Phase was clarified in the footnotes 
“w”, “x” and “y” o f Table 3 to be consistent with Section 6.2.
Thewindow for bone marrow aspi[INVESTIGATOR_6706]/or biopsy , peri pheral bl ood sm earand, if 
applicable, cy togeneti cs, during the Follow -up Phase was corrected in Section 6.3 to
±14 day s to be consistent with the footnote “q” of the Protocol, Table 3, Table of 
Events.
The parameters of chemistry  and cardiac m arker panels were updated.
Truncated sentence sin Sect ions8.1 and 10.6 were completed.
The el apsed time from  azaci tidine reconst itution to administration in Method A of 
Appendix K was updated with addit ion of the specificat ion in the [LOCATION_002].
Specificat ion of azacit idine reconst itution with refrigerated water was added in 
Method B of Appendix K.
Correcti onsofminor typographical errors and incidental formatting changes were 
made throughout the document.
Approved
1.0
v